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CHAPTER 
I 
GENERAL INTRODUCTION 

Chapter 1 
Hematopoiesis 
Introduction 
Mature blood cells have a finite life span and are continuously replenished by the 
proliferation and differentiation of lineage-specific progenitor cells derived from 
rare pluripotent hematopoietic stem cells. l. 2 Stem cells are capable of reproducing 
them-selves (self-renewal) and of producing cells belonging to all lineages of blood 
(hematopoietic) cell differentiation (Figure 1.). Definitions of stem cells vary on 
the model of hematopoiesis used but. in general, these cells are referred to by the 
functional property of being capable of long-term reconstitution of the 
hematopoietic system of recipients. 
Bone marrow transplantation (BMT) is potentially used for the treatment of 
hematopoietic disease such as leukemia, autoimmune diseases and to improve 
hematopoietic recovery and prevent mortality after intensive treatment of cancer 
patients. The purpose of BMT is to provide the recipient with a new, permanently 
functioning hematopoietic system. As has been shown in transplantation assays in 
mice, hematopoietic recovery after BMT develops through 2 distinct phases with 
the initial wave of hematopoiesis being brought about by stem cells with short term 
repopulating ability (STRA) with transient and restricted potential and the second 
phase of sustained multilineage hematopoiesis being established by stem cells with 
long-term repopulating ability (LTRA)3. 4 
The majority of hematopoietic stem cells in vivo are quiescent and in the GO phase 
ofthe cell cycle (as demonstrated by S-phase specific or cycle-dependent agents), 
only a small number of hematopoietic stem cells are actively proliferating5 
Candidate stem cells possess a range of phenotypic properties that can be exploited 
in stem cel! purification and enrichment procedures. These include the expression 
of the cell surface antigens CD346 and Thy-17, the absence of lineage-related 
markers, transferrin receptors8 and the high molecular weight form of the human 
leukocyte antigen CD45RA9, a low expression ofHLA-DRlO and a low uptake of 
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Rhodamine!".11 Physical features such as size and light scatter properties add to 
distinguish cells of different stages of hematopoietic development. 
CD34-expression on stem cells 
The CD34 antigen (a 90-120 kD integral membrane glycoprotein) is expressed on 
developmentally early lympho-hematopoietic stem and progenitor cells6, small-
vessel endothelial cells12 and embryonic fibroblasts13 Human BM cells 
expressing the CD34 antigen comprise -1.5% of marrow nuclear cells and are 
enriched for progenitor cells.6 However, this population is heterogeneous, with 
most cells already committed to either erythroid, lymphoid, or monomyeloid cell 
lineages. 14 The function of CD34 is not clear yet. 
CD34+ cells co-express L-selectin (CD62L; a surface adhesion glycoprotein) which 
is involved in redistribution and homing of hematopoietic progenitor cells to the 
bone marrow (BM) following cytotoxic damage15 In addition, recent experiments 
indicate that CD34 expressed on endothelial cells may play a role in leukocyte 
adhesion and "homing" during the inflammatory process acting as a ligand for L-
selectinl6, 17, and it has been hypothesised that CD34 plays a role in 
stem/progenitor cell localisation/adhesion in the BM6 It may also be involved in 
maintenance of the stem celllprogenitor phenotype.! 8 CD34 is widely used to 
enrich for progenitor cells to use in transplantation and gene therapy studies, 
including studies to expand hematopoietic stem/progenitor cells ex vivo. 
Long-term culture of human hematopoietic stem cells l9, the use of 
immunodeficient mouse models as in vivo assay for human hematopoiesis20, and 
successful transplantation of CD34-selected BM cells into baboons21 , 22 and 
humans23 have demonstrated that CD34+ cells are responsible for short-term 
repopulation and probably for long-term repopulation as well. 
Multidimensional flow cytometry of CD34- cells showed that expression of the 
CD38 antigen (a 45 kD glycoprotein) is an early event in the differentiation of cells 
into erythroid, myeloid, B-lymphoid and T-lymphoid lineages.24, 25 Candidate 
stem cells do not express the CD38 antigen (Figure 2.). Cells with the CD34+CD38' 
phenotype embrace a small population of -5% of the CD34+ subset and -0.05% of 
the total nucleated cell population). Long-term cell culture assays25 and 
transplantation of purified CD34+CD38' cells into inununodeficient non-obese 
diabetic/severe combined inununodeficient (NOD/SCID) mice26. 27 have shown 
that this subset contains cells involved in hematopoietic repopulation. 
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Figure I. Schematic representation of the hematopoietic cell hierarchy. 
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Studies performed in murine models support the presence of a CD34- cell 
population that is euriched for long-term repopulating cells and does not express 
detectable levels of cell-surface CD34.2S. 29 Single murine Lin-CD34- cells 
transplanted into lethally irradiated mice can sustain long-term multilineage 
engraftment. In the human hematopoietic system Lin-CD34- cells also seem to be 
able to repopulate the BM of NOD/SCID mice, but show limited biological 
function in vitro. These repopulating Lin"CD34- cells were found in all 
hematopoietic tissues, with the highest frequency found in foetal liver (3.25%) and 
foetal blood (2.65%). The lowest levels were found in BM (0.28%), suggesting that 
Lin-CD34- cells are produced at the highest levels early in human ontogeny30 
Human BM CD34- cells also repopulate the foetal sheep xenograft model31 The 
results of this study provide evidence for the existence of a primitive CD34-
(human) cell population with repopulating potential. Transplantation assays in mice 
have revealed that the expression of CD34 on immature SUb-populations of stem 
cells is reversible and associated with activation stage32 The majority of the stem 
cells with long-term repopulating ability in normal adult mice are CD34-, but in 
vitro and in vivo activation of stem cells results in reversible expression of CD34. 32 
These findings presently serve well in resolving a growing controversy on the 
CD34 state of repopulating cells. 
Stem cell commitment 
Hematopoiesis is a tightly regulated process that ensures that blood cell turnover is 
balanced by production of new blood cells and in which blood cell production can 
be rapidly adapted to increased demands due to blood loss, infection or other 
emergencies. Different models have been developed in which stem cell 
commitment and differentiation is described as either a stochasticlrandom process 
or in which stem cell fate is regulated by external stimuli33-36 Whatever the 
precise mechanism by which stem cell commitment, proliferation or differentiation 
occurs, the regulation of hematopoiesis relies on complex interactions between 
hematopoietic cells and stromal cells in the BM, growth factors and their receptors, 
extracellular matrix molecules and cell-cell interactions through specialised cell 
adhesion molecules. 
14 
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Figure 2. Flow cytometric analysis of human CD34+ enriched human hematopoietic cells 
stained with CD34 versus CD38. CD34TD3S· cells cover -5% of the CD34+ population 
and -0.05% of the total nucleated cell population. 
Hematopoietic growth factors 
Hematopoietic growth factors (GFs) or cytokines are involved in the proliferation 
and differentiation of the hematopoietic compartment and thus playa fundamental 
role in the regulation of blood cell production. Although GFs act mainly directly on 
the hematopoietic cells, GFs also have indirect effects through accessory cells 
releasing other cytokines2 Many GFs display overlapping biological activity 
(either in synergy or as antagonists) on a variety of cell types. Some GFs stimulate 
primitive cells as well as committed progenitors or end stage cells of specific 
lineages. Cytokines involved in stem cell proliferation/differentiation are stem cell 
factor (SCF)37, leukemia inhibitory factor (LIF)38, interleukin 3 (IL-3)39, 
interleukin 6 (IL-6)40 and the more recently cloned fins-like tyrosine kinase-3 
ligand (F1t3-L)41 and thrombopoietin (TPO).42-45 Lineage specific factors (late 
acting), such as granulocyte-colony stimulating factor (G-CSF)46, monocyte-
colony stimulating factor (M-CSF)47, erythropoietin (EPO)48, interleukin 1 (IL-
1)49 and interleukin 2 (IL_2)50, but also IL-3, IL-6 and TPO act on the specific 
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differentiation into blood cell lineages, i.e., granulocyte (G-CSF) and monocyte 
(M-CSF) differentiation, erythropoiesis (EPO) or megakaryocytopoiesis (TPO). 
Hematopoietic growth factors are produced locally by stromal cells or cells in the 
hematopoietic organs, by mature blood cells, endothelial cells, and by specialised 
cells in various organs, such as lungs, brain, pancreas, kidneys and liver. Apart 
from stimulatory GFs, also negative regulators influence the differentiation and 
proliferation of stem and progenitor cells, i.e., TGF-J351, macrophage inflammatory 
protein-1a (MIP-la)52, interferon-y (IFN-y) and tumour necrosis factor-a (TNF-
a)53 
Analysis of expression of GF-receptors (GF-R) on hematopoietic cells showed that 
peripheral blood (PB) and BM CD34+ cells express diverse high affmity 
hematopoietic GF-R, mainly IL-3-R, IL-6-R, GM-CSF-R, c-kit (SCF-R) and c-mpl 
(TPO_R)54-57 Small size CD34+ cells are characterised by more intense expression 
of the GF-R than large ones58 EPO-R, G-CSF-R and M-CSF-R are expressed at 
barely detectable levels59-61 Receptors for late acting GFs are ahnost exclusively 
expressed with high levels on cells of specific subsets, i.e., the EPO-R is expressed 
on more mature CD34+CD3S+CD71 ++ erythroid progenitors but not on 
CD34+CD3S+CD64+ GM-CFU62. 63 Hematopoietic GFs, which are all 
glycoproteins, mostly belong to two GF-receptor families, the tyrosine kinase 
receptor family64. 65 and the hematopoietin or cytokine receptor super family66 
The tyrosine kinase receptor family consists of cell-surface receptors that are 
classified into three subclasses based on structural differences. Subclass I receptors 
include the receptor for epidermal growth factor (EGF)67, Subclass II receptors 
include receptors for insulin and insulin-like growth factor-1 6S, 69, and subclass III 
contain the SCF-receptor, the M-CSF-receptor, FIt3 (receptor for FIt3-L) and 
platelet-derived growth factor (PDGF) receptor.70-73 The cytokine receptor 
superfamily include receptors for most other GFs, such as receptors for IL-2, 3, 5, 
6, 7, 9 and II, GM-CSF, G-CSF, EPO, TPO, LIF.74-86 Hematopoietic GFs can 
also be grouped according to their phylogenetic background. TPO, for instance, 
consists of a highly conserved amino-terminal domain that is related to EPO. 
Similar to EPO, TPO contains 4 cysteins, of which 3 present in EPO are at similar 
positions in TPO.42. 87 SCF, M-CSF and Flt3-L may have been derived from a 
common ancestral gene as these GFs have similar intronlexon structures88, and the 
GM-CSF gene is closely linked with the IL-3 gene, which also might originate 
from one gene as GM-CSF and IL-3 are structurally similar and share overlapping 
functions.89. 90 It is of interest for evolution genetics that the mouse has two 
closely related IL-3-receptor J3-chains, one shared with IL-5 and GM-CSF, one 
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specific for IL-391 , whereas primates, including humans, have only the former. 
Remarkably, IL-3 is one of the fastest evolving proteins known.92 
The precise actions of individual GFs on stem cell maintenance, proliferation, 
commitment and differentiation are not well understood. A major challenge is to 
elucidate these mechanisms and to select the most suitable GFs or GF 
combinations and culture conditions to maintain or increase stem cell numbers in 
vivo and influence their differentiation. This is, for instance, relevant in studies 
directed at ex vivo expansion of immature cells for transplantation purposes and 
gene transfer. 
Stem cell sources 
Until recently, the most frequently used source in clinical stem cell transplantation 
was BM. However, hematopoietic cells mobilised into the PB by growth factor 
treatment are increasingly replacing BM for clinical transplantation. Human 
umbilical cord blood (UCB) is a rich source of hematopoietic stem/progenitor 
cells93 and in 1989 experimental and clinical studies were published indicating that 
human UCB could be used in clinical settings. UCB has a significantly higher 
number of primitive and committed progenitors than adult pB.94 Compared to BM, 
UCB contains a higher proportion of immature CFC (i.e., CFU-GEMM, CFU-GM 
and CFU-MK)95. 96, an 8-fold higher frequency of HPP-CFC97, and similar 
frequencies of LTC-IC98 The frequency of CD34+ cells is about the same in BM 
and UCB (_1%)99-102 Additionally, the cloning efficiency of CD34+CD38- UCB 
cells is higher as compared to BMI03 which may imply a more efficient 
engraftrnent after transplantation104 In contrast to allogeneic BM and PB, UCB 
has a low risk for acute graft-versus-host disease. However, problems associated 
with the use of UCB for transplantation are that the collection can only take place 
once. One cord blood sample may not contain sufficient numbers of stem cells to 
transplant adults and in case an additional graft is needed there is no possibility to 
aspirate another. 
The first UCB transplant was successfully performed in a 14-year old child with 
Fanconi's disease104 Although more than 500 UCB transplants have taken place 
world-wide, the biology of cord blood stem cells is not yet fully understood. As the 
number of stem cells in an average UCB sample is too low to transplant large 
adults, ex vivo expansion of hematopoietic stem cells would seem to be necessary 
to make UCB stem cell transplantation a feasible option for adults. For the 
development of procedures to efficiently expand the numbers of transplantable 
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stem cells in culture, characterisation of stem cell physiology and knowledge about 
stem cell regulation by GFs is essential. 
Progenitor cell assays (in vitro / in vivo) 
Many in vivo and in vitro assays have been developed to study mechanisms 
controlling cell differentiation at specific stages to identifY, quantitate and 
characterise hematopoietic cells and to manipulate the expansion of the progeny. 
Furthermore, in vivo transplantation assays are used for tracing early representants 
of the stem cells and for evaluation of the function of BM stroma. Although the 
various functional definitions may overlap as some cells may show up in multiple 
assays, none of these assays fully satisfies the criteria for hematopoietic stem cell 
analysis. The definition of stem cells has changed through the years as result of the 
development of new techniques and assays to characterise these multipotential 
cells, resulting in a more precise link between phenotypes and functional 
properties. 
In vitro frequency analysis of hematopoietic stem cells and progenitors is often 
performed in a semi-solid colony assay (CFU-C), which is, however, neither 
specific nor predictive for the most immature stem cells with long-term 
engraftment potential but identifies more committed cells with limited proliferative 
and differentiation capacity. The first colonies grown from normal mouse bone 
marrow cells were composed of neutrophilic granulocytes and/or macrophages 
(GM_CFU)105-107 and represented a heterogeneous population of hematopoietic 
progenitor cells. Cells of the erythroid lineage Can grow in EPO-stimulated semi-
solid cultures forming erythroid colony-forming units (CFU_E)I08 The existence 
of a cell type of greater erythroid colony-forming capacity was termed erythroid 
burst-forming unit (BFU-E) because of the disperse appearance of the colonies 
containing abundant numbers of erythroid cellsI09 BFU-E are developmentally 
early, EPO-independent progenitor cells, and CFU-E late, EPO-dependent 
progenitors 1 09 Also megakaryocyte progenitors can be cultured in semi-solid 
medium to form megakaryocyte colonies (Meg-CFU)11 O. 111 The CFU-GEMM 
are multipotential progenitor cells that can form colonies comprising mixtures of 
granulocytes, erythroblasts, megakaryocytes and macrophages. Another clonogenic 
assay for the analysis of primitive cells is the high proliferative potential colony-
forming cell assay (HPP-CFC). HPP-CFC contain progenitors of granulocytes, 
erythrocytes and megakaryocytes, and cells from these colonies are able to 
repopulate the BM ofmice112 
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In vitro hematopoiesis can be sustained for weeks or even months in culture 
systems in which hematopoietic cells are maintained using a layer of marrow-
derived stromal cells. At first, these long-term bone marrow cultures (LTBMC) 
were developed to support replication of mouse pluripotent stem cells113. 114, and 
were adapted to sustain long-term hematopoiesis with bone marrow of primates, 
including humans1l5. 116 Changes in hematopoietic activity are usually monitored 
by periodic measurement of the production of committed progenitors, assayed in 
colony assays (long-term culture initiating cell assay, LTC-IC assay)19, 117 or by 
detection of characteristic areas of hematopoietic cells which are in close contact 
with the stroma, so called cobblestone areas (cobblestone area forming cell assay, 
CAFC assay)11S-120 The CAFC assay can be used to measure the frequency of 
different hematopoietic stem cell subsets under limiting dilution conditions using 
Poisson statistics. In addition, the colony forming cell production in the LTC-IC 
assay is used to estimate the total graft quality, and in combination, these assays 
can be applied to calculate the average quality of individual stem cells.121 Studies 
focussing on the hierarchy of stem cell subsets revealed that early appearing (week 
2) CAFC represents a more mature subset, than the late appearing (week 6) 
CAFC122 The former correlates with the number of spleen colony forming cells 
day 12 (CFU-Sd and cells with short-term repopulating ability, whereas the latter 
correlates with cells with long-term repopulating ability. 
Definitive information about functional primitiveness of cells and the ability to 
repopulate the BM of recipients can only be gained by transplantation assays. The 
spleen colony forming (CFU-S) assay123 was previously considered the only true 
stem cell assay available. In this assay, irradiated mice are transplanted with BM 
cells. The number of macroscopic colonies that appear on the surface of the spleen 
of the recipient, 7 to 13 days after injection is directly proportional to the number 
of BM cells transplanted. The cells in the CFU-S compartment are structured in a 
hierarchic system; early appearing day 8 CFU-S lack stem cell properties and 
overlap with the committed progenitor populations as measured by the in vitro 
erythrocyte burst-forming unit (BFU-E) assays124 Late-appearing day 12 CFU-S 
are capable of some self-renewal as demonstrated by serial transplant studies in 
mice.1 25 Other studies show no overlap oflong-term reconstituting cells and day 
12 CFU-S3 The methodology involved in spleen colonies for a stem cell assay has 
been published in detail. 126-12S 
In 1985, an in vivo assay was developed to determine the marrow-repopulating 
ability (MRA) of transplanted bone marrow cells in the mouse. The MRA assay129 
measures a more primitive cell population than the CFU-S. In the MRA assay, BM 
19 
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from irradiated mice is collected and injected into lethally irradiated recipient mice. 
After 13 days colony-fonning cells are analysed in the BM of the recipient mice. 
The number of secondary in vitro clonogenic progenitors in the BM of such 
recipients is a measure of the MRA of the graft which are cells closely associated 
with those that provide sustained hematopoiesis after BM transplantation. In 
contrast to the MRA assay, which is analysed at one time point of the repopulation 
in the BM after 13 days, the long-terru repopulating ability (LTRA) assayJ30 
measures the dynamiCS and the level of multilineage reconstitution over extended 
periods of time, thus giving insight into hematopoietic stem cell development in 
vivo. The LTRA assay is perforrued in mouse strains that enable a discrimination of 
donor-derived and recipient-type cells, such as a-thallassemic Hbath!+ mice which 
are genetically anaemic. Infusion of norrual mouse BM cells into sublethally 
irradiated a-thallassemic mice results in chimeric mice in which differences in size 
between a-thallassemic red blood cells and healthy (donor-type) red blood cells are 
detected using flow cytometry131 This red blood cell chimerism is used at 
different time intervals as a measure for chimerism at the level of the 
hematopoietic stem ceIL A similar approach, using unirradiated W'I!WI anaemic 
mouse mutants, was used to study lymphoid and erythroid repopulation132 Recent 
work on the mechanism of the radioprotective effect of TPO further supported the 
functional hierarchy ofLTRA, MRA, and CFU-S133 
These in vivo assays (CFU-S, MRA, LTRA) are used for quantitative analysis of 
murine hematopoiesis. In vivo studies for primate hematopoietic stem cells can 
only be perforrued in models such as developed in rhesus monkeys and baboons. 
The use of immunodeficient mice as a transplantation assay for human 
repopulating cells is a helpful alternative assay for human repopulating stem cells. 
The inter-relationship of the different assays for hematopoietic stem cells is 
presented schematically in Figure I. 
Immunodeficient mouse models for human cell transplantation 
Congenital immunodeficiency in mice has shown to be useful to assess human 
stem cell capacity in a transplantation assay134-136 Mouse strains originally used 
for these studies include beige athymic nude X-linked (bnx) immunodeficient 
micel36, and C.B-17 scidiscid severe combined immunodeficiency (SCID) which 
are superior in human cell engraftment as compared to the bnx mice. 13 7 The SCID 
mouse has an autosomal recessive mutation mapping to mouse chromosome 16138 
that causes Severe Combined Immunodeficiency (SCID)I39 Characteristic for 
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SCID mice is the lymphocytopenia, a rudimentary thymic medulla, and relative 
empty splenic follicles and lymph nodes140 The low numbers of functional Band 
T cells is due to a defective V(D)J recombination 141 and a defect in the repair of 
DNA double-strand breaks results in hypersensitivity to ionising radiation142 To 
overcome the non-specific immunity which is still present in the mouse, SCID 
mice have been treated with injections of the polyc1onal rabbit antibody anti-asialo 
GM1143, 144 or liposomes capturing di-chloromethylene-di-phosphonate 
(CL2MDP) 145 as a conditioning regimen for transplantation with human 
hematopoietic cells. In order to facilitate the selective elimination of NK cell 
activity, the scid mutation was back-crossed in the non-obese-diabetic (NOD)lLt 
background, which results in an immunodeficient stock (NODlLtSz-scidlscid; 
NOD/SCID) with multiple defects in adaptive as well as non-adaptive immune 
function 146 and, provides a more suitable microenvironment for reproducible 
reconstitution with human hematopoietic cells.27, 147 NOD/SCID mice support 
approximately five-fold higher levels of human stem cell marrow engraftment than 
do SCID mice147 
Use of immunodeficient mouse models 
To study the human immune system, humanised SCID mice (SCID-hu) have been 
developed by co-implantation of small fragments of human foetal liver, thymus and 
lymph node beneath the kidney capsule134 These mice showed reproducible and 
long-term reconstitution of human T and B-ce11 activity,!48, 149 Also mice 
transplanted with human foetal bone, spleen and thymus (SCID-hu-BTS) showed a 
multilineage graft able to produce hematopoietic cells for at least 36 weeks1SO, lSI 
Also subcutaneous implantation of human foetal bone fragments in non-irradiated 
SCID mice (SCID-hu-bone)152 has been used to study the effects of various 
recombinant human hematopoietic growth factors on the development of different 
hematopoietic lineages,!S3 However, the SCID-hu-bone model was not able to 
maintain progenitors after 12 weeks post-transplant58, 152, IS3 Functional studies 
such as the injection of Staphylococcal enterotoxins in the SCID-hu mice, showed 
effect on the development and responsiveness of human T cell populations. 154 Hu-
PBL-SCID mice (ScrD mice transplanted with peripheral blood lymphocytes) 
were developed as models to study xenogeneic graft-versus-host-disease 
(XGVHD) and for evaluation of immunosuppressive agents and transplantation 
protocols for XGVHD.IS5 
21 
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Apart from studies on the immune system, immunodeficient mice are used for stem 
cell assays. Intravenous (iv.) transplantation of unfractionated human BM cells 
resulted in reconstitution of (3 to 4 Gy) irradiated SCID mice BM with myeloid, 
erythroid and B cell lineages156 Human hematopoiesis was spurred in these 
animals by recombinant human cytokines injected intraperitoneally (ip.) at 48 hour 
intervals during the engraftment period. 137 Transgenic SCID mice expressing the 
genes for human IL-3, GM-CSF and SCF have also been developed and, when 
compared to non-transgenic SCID mice, these transgenic mice engrafted CD34+ 
selected umbilical cord blood cells for periods twice as long (for up to 6 
months ).157 In contrast to studies with human BM, treatment with human cytokines 
was not required for unseparated or Ficoll-fractionated human UCB or peripheral 
blood stem cells to establish high-level engraftment in SCID mice, suggesting that 
neonatal cells either respond differently to the murine micro environment, provide 
their own cytokines in a paracrine fashion15S, or that UCB is more enriched for 
primitive progenitors159 However, some studies indicate that, while UCB cells 
may not require cytokine supplementation to achieve short-term engraftment, more 
durable engraftment is dependent on cytokine support. 157 
Early studies in SCID mice, showed that primitive human cells are responsible for 
the multilineage engraftment in immunodeficient mice. One of the first 
experiments to suggest this involved growth factor treatment of the SCID mice 
after transplantation of human BM cells. Injection of GFs immediately after 
transplantation resulted in increased numbers of human cells as compared to 
untreated mice. When these GF s were administered one month after BM 
transplantation, a 10 to 100-fold cell increase was found as compared to animals 
that did not receive GFs, indicating that resting primitive cells that were still 
present m the mouse BM can engraft and SlirVlve in the mouse 
microenvironment. 137 
More evidence was found in that engrafted mice contained significant numbers of 
CD34+Thy-I!O human cells (a phenotype very immature in in vitro assays)25 and 
human LTC-IC, which is the earliest cell type that can be assayed in vitro. Initial 
stndies showed that only CD34- and not CD34' BM and UCB cells are responsible 
for SCID mouse and NOD/SCID mouse160 engraftment. In subsequent 
experiments, when NOD/SCID mice were more commonly used for stem cell 
characterisation, it was found that a small subpopulation of CD34+, i.e., 
CD34+CD38' cells were exclusively able to repopulate the mouse BM20, 27 Cells 
of this immature phenotype were able to reconstitnte the mouse BM with lymphoid 
and myeloid cells as well as with CD34+CD38' cells. 
22 
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Through limiting dilution analysis using Poisson statistics (assuming a single-hit 
action) a frequency of I (NOD)SCID repopulating cell (SRC) in 61720 or in 
3,50027 CD34+CD38- UCB cells was estimated. Using a similar approach, 
differences in SRC frequencies have been observed between the frequencies in 
UCB of 1 in 9,3x105 unfractionated cells, which was significantly higher than the 
frequency of 1 SRC in 3,Oxl 06 adult BM cells or 1 in 6,Oxl06 mobilised peripheral 
blood cells from normal donors. 161 
Administration of combinations of SCF, Flt3-L, IL-3, IL-7 and GM-CSF to 
NOD/SCID mice transplanted with CD34+Lin- UCB cells can modulate the lineage 
distribution of the human graft in vivo162 Flt3-L and IL-7 promote stromal-
independent expansion differentiation of human foetal pro-B cells in vitro. 163 In 
contrast, in vivo, Flt3-L and IL-7 (which work in synergy) did not induce T and B 
cell development, but instead a markedly reduced B cell development with a 
concomitant shift in the lineage distribution towards the myeloid lineage. 162 
The (NOD)/SCID mouse assay has provided a useful tool in the in vivo analysis of 
human hematopoiesis, although only the short-term repopulating ability of stem 
cells can be analysed due to the development of lymphomas and leakiness in 
ageing NOD/SCID mice. Furthermore, for quantitative analysis of transplanted 
human cells, NOD/SCID mouse assays are not entirely satisfactory due to large 
variations between individual mice. 
(NOD/)SCID mice are also suitable hosts for hematopoietic cells from human 
proliferative diseases such as leukemia. 156• 161, 164 Cells from patients with acute 
lymphoblastic leukemia (ALL) are known to grow in a pattem similar to the 
growth of the leukemic cells in the patients. 165• 166 This feature makes the assay a 
useful tool to study the development of the disease but also to test treatment 
regimens meant to counteract disease progression. In contrast to ALL, some acute 
myeloid leukemias (AML) grow less well in immunodeficient micel67, 168 unless 
the mice are treated with cytokines (IL-3) to stimulate leukemic proliferation169 
Similar to healthy hematopoietic cells, CD34+CD38- as well as CD34+CD38+ AML 
cells were able to give rise to colonies in vitro, but only the CD34+CD38- cells 
could re-establish leukemia in transplanted SCID mice, suggesting a hierarchy 
within the leukemic cell clone and the existence of a leukemic stem cel1. 169 
However, other studies show that CD34- AML of some patients have a similar 
capacity to initiate and maintain long-term growth of AML in vivo (SCID mice) 
and in vitro (CAFC assay) as has the CD34+ fraction. 170 This indicated that, at 
least in some patients, the immunophenotype of engrafting AML cells does not 
correspond with that of their normal counterparts andlor that the leukemogenic 
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potential of leukemic stem cells is not always lost during differentiation. 
Alternatively, the finding may support the contention that CD34 is expressed 
reversibly, dependent on activation state and independent on differentiation 
stage32 Philadelphia-chromosome positive (Ph",) leukemic cell lines and primary 
blast crisis cells from chronic myeloid leukemia (CML) patients also grow 
predominantly in immunodeficient mice, with exclusive production ofPh+ cellsl71 
Engraftment of low density or purified CD34+ ceils from chronic phase CML 
patients after injection in immunodeficient mice is 10wl72, 173 which may be due to 
low numbers of stem cells in the grafts. 
Ex vivo expansion 
Ex vivo stem cell manipulation might be necessary to expand cells to gain enough 
immature (UCB) cells for transplanting large adults or for gene therapy purposes. 
One of the current problems in stem cell expansion is that the stem cell GF receptor 
phenotype of repopUlating stem cells is not sufficiently well known. Hence, 
stimulation of suspensions of hematopoietic cells with GFs or GF combinations 
may result predominantly in activation and expansion of progenitor cells rather 
than stem cells. Stem cells may either be insufficiently stimulated, or when 
stimulated, lose repopulating activity through differentiation. Furthermore, GF 
stimulation may have an effect on the homing of stem cells as several 
hematopoietic GFs, such as IL-3 and GM-CSF, are involved in the interaction 
between stromal cells and hematopoietic stem cells174-176 Many studies have 
focussed on culture conditions in which immature cells proliferate without 
differentiation and maturation20, 177-185 To date, approximately 25 cytokines with 
prominent actions on the hematopoietic system have been identified. In early ex 
vivo expansion studies and gene transduction studies the most commonly used GF 
combination included SCF, IL-3 and IL-6, but with the cloning of new GFs such as 
TPO and Flt3-L, these combinations have become obsolete and replaced by GF 
combinations with SCF, TPO and Flt3_L186, 187 Results of transplantation studies 
in mice have shown that Flt3-L induces proliferation of highly purified 
hematopoietic progenitor cells in synergy with other GF such as IL-6, IL-3, G-CSF 
or SCF188 Using human hematopoietic cells, Flt3-L appeared to act in synergy 
with IL-3, IL-6 and SCF to induce proliferation of CD34+CD3S- BM cells and 
expansion of colony-forming units (CFU) from LTC-IC.189 The effect ofFit3-L on 
CD34+CD3S+ cells and on immature CD34+CD3S- UCB cells was less 
pronounced.l 89 However, other studies show that Flt3-L does not expand the stem 
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cell pool by itself but ratber acts as a costimulatory factor in the recruitment and 
proliferation of myeloid and lymphoid progenitors. 190 Next to the effect of SCF on 
stem cells, specific activities of SCF include promotion of erytbroid cell 
formation191 and mast cell regulation. l92 TPO is, apart from regulating the platelet 
production involved in tbe reconstitution of immature multilineage repopulating 
stem cells. 193 Certain stromal cell lines also have tbe capacity to support stem cell 
proliferation179, 194-196 Cocultured adult BM or UCB cells with allogeneic human 
stroma were assayed in CFC, LTC-IC and transplanted in irradiated NOD/SCID 
mice. The SRC frequency declined 6-fold after one week of culture. In contrast to 
this loss, the transplanted inocula of cultured cells frequently contain equal or 
higher numbers ofCFC and LTC-IC as compared to tbe inocula of fresh cells. The 
mechanisms that underlie the loss of SRC during culture on stroma is not known 
and could be due to differentiation of primitive cells during culture or changes in 
tbe expression and/or function of adhesion receptors that could affect the 
engrafunent potential of the immature repopulating cells.98 
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Gene transfer 
Strategies for efficient gene transfer into hematopoietic cells 
The hematopoietic stem cell has been an obvious target for gene-transfer because 
of its ability to permanently reconstitute the hematopoietic and immune systems 
after transplantation. A relatively small number of genetically modified 
hematopoietic stem cells could potentially generate large numbers of differentiated 
hematopoietic cells carrying and expressing an exogenous gene for long periods of 
time, possibly the life span of the recipient. 
Effective stem cell gene transduction can be used as somatic gene therapy for the 
correction of mutations or deletions as treatment of hereditary diseases only 
affecting (part of) the hematopoietic system such as adenosine deaminase (ADA) 
deficiencyl81. 197-199, chronic granulomatous disease200 or diseases affecting both 
the hematopoietic system and other organs such as Gaucher's disease201 In 
addition, genes can be introduced as a vehicle for products that are deficient in 
other organs, as an adjuvant to cancer therapy or to create resistance against 
infectious disease. Another aspect of introducing genes into primitive 
hematopoietic cells is its use in stem cell characterisation. By stable integration of 
marker genes into the DNA of purified immature hematopoietic subsets, the 
mechanisms involved in in vivo repopulation of the BM after transplantation can be 
elucidated by tracing the transduced cells and their progeny, which in tum may 
yield useful information on the option of ex vivo stem cell expansion. 
At this time point, only two of the currently available gene transfer systems can 
possibly accomplish this. The systems include viral vectors based on retroviruses 
and adeno-associated viruses (AA V). Vectors based on, for instance, adenoviruses 
and liposome-based DNA delivery methods have no potential for stable gene 
transfer at high frequencies and are therefore less useful for studying long-term 
hematopoiesis. 
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Adeno-associated virus mediated gene transduction 
Adeno-associated viruses (AA V) are non-pathogenic and replication-defective 
human parvoviruses with a single-stranded DNA genome. AA V needs co-infection 
with helper virus (for instance herpes simplex virus or adenovirus) for stable 
integration into a wide variety of hosts and are used in studies for treatment of 
hereditary diseases202. 203, anti-viral approaches to AIDS204, anti-oncogenic 
strategies205 and stem cell characterisation.206 
Retrovirus mediated gene transduction 
Retroviral vectors, the prototype based on Moloney's munne leukemia VITUS 
(MoML V), are most commonly used for transduction of hematopoietic cells. The 
genomes of these viruses contain the 3 genes gag, pol, and env, encoding proteins 
involved in virion encapsidation and assembly, reverse transcription of viral RNA 
and integration of viral DNA into host chromosomal DNA, and virus adsorption to 
the target cells, respectively207 Upstream of the gag, pol and env genes the 
packaging signal (<p) is located (Figure 3). This signal directs specific packaging of 
full-length viral RNA into virions. The protein coding sequences (gag, pol and env) 
are not included in the retroviral vector, but are provided by packaging cell lines, 
transfected with the viral genes. Packaging cell lines that by themselves can only 
produce virus particles without viral genome or soluble viral proteins, can package 
retroviral genomes into virions208 Because the packaging sequence is devoid of 
the packaging signal <p and the coding sequences for viral proteins in the retrovirus 
vector are replaced by a gene of interest, the virus particles can only go through 
one round of replication and are therefore replication defective (Figure 4). 
Retrovirus genomes contain long untranslated regions at both their 5' and 3' ends, 
the so-called long-terminal repeats (LTR) which include signals needed for the 
initiation of transcription by RNA polymerase and for 3' cleavage and 
polyadenylation of transcripts. 
Depending on the specific envelope gene (env) expressed in individual packaging 
cell lines, replication-defective retroviruses can be generated with an ecotropic 
(infectious to rodent cells) or an amphotropic (infectious to cells of several 
mammalian species including humans) host range. Ecotropic packaging cell lines 
synthesise specific envelope proteins different from amphotropic cell lines, which 
bind to specific cell surface receptors on the target cells. The amphotropic 
(MoML V) receptor (sodium-dependent phosphate transporter-2; Pit-2 or receptor 
for amphotropic murine retrovirus-I; Ram-I) shows significant sequence similarity 
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with the gibbon ape leukemia virus (GAL V) receptor (sodium-dependent 
phosphate transporter-I; Pit-lor gibbon ape leukemia virus receptor-I; GLVR-l), 
although the binding to these receptors by virions occurs without cross-
interference.209 
'1'+ 
5' LTR poll gag I env gene of 3' LTR interest 
Figure 3. Schematic presentation of the structure ofa retrovirus vector containing gag, pol 
and env sequences, the packaging signal (<p) and sequences of the gene of interest bernreen 
the 5' and 3' long-terminal repeats (LTR). 
The level of expression of the amphotropic receptor, as measured by mRNA levels, 
appears low in human and primate CD34+ hematopoietic cells which has led to 
speculation that the low level of expression of the receptor protein is among the 
causes for the low level transduction using amphotropic-packaged vectors210-212 
Most human hematopoietic cells analysed express higher levels of the gibbon ape 
leukemia virus (GAL V) receptor GL VR-1213, 214 and this might explain the higher 
gene transfer into human progenitors using viruses packaged into the pseudotyped 
GAL V envelope protein as compared to viruses that express the amphotropic 
envelope21S 
Vectors based on the onco-retroviruses, induding MoML V depend on cell 
proliferation for integrating genes in the genome of the target cells. Stem cells are 
not cycling and consequently resistant to gene transfer if not appropriately 
stimulated.216 Lentiviruses (a subgroup of retroviruses, an example being the 
acquired immune deficiency syndrome virus HIV) differ in that they are relatively 
independent of cell division and therefore might facilitate the transduction of 
quiescent human hematopoietic stem cells217 Unlike murine retroviruses, 
lentiviruses have a complex genome that, in addition to the essential structural 
genes, env, gag and pol, also contains regulatory (tat and rev) and accessory genes 
(vpr, vif, vpu and nej), with which a pre-integration complex can be made to 
traverse an intact membrane of the nucleus of a target cell21S However, 
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lentiviruses can not transduce GO cells because they need reverse transcriptase 
activity (present in Gl phase) to translate the viral RNA genome into DNA219, 220 
Thus, lentiviruses can infect nondividing cells, but they need a basal activity 
(reverse transcriptase) for integration into host DNA. The lentiviral vector is 
speculated to be superior to the retroviral vector for the transduction of non-
dividing, primitive hematopoietic progenitors221 Recent studies reveal a high 
efficiency transduction using a lentiviral vector based on HIV, in the absence of 
cytokine stimulation which resulted in trans gene expression in multiple lineages of 
human hematopoietic UCB cells transplanted into NOD/SCID mice222, 223 
However, the transduction efficiency of the retroviral vector used in this study for 
comparison was exceedingly low compared to that found in other studies224 and 
the transduction levels of repopulating hematopoietic cells with the lentiviral 
vectors were similar to those found with retrovirus vectors in previous studies224 
In addition, transduction of primitive CD34+CD3S- human hematopoietic cells 
resulted in transduction levels of 12% in contrast to an amphotropic retroviral 
vector which could not transduce this cell subset at a1l221 Although high levels of 
transduction can be reached, the possibility of recombination between transfer and 
packaging vectors, which may give rise to replication-competent virus with 
pathogenic potential, gives rise to safety concerns.225 To eliminate this potential 
risk, vectors derived from nonhuman lentiviruses such as simian immunodeficiency 
virus, bovine immunodeficiency virus, or equine infectious anemia virus could be 
developed226, 227 Also the construction of self-inactivating HIV vectors (by 
replacement of part of the upstream L TR in the vector construct by constitutively 
active promoter sequences which abolishes the LTR promoter activity but does not 
affect the vector titers or the trans gene expression in vitro) may improve the 
biosafety of HIV -derived vectors226, 228, 229 
Selectable reporter molecules 
Retroviral vectors encoding selectable reporter molecules have been used to study 
the efficiency of transduction in immature hematopoietic cells. The most widely 
used of these have been intracellular components that confer resistance to toxic 
compounds such as neomycin230.232, hygromycin233, 234, methotrexate235.238, 
mycophenolic acid239 and various chemotherapy agents.240·243 The neomycin 
phosphotransferase gene (neo) has proven to be particularly useful in tracking 
retrovirus transduced human hematopoietic cells, both in vitro as in vivo, and has, 
for instance, been used for the identification of cells capable of causing leukemic 
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relapse after autologous BM transplantation244-246 These intracellular markers are 
less suitable for the enrichment of immature and transduced hematopoietic cells, 
mostly because selection requires time-consuming exposure to toxic drug 
concentrations under in vitro culture conditions that stimulate cell division and 
terminal differentiation. The bacterial j3-galactosidose gene (LacZ) has also been 
used as a selectable reporter molecule for hematopoietic cells247-250 The 
expression of the gene is measured by a colorimetric test for its product, the 
enzyme j3-galactosidose. However, the relatively high endogenous j3-galactosidose 
activity in some cell types and the requirement for transporting fluorogenic 
substrates across the cell membrane while maintaining cell viability have limited 
its application. 
Transduction of hematopoietic stem cells with retroviral vectors encoding marker 
molecules expressed at the cell surface offers several advantages, such as rapid, 
non-toxic and quantitative analysis and selection of the transduced cells by flow 
cytometry. Oenes encoding for molecules that are expressed on the cell surface of 
various cell types such as the human multi-drug resistance (MDRl) gene251 , mouse 
CD24252. 253, CD9254 or nerve growth factor255, are incorporated into vectors. 
Transduced cells can be identified after staining with a specific antibody 
conjugated to a fluorochrome by flow cytometry. Disadvantages of this type of cell 
surface markers are the low-level expression of the reporter molecule in the target 
cells, the requirement for specific antibodies to detect the marker and relatively 
large genes used as a selectable marker, leaving limited space for other genes of 
interest. In contrast to these markers, use of the autofluorescent green fluorescent 
protein (OFP) or its derivatives allows rapid identification of transduced cells by 
fluorescence microscopy or flow cytometry in living cells in real time without 
additional staining steps. 
The Enhanced Green Fluorescent Protein (EGFP) marker gene 
In nature OFP is produced by the jellyfish Aequorea victoria found in the Pacific 
Ocean. Light is emitted when calcium binds to the photoprotein aequorin in 
response to shaking or attack. In 1994 Chalfie et al. demonstrated that OFP, 
expressed in prokaryotic cells (Escherichia coli) and eukaryotic cells 
(Caenorhabditis elegans) is capable of producing a strong green fluorescence when 
excited by blue light256 Purified OFP (a protein of 238 amino acids257) absorbs 
blue light (maximally at 395 run) and emits green light (peak emission at 509 
run)258.259 The fluorescence is stable with virtually no photobleaching.256 
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Retrovirus vector lS'LTRI 'P IgeneH3'LTRr 
Producer cell 
rctrovirai vector 
1S'LTR I (,D I gencH 3'LTR~ e 
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Target cell e 
e 
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Figure 4. Retroviral mediated transduction. The retroviral vector, without sequences for viral 
proteins, is introduced into the packaging cell line that by itself can only produce empty 
virus particles without the viral genome. Within the packaging cell line, the retroviral 
genomes are packaged into virions and released outside the cell. These virus particles are 
replication-incompetent as they lack the essential gag, pol and env sequences. After infection 
of a target cell via specific receptors, the virus RNA will be reverse transcribed into DNA 
and integrated into the target cell DNA after which it can be expressed, 
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Because wt-GFP produces a weak (but stable) green fluorescence signa!, several 
GFP variants have been created which shift the maximal excitation peak to 
approximately 490 urn and are better suited for detection of expression by 
fluorescence microscopy and flow cytometry. The GFP (S65T) variant and its 
"humanised" form, hGFP (S65T) contain a Ser to Thr substitution at amino acid 
position 6526°; in the red-shifted GFP variant RSGFP the amino acids Phe-64, Ser-
65 and Gln-69 are substituted by Met, Gly and Leu, respectively261; the enhanced 
GFP (EGFP) contains the double amino acid substitution ofPhe-64 to Leu and Ser-
65 to Thr262. 263 In addition, hGFP (S65T) and EGFP are optimised to obtain 
higher expression levels in mammalian cells by silent substitution of Aequorea 
victoria codons for the preferred human codons (i.e. humanised)263 The relative 
intensities of peak green fluorescence observed with different GFP mutants were in 
the order EGFP>hGFP(S65T»GFP-PTS I or RSGFP>wtGFP 264 
Gene transfer of hematopoietic cells in transplantation assays 
Early experiments using retroviral gene transfer showed that while CFU and L TC-
IC are easily transduced, these gene-marked cells do not contribute significantly to 
the repopulation of engrafted NOD/SCm mice, suggesting that the efficiency of 
gene transfer into SRC is low265 It is, therefore, of importance to study the 
characteristics of transduced cells in in vivo models. 
In rodent models, efficient and reproducible gene transfer to a high percentage of 
long-term repopulating stem cells has been achieved and long-term expression of 
introduced genes in several lineages243. 266-26S In large animal models, retroviral 
gene transfer has been much less efficient, although long-term expression of 
transferred genes has been shown.23S. 269-274 
Gene transduction in large animals (canine, nonhuman primates) has shown 
disappointing results on the long-term repopulation of the transduced 
hematopoietic precursor cells, possibly caused by the lack of receptors expressed 
for the retroviral vectors used in most studies. Also the low number of 
hematopoietic stem cells in most target populations might lead to low efficiencies. 
Another explanation could be that hematopoietic stem cells might be inherently 
resistant to transduction or (transduced) stem cells may be unlikely to proliferate 
due to their quiescent nature. The problem might be of a more technical nature in 
that the conditions during the transduction procedure may not be optimal275 
To stimulate hematopoietic stem cells to enter the cell cycle, donors have been 
conditioned in vivo with growth factors (G-CSF / SCF)276 and/or non-specific 
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killing of differentiated blood cells (5-fluorouraciI277-279 and hydroxy-urea280). 
Also ex vivo incubation of bone marrow cells with growth factorsl77-184 with or 
without stromallayersl79. 195 has been used to stimulate stem cells into cycle to 
increase the gene transduction levels. For instance, the transduction efficiency of 
purified CD34+CD3S· UCB cells in the presence of combinations with Flt3-L, SCF, 
1L-6, TPO, IL-3, IL-6, G-CSF was tested281 , and resulted in the largest 
transduction levels (after transplantation into NOD/SCID mice and in LTC-IC 
assays) with Flt3-L, SCF, IL-6, TPO or Flt3-L, SCF, IL-3, IL-6, G-CSF. 
Optimisation of gene transfer protocols 
Stimulation with different growth factor combinations and culturing on stromal 
layers has been shown to result in increased efficiency of gene transfer into 
primitive cells. Physical methods such as adherence to human fibronectin have also 
been shown to increase the likelihood of target cell-vector interaction. Fibronectin 
has been successful in improving gene transfer efficiency into hematopoietic cells 
in vitro by colocalising the virus particles and the target cells. Its use eliminates the 
need for cocultivation, the use of polycations such as polybrene (hexadimethrine 
bromide) or protamine sulphate, and extended in vitro exposure to growth factors 
and/or stromal cells282. 283, thus improving the chance that cells with repopulating 
ability are maintained. Polycations have essentially the same effect as fibronectin; 
they neutralise the opposing charges on virus particles and the target to facilitate 
transduction. Fibronectin is an extracellular matrix molecule which is abundantly 
expressed in the BM microenvironment.284. 285 It participates in cell adhesion 
through at least 3 cell binding sites (Figure 5), including a cell binding domain 
(CBD) which mediates adhesion via the integrin VLA-5, the heparin binding 
domain which interacts via cell surface proteoglycan molecules, and the CS I 
sequence which mediates adhesion via the integrin VLAA. Adhesion of primitive 
hematopoietic stem cells to fibronectin takes place at the C-terminal cell adhesion-
promoting sequence which is formed by the combination of the CS I peptide and 
the adjoining sequences in the heparin binding domain (type IIII2-14) of 
fibronectin286-288 
Retrovirus particles bind directly and with high efficiency to sequences within the 
type III12-14 repeats of fibronectin. A recombinant human fibronectin fragment 
(CH-296, also termed retronectin®) which consists of the 3 binding sites (Figure 
5B), was most efficient in transducing hematopoietic progenitor cells with 
efficiencies comparable to co-culture of the target cells directly on the producer 
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cells282 The fibronectin fragment is thought to bring retroviruses and target cells 
into close proximity, thus improving the likelihood that these cells will interact282 
Subsequently, short-range-specific binding is mediated by the envelope protein on 
the retrovirus and the cognate receptor on the cell (for instance GAL V-receptor or 
MoMLV-receptor), a process called adhesion strengthening289 Another parameter 
which can be expected to determine the efficiency of retroviral supernatant 
transduction is the virus-to-target cell ratio (multiplicity of infection, or m.0.i.)290 
o Fibronectin type I repeat (45 AA) 
CH-296 
o Fibronectin type II repeat (60 AA) 
D Fibronectin type III repeat (90 AA) 
Hematopoietic progenitor cell cell su.rf_a_ce_"\, 
Recombinant human 
fibronectin fragment CH -296 
CBD heparinCSl 
-hepannCSl 
t 
Retroviral particles viral surface ~ =~---I~)------
COOH 
ss 
II 
Figure 5. Schematic representation of human fibronectin a-chain and the recombinant 
human fibronectin fragment (CH-296). The fibronectin fragment contains three domains at 
which target cells and virus particles can bind. The cell binding domain (cell, CBD) binds 
hematopoietic cells via the integrin VLA-5. The CS1 sequence is known to bind cells via 
the integrin VLA-4 and the heparin binding domain binds cells and virus particles via 
proteog1ycans. Adapted from Williams DA. et ai, 1991286 
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A linear relation exists between amphotropic retrovirus supernatant-dilution and 
gene transfer efficiency to NIH!3 T3 cells suggesting that a high virus titer is of 
importance for increasing transduction levels. In co-cultivation assays the direct 
relation between virus titer and transduction efficiency was not found291 
Additional techniques to improve the transduction efficiency include centrifugation 
of the retrovirus and the target cells292. 293, increasing the viral titer via filtration, 
the use of roller bottles or other cell culture systems292. 294. 295 or 'flow through' 
technology296 Cryopreservation of target cells before transduction with an 
amphotropic retroviral vector upregulates the amphotropic receptor (amphoR) 
levels297-299, which has been reported to result in higher transduction 
efficiency.300 It is possible that other retroviral receptors, such as the GAL V 
receptor (Pit-lor GL VR-l) which is present on hematopoietic progenitor cells, is 
upregulated as well following cryopreservation. 
In addition to approaches to optimise gene transfer in vitro, in vivo approaches to 
increase the transduction efficiency may be relevant. Hematopoietic stem cells 
could be manipulated in vivo to trigger the cells into cycle, for instance, using 5-
fluorouracil (5_FU)277-279 which has extensively been used in mouse experiments 
but not in large animal models, or hydroxy-urea as an S-phase killer280 to 
synchronise the cell cycle. Also an increase of the viral-receptor density on the 
target cells might be of importance to reach high transduction efficiencies in long-
term repopulating cells. Growth factor stimulation is known to alter receptor 
expression 182 and it is conceivable that receptor expression of certain retroviral 
receptors can be affected by administration of various growth factors. Bone 
marrow or PB obtained from rhesus monkeys after treatment with hematopoietic 
GF (G-CSF and SCF) were more efficiently marked than cells obtained from 
untreated animals276 
Rationale and outline ofthis thesis 
This thesis is firstly based on the hypothesis that hematopoietic stem cell 
characterisation requires the (further) development of transplantation assays. For 
human hematopoietic stem cells, such assays are not feasible other than the use of 
specifically adapted experimental animals as recipients or the use of a nonhuman 
primate species as a model. Hence, the use of SCID mice as recipients of human 
35 
Introduction 
nonnal and malignant stem cells was examined in detail with emphasis on its 
quantitative use, and advantage was taken of the existing quantitative model in 
rhesus monkeys301-304 Second, it was hypothesised that 1) the development of 
retrovirus mediated gene transfer required elucidation of stem cell biology rather 
than the development of novel vectors305 and 2) gene marking of in vivo 
repopulating stem cells serves stem cell characterisation and the development of 
gene therapy equally well. 
Based on these hypothesis the studies summarised in this thesis are directed at 
gaining insight into the characteristics of cells capable of multilineage in vivo 
repopulation. The approach chosen involved the further development of 
transplantation assays in immunodeficient (ScrD) mice l37. 145, 158,306 for nonnal 
and leukemic human stem cells (chapters 2, 3 and 6). In addition, gene marking of 
purified hematopoietic cell subsets using a fluorescent marker was developed to be 
able to track the transplanted cells after transplantation in the mouse assay (chapter 
4). Marking and transplantation of distinct hematopoietic cell subsets, for instance 
purified Philadelphia-chromosome + (Ph l and Ph- cells from chronic myeloid 
leukemia patients, could be used to study the possible selective outgrowth of such 
cells in vivo. For genetic marking the gene encoding the enhanced version of the 
green fluorescent protein (EGFP) was selected for the transduction of human 
umbilical cord blood immature cells and rhesus monkey BM cells, based on 
previous studies in the laboratory264. 307, 308 The use of the autofluorescent EGFP 
gene as a marker allows visualisation of the transduction efficiency and tracking of 
the fate and progeny of the transplanted cells in real time, without additional steps. 
The EGFP is transduced using retroviral vectors which were expressed using 
amphotropic and pseudotyped virus producer cell lines (Am12 and PGl3, 
respectively). Although studies with mice have confinned that retrovirus vectors 
are efficient vehicles to integrate exogenous genes into the DNA of pluripotent 
repopUlating stem cells, it has been difficult to achieve a similarly high efficiency 
of gene transfer into human stem cells. Therefore, analysis of the variables 
influencing transduction efficiency and optimisation of the transduction protocol 
was of major importance to gain high transduction levels in stem cells (chapter 5), 
making use of co-localisation of virus vector and target cells282, 283, and novel 
growth factors to stimulate immature cells, in particular thrombopoietin, c-kit 
ligand and Flt3 ligand. Subsequent transplantation of transduced UeB cells into 
NOD/ScrD mice and rhesus BM cells into rhesus monkeys enabled tracking of the 
short- and long-tenn repopulating cells. The thesis is concluded by a general 
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discussion (chapter 7) relating the progress made to concurrent other studies and 
developments. 
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Abstract 
In vivo expansion and multilineage outgrowth of human immature hematopoietic 
cell subsets from umbilical cord blood (UCB) were studied by transplantation into 
hereditary immunodeficient (ScrD) mice. The mice were preconditioned with 
ChMDP-liposomes to deplete macrophages and 3.5 Gy total body irradiation 
(TBl). As measured by immunophenotyping, this procedure resulted in high levels 
of human CD45+ cells in SCID mouse bone marrow (BM) 5 weeks after 
transplantation, similar to the levels of human cells observed in non-obese diabetic 
(NOD) /SCID mice preconditioned with TBL Grafts containing _107 
unfractionated cells, _105 purified CD34+ cells or 5xlO' purified CD34+CD3S' cells 
yielded equivalent numbers of human CD45- cells in the SCID mouse BM. which 
contained human CD34- cells, monocytes. granulocytes. erythroid cells and B-
lymphocytes at different stages of maturation. Low numbers of human GpA-
erythroid cells and CD41- platelets were observed in the peripheral blood (PB) of 
engrafted mice. CD34-CD3S- cells (5xI04/mouse) failed to engraft. while CD34' 
cells (107/mouse) displayed only low levels of chimerism, mainly due to mature T 
lytnphocytes. Transplantation of graded numbers of DCB cells resulted in a 
proportional increase of the percentages of CD45- and CD34+ cells produced in 
SCID mouse BM. In contrast. the number of immature, CD34-CD3S' cells 
produced in vivo showed a second-order relation to CD34+ graft size. and mice 
engrafted with purified CD34-CD3S' grafts produced IO-fold fewer CD34+ cells 
without detectable CD34-CD3S' cells than mice transplanted with equivalent 
numbers of unfractionated or purified CD34+ cells. These results indicate that 
SCID repopulating CD34-CD3S' cells require CD34-CD3S- accessory cell support 
for survival and expansion of immature cells. but not for production of mature 
multilineage progeny in SCID mouse BM. These accessory cells are present in the 
purified. non-repopulating CD34+CD3S+ subset as was directly proven by the 
ability of this fraction to restore the maintenance and expansion of immature 
CD34-CD3S' cells in vivo when added to purified CD34-CD3S' grafts. The 
possibility to distinguish between maintenance and outgrowth of immature 
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repopulating cells in SCID mice will facilitate further studies on the regulatory 
functions of accessory cells, growth factors (GF) and other stimuli. Such 
information will be essential to design efficient stem cell expansion procedures for 
clinical use. 
Introduction 
Traditional sources of hematopoietic stem and progenitor cells for transplantation 
include autologous and allogeneic bone marrow and mobilised peripheral blood 
(PB). Recently human umbilical cord blood (VCB) has been shown to be a realistic 
alternative source of stem cells1 . 2 VCB contains cells of all hematopoietic 
lineages including cells that can produce granulocyte-macrophage colony forming 
unit (GM-CFV) after extended long-term stromal cell supported culture. Most of 
these long-term culture-initiating cells (LTC-IC) are found in the small subset of 
CD34+CD3S- cells3 The ability to cryopreserve, select, and expand progenitors 
without loss of proliferative capacity4 makes VCB an appropriate model to identify 
immature hematopoietic cell subsets involved in hematopoiesis in vivo, select 
appropriate growth factor (GF) combinations and culture conditions to maintain 
and expand stem cells in vitro, and design optimal gene transfer conditions aimed 
at efficient and stable transduction of transplantable stem cells.5 
Hereditary immunodeficient scm and NOD/scm mice are useful recipients to 
assess human stem cell capacities in a transplantation assay and appear particularly 
suitable to assess the outgrowth of purified VCB cell subsets and the effects of ex 
vivo manipulation on hematopoietic capacities after transplantation. Several 
approaches for engrafting immunodeficient mice with normal or leukemic human 
hematopoietic cells have been described. The most frequently used systems involve 
injection of mobilised human PB, BM6 or VCB cells in sublethally irradiated 
mice7. 8, electively followed by human growth factor (GF) treatment9-12 and/or 
cotransplantation with non-repopulating CD34- accessory cells l3 , human BM long-
term culture-derived stromal cells or rodent cell lines that produce human GFs14 
Transgenic scm mice expressing the genes for human IL-3, GM-CSF and SCF 
have also been used to promote human cell engraftmentl5 , while human fetal liver, 
thymusl6. 17 and/or bone fragrnent18 implantation has been used to create a human 
micro-environment in the mouse. Injection with human cytokines or other 
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additional treatment is not required to establish high-level human cell engraftment 
after transplantation of human UCB cells in immunodeficient mice, which 
suggested that neonatal cells either respond differently to the murine 
microenvironment or provide their own cytokines in a paracrine fashion7 , S 
However, analysis of the hematopoietic potential of UCB cells in scm is limited 
by the large number of cells required to achieve significant engraftment levels, 
possibly because of low seeding efficiencies of stem cells or elimination of 
transplanted cells by natural killer (NK) cells or the mononuclear phagocytic 
system, which are intact in scm mice, More reproducible and higher levels of 
engraftment with smaller graft sizes have been achieved with NOD/SCID mice, 
which has been attributed to the lack of functional macrophages, NK cells and 
complement activity in this mouse strain19 Specific elimination of phagocytic cells 
in spleen and liver of scm mice can be achieved within 24 hours after a single iv. 
Injection of liposome-encapsulated dichloromethylene diphosphonate 
(CI2MDP)20-22 As shown recently for human acute myeloid leukemia (AML) and 
UCB cells, macrophage-depleted scm mice supported the production of similar 
levels of human cells from 10-fold fewer transplanted cells as compared to SCID 
mice conditioned with TEl alone. For AML cells, preconditioning of scm mice 
with liposomes led to similar levels of engraftment as observed in NOD/SCm mice 
which suggested that macrophages have a prominent role in eliminating injected 
human cells in scm mice22 The present study was undertaken to quantitatively 
analyse the maintenance and outgrowth of distinct UCB immature cell subsets in 
macrophage-depleted scm mice and to assess the hematopoietic cell lineages 
produced. 
Material and methods 
Human umbilical cord blood cells 
UCB samples were obtained after informed consent in conformity with legal 
regulations in The Netherlands from placentas of full-term normal pregnancies. 
Mononucleated cells were isolated by Ficoll density gradient centrifugation (1.077 
g/cm2 , Nycomed Pharma AS, Oslo, Norway), and were cryopreserved in 10% 
dimethylsulphoxide, 20% heat-inactivated fetal calf serum (FCS) and 70% Hanks 
Balanced Salt Solution (HESS, Gibco, Breda, The Netherlands) at -196°C as 
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described23 After thawing by stepwise dilution in HBSS containing 2% FCS, the 
cells were washed with HBSS containing 1 % FCS and used for flow cytometric 
analysis, transplantation into SCID mice (unfractionated grafts) or subset 
purification. 
Subset purification 
Purification of CD34+ cells was performed by positive selection using Variomacs 
Immunomagnetic Separation System as described24 (CLB, Amsterdam, The 
Netherlands). The percentage CD34+ cells in the unseparated population 
(unfractionated UCB) and in the purified CD34- and CD34- fractions was 
determined by FACS-analysis. For isolation of CD34+CD38+, CD34-CD38+/- and 
CD34~CD38- subsets, purified CD34~ cells were stained with fluorescein 
isothiocyanate (FITC) and R-phycoerythrin (PE) conjugated antibodies against 
human CD34 and CD38 (CD34-FITC, CD38-PE, Becton Dickinson) for 30', on ice 
in HFN (HBBS, 2% (wt/vol) FCS, 0.05% (wt/vol) sodium-azide) containing 2% 
(vol/vol) normal human serum (NHS). After incubation, the cells were washed 
twice, resuspended in HBSS and sorted using a FACS Vantage flow cytometer 
(Becton Dickinson, San Jose, CAl. 
Transplantation of UCB cells into immunodeficient mice 
Female, specified pathogen-free (SPF) CB-17-scidlscid (SCID) mice, 6 to 9 weeks 
of age, were obtained from Harlan, CPB, Austerlitz, The Netherlands. NODILtSz-
scidlscid mice (NOD/SCID) were obtained from The Jackson Laboratory (Bar 
Harbor, Maine, USA). The mice were housed under SPF conditions in a laminar 
airflow unit and supplied with sterile food and acidified drinking water containing 
100 mg/l ciprofloxacine (Bayer AG, Leverkusen, Germany) ad libitum. The plasma 
Ig levels of the mice were determined with an ELISA using a sheep anti-mouse 
antibody reacting with mouse IgG (Boehringer Mannheim Biochemica, Penzberg, 
Germany) and animals with plasma Ig levels over 40 ).Ig/ml were excluded25 To 
deplete macrophages, the SCID-mice were injected iv. into a lateral tail vein with 
200 ).II liposome stock solution containing di-chloromethylene di-phosphonate 
(ChMDP, a gift of Boehringer Mannheim GmbH, Germany) one day prior to 
transplantation of hematopoietic cells26 In previous studies22 with human acute 
leukemia and UCB cells this approach required ten-fold fewer cells for uniform 
engraftment than in SCID mice conditioned with TBI alone. All mice received total 
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body irradiation (TBl) at 3.5 Gy, delivered by a 137 Cs source adapted for the 
irradiation of mice (Garnmacell, Atomic Energy of Canada, Ottawa, Canada), 2-4 
hours before transplantation. The transplants were suspended in 200 Jll HBSS 
containing 0.1 % BSA (Sigma) and injected iv. into a lateral tail vein. Transplanted 
cell numbers were 107 (unfractionated and CD34- cells), 105 (CD34- cells), 5xl04 
(CD34~CD38+ cells) and 5xl03 (CD34+CD38- cells) unless stated otherwise in the 
results. 
In vitro colony assay 
Unfractionated and purified CD34+ and CD34- grafts as well as chimeric mouse 
BM samples were assayed for the presence of GM-CFU and erythroid burst-
forming units (BFU-E) by in vitro colony formation in viscous methy1cellulose 
culture medium as previously described.27-29 Briefly, unfractionated and CD34-
cells were plated at a concentration of 25,000 per 35 mm Petri dish (Becton 
Dickinson), CD34+ purified grafts at 1000 per dish and chimeric mouse BM at 
50,000 per dish. Culture medium consisted of 1 ml Dulbecco's medium (Gibco, 
Gaithersburg, MD), containing 0.8% (wt/vol) methy1cellulose, 5% (vol/vol) FCS, 
and further supplemented with 1.5% (wt/vol) BSA, 10 mg/ml insulin, 0.3 mg/ml 
human transferrin, 15 mmollL B-mercaptoethanol, 0.1 mmollL sodium selenite, 1 
mg/ml nucleosides, 15 JlmollL linoleic acid, 15 JlmollL cholesterol, 100 U/ml 
penicillin, and 50 mglml streptomycin. For BFU-E, cultures were supplemented 
with 0.2 mmollL bovine hemin (Sigma, St_ Louis, USA), 200 ng/ml human SCF 
and 4 U/ml (25 Jlg/ml) human recombinant Epo (Behringwerke AG, Marburg, 
Germany). For GM-CFU, cultures were supplemented with 5 nglml human 
recombinant GM-CSF (Behringwerke AG, Marburg, Germany), 200 ng/ml SCF 
and 30 ng/ml human recombinant IL-3. The cultures were maintained in a 
humidified atmosphere of 10% CO2 at 37°C for 14 days, after which the colonies 
were counted. Data of duplicate dishes were expressed as average number of 
colonies per 105 cells plated. 
Tissue collections and analysis 
Mice were examined at a single time point, 35 days after transplantation, to enable 
meaningful comparisons between experiments, because individual hematopoietic 
subsets show differences in engraftment kinetics in immunodeficient mice. 12 Mice 
were killed by CO2 inhalation followed by cervical dislocation in accordance with 
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institutional animal research regulations. From each mouse, both femurs were 
collected and BM cell suspensions were prepared by flushing. After counting, the 
cells were cultured in colony assays and analysed by flow cytometry to determine 
the percentage of human cells in the mouse bone marrow. Cells were suspended in 
HBSS containing 2% (vol/vol) FCS, 0.05% (wt/vol) sodium azide, 2% (vol/vol) 
human serum and 2% (vol/vol) mouse serum and stained for 30' at 4°C with the 
pan-leukocyte surface marker CD45-FITC antibody and with CD33-PE antibody. 
Positive samples were further analysed by incubation with FITC and PE labelled 
mouse monoclonal antibodies to human CD34, CDI9, CDI6, CDI5, CD38, CD33, 
CD56, CD4, CD8 (Becton Dickinson Immunocytometry Systems, San Jose, CA, 
USA), and glycophorin A (GpA), CD3, CD71 (Dako AlS, Denmark). Parallel 
samples were incubated with isotype matched control antibodies. Cell samples of 
non-transplanted mice were stained as negative controls. Fluorescence was 
measured using a F ACScan flow cytometer and Lysis II software (Becton 
Dickinson, USA). Dead cells were excluded by adding I !1g/ml propidium iodide 
(PI) and gating for PI" cells in the FL3 (PI) channel. For all samples 10,000 events 
were collected in a gate for PI" cells. To quantitate CD34+ subsets in selected 
samples, 1,000 - 10,000 events were also collected in a gate that included all viable 
human CD34+ cells. CD34+ and CD34+CD38" expansion were calculated on the 
assumption that one femur contains 8.5% of all bone marrow cells.30 
10' cr---~----
eD4S-FITe 
Figure 1. Flow cytometric analysis of chimeric mouse bone marrow stained with CD45-
FITC vs. CD33-PE (A), and CD45-FITC vs. CD34-PE (B). BM of non-transplanted mice 
showed no staining with the CD45-FITC (not shown) or CD33-PE antibody (C). 
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In a number of experiments, peripheral blood was collected weekly from the tail 
vein and analysed for the presence of human GpA + erythrocytes and CD41 + 
platelets, by flow cytometry. Blood samples were collected in EDTA coated tubes 
and stained with CD41-FITC (PharMingen, San Diego, USA) and GpA-FITC, 
respectively (Dako AlS, Denmark) in HBSS with 2% (vol/vol) FCS, 0.05% 
(wtlvol) sodium azide, 2% (vol/vol) human serum 2% (vol/vol) mouse serum and 2 
gIL EDTA for 30' at 4°C. Cell samples of non-transplanted mice and human blood 
cells were stained as controls. 
Statistical and regression analysis 
Results are expressed as individual data or as arithmetic mean ± standard deviation. 
The regression analysis of the percentage of human CD45-, CD34+ and 
CD34+CD3S- cells in the chimeric BM as a function of the number of CD34+ cells 
transplanted was done by plotting the data on a double logarithmic scale and 
calculating the regression using the general formula y = axb. By this method, an 
exponent b=l proves first order (single-hit) kinetics, i.e., direct proportionality 
(linearity) of chimeric cell numbers and cells transplanted, while an exponent b=2 
demonstrates second order (two-hit) kinetics. The frequency of repopulating cells 
in the scm mice was approximated using Poisson statistics. 
Results 
Chimeric bone marrow analysis 
Chimerism in scm mouse bone marrow was assessed by flow cytometric analysis 
35 days after UCB transplantation. Typical results of chimeric bone marrow 
stained with CD45-FITC vs. CD33-PE and CD45-FITC vs. CD34-PE are shown in 
Figure IA and IB, respectively. The percentage of CD45+ cells was used as a 
measure for engraftment levels of human cells in the mouse BM. Only mice with 
percentages larger than 1% CD4S- cells were considered to be engrafted. Positive 
staining for any of these markers was not found in non-transplanted mice (Figure 
IC and data not shown), demonstrating the specificity of the antibodies for human 
cells. As shown in Figure IA and IB, the CD4S- cells were heterogeneous with 
respect to CD33 and CD34 expression. 
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Parallel groups of mice were injected with unfractionated mononucleated UCB 
cells or with purified CD34" or CD34- cells (Figure 2) in scm mice conditioned 
with either TBI or TBI and macrophage depletion, or in TBI conditioned 
NOD/SCm mice. Transplantation ofunfractionated mononucleated UCB cells into 
macrophage-depleted SCID mice resulted in more prominent engraftment levels 
compared to scm mice conditioned with TBI alone. After transplantation with 107 
unfractionated or 105 purified CD34+ cells, the macrophage-depleted scm mice 
showed similar levels of chimerism as NOD/SCID mice preconditioned with TBI. 
CD34- cells (107 cells transplanted) did not result in high levels of chimerism in 
either mouse strain (Figure 2). 
Table 1. Engraftment ofUCB cells in pre-conditioned scm mice 
CD34+ cells CD34"'CD3S- cells 
Graft Chimcrict % Chimerism CelJsl E\.-paw:.ion CclJsl £'\-pansion 
Size* micdInjectcd (CDi:)ccl!s) MouscBM fucto, mouscBM facto, 
x106 x106 
unliact 10' '22fJ.2 34.5±193! 1.l±1.4§ 12.9±192 1.S4±2.7 2.19±4.92 
CD34' 10' 5/18 7.8±S.6 O.1±O.1 4.0±3.7 0 0 
CD34+ 10' 35/38 20.4±163 l.1±O.9 14.1±IS.6 6.9±132 1O.8±16.6' 
CD34'CD3S+ 5x104 1/4 1.7 0 0 0 0 
CD34+CD3S" 5xlcY 4/6 IS.4±S.7 O.1±O.1 18.6±52 0 0' 
* % CD34+ cells in graft: unfract. UCB 0.7 - 3.1 %, CD34+ 77- 83% and CD34- 0.1 - 0.6% 
-;- mice are considered chimeric at> 1 % CD45+ cells 
:; mean = SD of chimeric mice, results of 5 UCB 
§ CD34- BM cells, calculated on the assumption that I femur represents 8.5% of all BM 
ce11s30 
, significantly different from unfractionated graft (p=0.03, Fisher's exact test) 
As shown in Table I, transplantation of 107 unfractionated cells from 5 different 
UCB samples resulted in high levels of chimerism in all mice (n=22) transplanted. 
Transplantation of 105 purified CD34+ cells also resulted in high levels of human 
cells in 35 out of38 mice, whereas mice transplanted with ]07 CD34- cells showed 
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only low levels of engraftment in 5 out of IS mice transplanted. These results 
demonstrate that relatively low numbers of purified CD34~ UCB cells are capable 
of proliferation in the macrophage-depleted SCID mouse microenvironment 
without the support of accessory cells or addition of hematopoietic growth factors. 
The CD34+ cells were further separated into a CD3S~ subset (-50% ofCD34+ cells 
containing >90% of clonogenic progenitors) and a CD3S' subset (-5% of the 
CD34+ popUlation, enriched for immature, multipotent progenitors31 ) and 
transplanted into preconditioned SCID mice; cell numbers were 5xl04 and 5x103, 
respectively. The CD34+CD3S' subset showed high levels of engraftment in 4/6 
mice with chimerism levels similar to those obtained with 20-fold larger numbers 
of CD34+ cells and 200-fold larger numbers of unfractionated UCB (Table 1). 
Despite the la-fold larger cell numbers, only 1 of 4 mice engrafted with sorted 
CD34+CD3S+ cells at the low level of 1.7%. These results show that the ability to 
repopulate SCID mice resides exclusively in the CD34+CD3S' immature 
popUlation. 
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Figure 2. Engraftment levels of 4 different UCB samples in scm and SCIDINOD mice. 
The percentages CD45+ cells are shown for individual scm mice preconditioned with TEl 
and Cl,MDP (D). scm mice preconditioned by TEl alone (e) and NOD/SCID mice 
preconditioned by TEl alone (D). 
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Figure 3. Immunophenotyping of chimeric mouse BM. BM (>10% CD45l was stained 
with a panel of antibodies specific against different human blood cell lineages. FACS 
profiles of a representative mouse are shown for CD34 vs. CD38 (A), CDl5 vs. CD33 (B), 
CDl6 vs. CD56 (C), GpA vs. CD71 (D), CD3 vs. CD4 and CD8 (E) and CDl9 vs. CD20 
(F) expression, respectively. 
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Multilineage outgrowth of UCB cells 
BM cells of chimeric mice were cultured in standard methylcellulose culture under 
conditions of stimulation with recombinant human GF which selectively favour the 
outgrowth of human monomyeloid and erythroid progenitors and fail to stimulate 
mouse progenitors. Comparison of clonogenic cell numbers in 15 chimeric mice 
with the numbers of colony-forming cells in the grafts showed a median expansion 
of 2.7-fold (range: 0 - II) and l.7-fold (range: 0 - 13) for GM-CFU and BFU-E 
numbers, respectively, as measured 35 days after transplantation. Since these 
progenitor cell populations have a high turnover rate, this observation demonstrates 
that monomyelocytic and erythroid progenitors are produced from more immature 
progenitors in the mouse hematopoietic environment. The composition of the 
human cell population in the BM of chimeric mice was assessed by flow cytometry 
using a panel of lineage specific markers (Figure 3). The percentage of cells in 
each subset identified was expressed relative to the percentage cells stained with 
the panleukocyte marker CD45 (Figure 4). Mice transplanted with 107 
unfractionated UCB cells showed multilineage outgrowth (Figure 4A). The most 
prominent population (25-50% of the human CD45+ cells) consisted ofB lymphoid 
cells, which contained immature CDI9+CD20- as well as mature CDI9+CD20+ 
cells (Figures 3F, 4). CDI5+CD33- monocytes, CDI5+CD33+1- granulocytes, and 
CDI5-CD33- immature myelomonocytic cells were present at percentages ranging 
between 6 and 16% of the human cells (Figure 3B, 4). GpA+CD71++ erythroblasts 
and, occasionally, GpA+CD71- mature red blood cells (not visible in Figure 3D) 
were present in low numbers. In keeping with the presence of CD71 on activated 
non-erythroid cells, the large population of CD71 +GpA- cells (Figure 3D) 
contained cells of multiple lineages32 The composition of the BM of mice 
transplanted with CD34+ (Figure 4B) or CD34+CD38- cells (Figure 4C) was similar 
to that of mice transplanted with unfractionated UCB. The few mice that showed 
detectable chimerism after transplantation of CD34- cells also had outgrowth of 
low numbers of myeloid, erythroid and B lymphoid cells, which were possibly 
derived from the low numbers of CD34+ cells (0.1-0.6%) still present in the 
fraction. However, >50% of the cells growing in these mice consisted of mature 
CD3~ T lymphocytes, which also expressed CD4 or CD8. CD3+ cells were also 
identified in mice transplanted with unfractionated, CD34- or CD34+CD38- cell 
subsets, but these CD3+ cells neither expressed CD4 nor D8 (Figures 3, 4A-C). 
These cells may represent a subset of NK cells as CD3 is expressed on some 
CD56+ cells33 and CD56+ cells were also identified in low numbers in chimeric 
mice, including those transplanted with purified CD34+CD3S- cells (Figures 3C, 
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4C). The large population of CD3· cells which expressed CD4 or CD8 (Fig 3E), 
most likely consisted of CD4+ monocytes. In spite oflarge numbers of human cells 
in the BM of SCrD mice, very few human cells were detected in the leukocyte 
fraction of peripheral blood, spleen and thymus (data not shown). Whole tail vein 
blood samples of CD34+ transplanted mice collected at various time points after 
transplantation, contained human GpA positive erythrocytes at very low levels 
(-0.1%) which could only be detected if very large cell numbers (>105) were 
analysed (Figure SC). 
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Figure 4. Composition of the human CD45- cell population in chimeric scm mice stained 
for the human markers, shown in Figure 3. Results (average = SD) of 23 mice in total, 
transplanted with unfractionated DCB (A), purified CD34+ (B), CD34+CD3S- (C) and 
CD34·grafts (D) derived from 5 DCB samples. Percentage of cells in each subset was 
expressed relative to the %CD45- cells present in the BM of each mouse. The % chimerism 
ranged between 10 and 40% for the data shown in A-C, and between I and 15% for the data 
shown in D. 
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The largest quantities (0.1 - 0.2%) were found 2 weeks after transplantation. From 
the third week on the level decreased and became undetectable in the fifth week. 
Human CD41 + platelets could also be detected in the mouse peripheral blood and 
followed a similar time course as the erythroid cells, with peak levels of 0.5% in 
the second week (Figure 5B). 
Evidence for accessory cell requirement for immature cell expansion but not for 
outgrowth of human UCB cells in SCID mice 
The UCB cell number required for engraftment was analysed by injection of 
graded numbers ofunfractionated or CD34+ cells. Transplantation of2xl03 CD34+ 
cells resulted in a low, but measurable level of chimerism of 1.4% CD45+ cells 
(Figure 6). The level of chimerism increased proportionally with cell dose, 
reaching -60% human CD45+ cells after injection of 2xl05 purified CD34- cells. 
Engraftment after transplantation of unfractionated mononuclear UCB cells and 
purified CD34+ cells followed similar proportional patterns with exponents of 0.8 
and I, respectively (Figure 6). Also the percentage of human CD34+ cells detected 
in scm mouse BM after 35 days showed a linear relation with graft size (Figure 
6). These results demonstrate that the outgrowth of human UCB cells in the scm 
mouse BM does not require the support from accessory cells present in either the 
CD34+ or CD34- UCB fractions. Figure 3A shows that the CD34+ cells produced in 
scm mouse BM were heterogeneous with respect to CD38 expression and 
included cells with low CD38 expression, which suggested that very immature 
cells were maintained andlor expanded in the mOuse micro-enviromnent. 
As shown in Figure 6, the production of cells with an immature CD34TD38-
phenotype showed a much steeper dependence on the number of CD34+ 
transplanted, with an exponent of 2, demonstrating second order (two-hit) kinetics. 
CD34+CD3S- cells were not detected in BM of mice transplanted with purified 
CD34+CD38- cells (Table I, Figure 8B) while, in addition, the numbers of CD34+ 
cells in these mice were 10-fold lower than in mice transplanted with 
unfractionated or CD34+ grafts, despite similar levels of CD45- cells (Table I). 
Taken together, the non linear relation between graft size and % CD34+CD3S- cells 
after 35 days, the lower number of CD34+ cells and absence of CD34-CD38- cells 
in mice transplanted with purified CD34"CD38- grafts demonstrate that immature 
CD34+CD3S- cells can be maintained in the mouse micro-enviromnent, but only 
with the support of accessory cells. 
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Figure 5. Circulating CD41 + platelets and GpA - erythrocytes in the peripheral blood of 
CD34+ transplanted scm mice. Blood was collected in the presence of 2 gIL EDTA and 
stained immediately with CD41-FITC (B) and GpA-FITC (C). Figure SA shows blood ofa 
non-transplanted mouse stained with CD41-FITC. 
Figure 7 shows the actual expansion of CD34+CD3S- cells in BM of the 32 (from 
69) chimeric mice in which such cells were detectable. The expansion ranged 
between 0.2 and 22.1 with a median expansion of 3-fold for unfractionated 
mononucleated UCB cells and between 1.6 and 63.1 with a median value of 7-fold 
after transplantation of CD34+ grafts. This difference is statistically not significant. 
Direct proof of an accessory role of CD34+CD3S+ cells in the maintenance of the 
transplanted CD34-CD3S- population in vivo was obtained by transplantation of 
CD34+CD3S- cells, supplemented with CD34+CD3S+ cells. Dot plots of CD3S vs. 
CD34 expression, collected in a gate for CD34+ cells, show that transplantation of 
5xl03 CD34+CD3S- cells results in production of CD34+ cells, which are all CD3S+ 
(Figure SB). After transplantation of 5xlo' CD34TD3S- cells to which 25xl03 
CD34+CD3S+ cells were added, CD34-CD3S- cells were clearly produced in the 
mouse BM (Figure SC) at frequencies similar to those observed in mice 
transplanted with 105 CD34" cells (Figure SD). Also in this experiment, 
transplantation of 5xl04 CD34+CD3S- cells alone did not result in human cell 
engrafiment (similar to the data presented in Table I). Sorted CD34+CD3S-I- cells 
(corresponding to 20% of the CD34- cells) also repopulated transplanted SCID 
mice with propagation of immature CD34+CD3S- cells, which can be explained by 
the presence of repopulating and accessory cells in this subset (Figure 8£). 
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Figure 6. Relation between the number of CD34+ cells transplanted and percentage of 
human CD45+ (C), CD34+ (<» and immature CD34+CD3S- (0) cells detected in SCID mouse 
BM after 5 weeks. Results show the mean ± SD for 3 mice per data point For comparison, 
the numbers of CD45+ cells detected in BM of mice transplanted with graded numbers of 
unfractionated cells are also shown (m). 
Repopulating cell Ji'equency 
The maintenance or expansion of CD34+CD3S- cells in scm mice might be 
considered as a more significant characteristic of the capacity of repopulating stem 
cells than the ability to produce mature progeny. Taking into account that the 
seeding efficiency of repopulating cells in transplanted scm mice is unknown and 
the support provided by accessory cells may be suboptimal, a lower limit for the 
frequency of cells with the ability to maintain or expand the numbers of 
CD34-CD3S- cells was estimated using the pooled data of 69 mice engrafted with 
graded doses of unfractionated or purified CD34+ cells from 5 different VCB 
samples (Table 2). By using Poisson statistics, a value of 1 repopulating cell per 
70,000 CD34+ cells was estimated (95% confidence limits: 54,000 - 102,000). This 
would correspond to 1 repopulating cell per - 7x106 unfractionated VCB cells and 1 
per 3500 CD34+CD3S- cells_ 
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Discussion 
Engraftment ofUCB in scm mice preconditioned by 3.5 Gy TBI and injection of 
CLzMDP liposomes was more prominent than in scm mice conditioned with TEl 
alone and similar to that observed in NOD/SCID mice. The macrophage-depleted 
scm mice supported the multilineage outgrowth of unfractionated UCB, purified 
CD34+ cells and the immature subset of CD34+CD3S- UCB cells, with production 
of B lymphocytes, monocytes, granulocytes, erythroid cells, NK cells and platelets 
as well as production of CD34+ cells, including phenotypically immature 
CD34+CD3S- cells. Small numbers of purified CD34+CD3S- cells also engrafted 
efficiently with chimerism levels similar to those observed in accessory cell andlor 
GF supported NOD/SCm mice13, whereas CD34-CD3S- cells did not engraft, 
indicating that the scm repopulating potential resides exclusively in the 
CD34+CD3S- subset. 
I 
I 
individual mice 
Figure 7. Expansion of CD34TD38- cells after transplantation of unfractionated or CD34 + 
cells. Data for 32 mice which showed detectable CD34 TD38- cells from a group of 69 
chimeric mice (> 1% CD45+ cells) 28 mice were transplanted with unfractionated (unfrac!.) 
cells and 41 mice with CD34- grafts from 5 different DCB samples_ The arrow shows the 
median expansion factor ofCD34+CD38- cells in each group. 
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Figure 8. Distribution of human CD34 and CD38 in chimeric mouse BM after 
transplantation of CD34+ subsets, sorted as defined by the windows in (A). (B) through (E) 
provide the results 35 days after transplantation of 5xlO' CD34TD38' cells (B), 5xl03 
CD34-CD3S' + 25x103 CD34+CD3S+ cells (C), 105 CD34- cells (D), or 25xl03 
CD34TD3S+!' (E). One thousand to 10,000 events were collected in a window containing 
CD34+ cells only. Quadrants were set to indicate CD34TD38' and CD34-CD3S+ cells. The 
percentages indicate the frequency of human CD34+CD38' cells in mouse BM. 
CD34+CD3S+ cells did not engraft (data not shown). The dissociation of outgrowth of 
CD45+ cells and maintenance or expansion of CD34+CD38' cells is also in this experiment 
indicated by the CD45 percentages, ie, 25.1 % for (B) without CD34+CD38' cells and 5.5% 
for (C), 46.7% for (D), and 2.9% for (E) with similar frequencies ofCD34+CD38' cells. 
The detection of CD34+CD38' cells in scm mouse BM is consistent with the 
finding that CD34+CD38' cells recovered from the BM of engrafted scm and 
NOD/SCID mice have retained the capacity to produce clonogenic progeny in 
long-term culture and to differentiate into myeloid and lymphoid cells in single 
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cell/well cultures.34• 35 Results showing that purified human cells from NOD/SCm 
mouse BM may engraft secondary recipients, also suggest that repopulating stem 
cells are maintained in the BM of immunodeficient mice36 Taken together, these 
data demonstrate that immature CD34TD3S' UCB cells can survive and expand in 
transplanted immunodeficient mice. 
Table 2. Frequency analysis of repopulating cells 
Graft' CD34+ cells Mice positive for Mice negative for % negative 
transElanted"t CD34+CD38' CD34+CD38' 
(n) (n) 
CD34+ 1,660 0 2 100 
8,300 0 2 100 
16,600 I I 50 
80,000 10 12 55 
104,097 8 2 20 
166.000 3 0 0 
total 3,200 0 2 100 
9,600 0 3 100 
32,000 0 4 100 
60,000 2 3 60 
70.000 3 3 50 
111,000 2 33 
198,900 3 2 40 
, Only chimeric scm mice (> 1% CD45+ cells by flow cytometry) 
., n=5 DCB, 69 mice transplanted 
The level of expansion of the immature CD34"CD3S' subset in chimeric mouse 
bone marrow, but not the multilineage production of more differentiated progeny, 
appeared to be dependent on accessory cells. This is most clearly demonstrated by 
the second order (two-hit) kinetics of the relation between graft size and the 
numbers of immature CD34+CD38' cells produced in the SCID mouse BM in 
contrast to the directly proportional relation between graft size and the numbers of 
mature CD45- cells and the CD34" population as a whole (Figure 6). Additional 
data show that engraftment levels and types of human cells produced in the bone 
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marrow of mice transplanted with 5xl03 CD34"CD38- cell were similar to those 
obtained with 20-fold more CD34+ cells or 2000-fold larger numbers of 
unfractionated mononucleated VCB cells, which also demonstrated that accessory 
cells or exogenous GFs are not needed for multilineage outgrowth of immature 
human cells in immunodeficient mice. In contrast, the observation that scm mice 
transplanted with CD34+CD38- grafts produced 10-fold fewer CD34+ cells and no 
detectable CD34+CD38" cells, despite equal numbers of CD45+ cells, than mice 
transplanted with unfractionated or CD34+ grafts with equivalent numbers of 
CD34+CD38- cells (Table I), provides additional evidence for an involvement of 
accessory cells in the maintenance and expansion of immature VCB cells in the 
SCID mOuse microenvironment. Because mice transplanted with unfractionated 
mononucleated VCB cells did not show larger numbers of CD34+ cells (Table I) or 
more extensive expansion of CD34"CD38- cells (Figure 7) than mice transplanted 
with purified CD34+ cells, we postulate that the accessory cells needed for the 
support of immature VCB cells are present in the CD34- population. Formal proof 
was obtained by injection of CD34+CD38- cells supplemented with CD34-CD38-
cells (Figure 8). Whereas transplantation of CD34+CD38- cells alone did not result 
in the maintenance of these cells, the addition of 50% CD34+CD38+, a fraction that 
by itself did not result in substantial chimerism, restored the propagation of 
CD34-CD38- cells in engrafted mice (Figure 8). 
One possible function of the accessory cells VCB cells might be to prevent 
elimination of the small numbers of CD34+CD38- cells by residual immune-
reactivity in the SCID mouse by providing an excess of human cells. However, 
because small numbers of CD34+CD38- cells produced equal numbers of mature 
progeny in the macrophage-depleted scm mice than much larger unfractionated or 
CD34+ grafts (Table 1), it is unlikely that such a mechanism plays a prominent role 
in promoting CD34+CD38- cell engraftment. It is more likely that accessory cells 
provide essential GF s or other stimuli needed for the self-renewal of immature 
human cells which are not provided by the mouse microenvironment. CD34- VCB 
cells and their immediate progeny have been demonstrated to produce various GFs, 
including IL-3, G-CSF and GM-CSF, which stimulate in vitro colony formation by 
VCB in an autocrine or paracrine fashion37 A role of accessory cell derived GF in 
the maintenance of immature cells is also suggested by the supportive role of a 
cocktail of Epo, SF, IL-3 and GM-CSF for expansion of human cells in 
NOD/SCm mice transplanted with high numbers of unfractionated human BM 
cells. This was only observed late after transplantation, when the number of human 
cells was reduced12 Further studies are required to examine to what extent optimal 
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combinations of these or other GFs can replace accessory cells in maintaining and 
expanding CD34~CD3S- cells in immunodeficient mice. 
Estimation, by Poisson statistics, of the frequency of original UCB cells that can 
maintain or expand CD34-CD38- cell numbers during the five weeks engraftment 
period yielded a value of I in 70,000 CD34+ cells (corresponding to I in 3500 
CD34~CD3S- cells). This value is lower, but in the same order of magnitude than 
the I in 600 scm repopulating CD34-CD38- cells which has been calculated on 
the basis of the frequency of transplanted NOD/SCm mice with detectable 
numbers of human cells in the BM as assessed by Southern blots.38 The difference 
is most likely due to the criteria chosen in that the ability to expand CD34+CD38-
cells is a more stringent parameter for engraftment of immature cells than the 
production of mature progeny at a level of as low as 0.05% human cells detected 
by DNA blotting analysis38 Such low engraftment levels can in principle be 
derived from contaminating mature cells, as demonstrated in our study by the low, 
but detectable (>0.5% of mouse BM), engraftment with mature T cells in some 
mice transplanted with purified CD34- cells. The ability to maintain or expand 
CD34+CD3S- cell numbers in scm mouse BM is probably more characteristic for 
repopulating stem cells than production of mature progeny per se, because it may 
reflect an essential hematopoietic stem cells feature, i.e., the ability to maintain its 
ovvn numbers in vivo. 
The differences in repopulating cell frequencies might also be due to the co-
transplantation of accessory cells and/or administration of growth factors in the 
NOD/SCID mouse model which may have promoted human cell engraftment38 
Although it is clear that CD34-CD38- cells still represent a heterogeneous cell 
population with only a minority of cells capable of hematopoietic reconstitution, all 
frequency-estimates of the scm mouse repopulating human cells likely 
underestimate the frequency of human repopulating cells and should be treated 
with caution. In particular, the seeding efficiency of these cells has not been 
assessed yet, while the efficacy of the growth stimuli provided by the xenogeneic 
environment, accessory cells in the transplant or exogenous growth factor 
administration might very well be suboptimal. Studies into the kinetics of human 
BM cell engraftment in immunodeficient mice have shown that the number of 
immature, CD34+Thy-l + cells that can be detected in the mouse BM two days after 
transplantation is at least two logs lower than input numbers, suggesting that only a 
very small fraction of the immature human cells develop in these mice. 12 
The present study provides evidence for differential regulation of the expansion as 
opposed to multilineage outgrowth of immature human hematopoietic stem cells in 
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transplanted SCID mice. The possibility to distinguish experimentally between 
these essential functions in the SCID mouse transplantation assay now opens an 
experimental approach to examine the effects of various GFs, cell subsets and other 
agonists on the self renewal of human immature stem cell subsets. This information 
will be essential to design and test conditions for ex vivo activation and expansion 
of immature hematopoietic cells and for various experimental purposes, such as 
required for the development of efficient gene transfer protocols into hematopoietic 
cells with retention of repopUlating ability. 
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Abstract 
In this study the ability of malignant and normal progenitors in peripheral blood 
(PB) and bone marrow (BM) of chronic myeloid leukemia (CML) patients in 
chronic phase to proliferate and produce mature progeny after transplantation into 
hereditary immunodeficient (SCm and NOD/SCID) mice was examined. 
Engrafiment in NOD/SCID mice preconditioned by total body irradiation (TBI) 
alone was 10-fold higher than in scm mice preconditioned by macrophage 
depletion and TEl, demonstrating that NOD/SCm mice are more suitable for 
engrafiment of chronic phase CML cells. Low-density cells at cell doses of 10-
30xl06 and purified CD34+ cells at doses of -0.2xI06 engrafted NOD/SCm mice, 
with levels of 2 to 20% CD4S+ cells with production of monocytes, granulocytes, 
erythroid cells, B-Iymphocytes, CD34- cells and variable frequencies of erythroid 
and myeloid colony forming cells. As demonstrated by fluorescent in-situ 
hybridisation (FISH) analysis, purified human myeloid, B-Iymphoid, erythroid and 
CD34" cells from chimeric mouse BM contained Philadelphia-chromosome (Ph)-
positive cells and Ph' cells in similar frequencies as primary cells from the CML 
patients. These results demonstrate that production of mature normal as well as 
malignant cells of multiple lineages were supported with similar efficiency. In 
contrast, all human erythroid and myeloid clonogenic cells detected in the mice 
were Ph', which can be attributed to less efficient maintenance or more rapid 
differentiation of immature Ph + cells in the mouse microenvironment. CML blast 
crisis cells also grew well in NOD/SCID mice, with 80-90% of human cells 
produced containing the Ph-chromosome. The availability of an in vivo assay that 
supports outgrowth of normal and malignant stem cells from chronic phase and 
blast crisis CML patients will facilitate examination of differential effects of 
growth factors, inhibitory cytokines and cytotoxic drugs on survival of normal and 
malignant stem cells in vivo and on progression of chronic phase CML towards 
blast crisis. 
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Introdnction 
Chronic myeloid leukemia (CML) is a clonal cancer ansmg from neoplastic 
transfonnation of the hematopoietic stem cell (HSC). The hallmark of CML is the 
so-called Philadelphia (Ph) chromosome, resulting from a reciprocal translocation 
between chromosomes 9 and 22. The translocation results in the fonnation of a 
chimeric oncogene based on the c-abl gene from chromosome 9 and the bcr gene 
on chromosome 22. The bcr/abl oncogene encodes a protein with enhanced 
tyrosine kinase activity, which perturbs the proliferation and differentiation of the 
neoplastic stem cell and its progeny, eventually resulting in suppression of nonnal 
hematopoiesis and overgrowth by malignant cells. All myeloid lineages and often 
the B cell lineage as well are involved in CML, but expansion of the granulocyte 
lineage is usually most prominent. Bone marrow (BM) and peripheral blood (PB) 
of newly diagnosed as well as treated chronic phase CML patients contains nonnal 
and malignant stem cells at variable frequencies. I. 2 Thus, improved treatment 
strategies may be aimed at purification of nonnal stem cells for auto grafting or at 
selectively inhibiting the survival and outgrowth of Ph+ cells, by exploiting 
differences in phenotype andlor growth properties between nonnal and malignant 
stem cells3 -7 
The development and successful implementation of more selective anti-neoplastic 
approaches in CML will require the availability of functional assays in which the 
effects of growth factors (GF), inhibitory cytokines and cytotoxic drugs on survival 
and outgrowth of nonnal and malignant stem cells can directly be compared in a 
quantitative manner. Long-tenn nonstromal cultures in defined serum-free medium 
have provided infonnation about the GF requirements of immature nonnal and 
malignant progenitors8 Long-tenn culture and cobble-stone area fonning cell 
(CAFC) assays supported by the murine stromal cell line FBMD-l have been 
developed to examine the frequency of immature nonnal and malignant cells in 
purified subsets, as nonnal and malignant stem cells are maintained in this assay 
with similar efficiency9 and these assays have been used to examine the 
differential responses to Interferon-a of nonresponding vs. responding CML 
patients at the stem cellleve!.! 0 
The regulatory mechanisms of proliferation and differentiation of human 
hematopoietic cells with in vivo hematopoietic capacity can also be studied in 
animal models using immunodeficient mouse strains. Severe combined 
immunodeficient (SCID) mice and non-obese diabetic SCID (NOD/SCID) mice 
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have been shown to be suitable hosts for normal human hematopoietic cells from 
various sources as well as for different types of human leukemiasll-15 Cell lines 
and primary leukemic cells from acute (pre) B cell, T cell or myeloid leukemias 
proliferate extensively in SCID mice and show a highly reproducible pattern of 
infiltration reminiscent of that observed in patients16-23 Ph-leukemic cell lines 
and primary blast crisis cells from CML patients also grow predominantly m 
immunodeficient mice, with exclusive production ofPh+ cells24 
Preferentially a reliable transplantation assay for chronic phase CML cells in 
immunodeficient mice will require that the mouse-microenvironment can support 
the outgrowth of normal and malignant cells with in vivo reconstituting ability with 
similar efficiency. Only in case such conditions are met, a mouse transplantation 
assay for human CML cells will be valuable to study the different effects of 
cytokines, cytotoxic drugs or other agents on the survival and outgrowth of normal 
vs. leukemic stem cells in vivo and to assess the feasibility of stem cell purification 
strategies to eliminate malignant cells from autologous grafts. In a recent study, 
BM and PB cells from chronic phase CML patients repopulated SCID mouse BM 
with levels of chimerism between 5 and 10% but only after injection of high cell 
numbers (8 to 14xl0710w density cells). In other studies, higher engraftment levels 
were obtained in NOD/SCID mice25• 26 In the latter studies, purified CD34+ cells 
also engrafted if very large cell numbers were transplanted, similar to those used 
with unfractionated grafts, suggesting the CD34+ cells engrafted sub optimally. The 
majority of human colony forming cells produced in SCID mice were Ph-24, while 
in another study, in which NOD/SCID mice were used, both normal and malignant 
progenitor cells were detected in the mice26 
In this study the degree of mosaicism of malignant and normal cells before 
transplantation and after engraftment in immunodeficient mice was evaluated. 
Specifically, we set out to compare the outgrowth of malignant and normal cells 
from individual CML patients in SCID and NOD/SCID mice and to assess the 
relative contribution of normal and leukemic progenitors to the various subsets of 
human hematopoietic cells produced in the NOD/SCID mouse. 
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Material and methods 
CML progenitor cells 
Hematopoietic progenitor cells were obtained from 10 patients after informed 
consent. Two patients were diagnosed as CML blast crisis and progenitor cells 
were recovered directly from the peripheral blood (PB). Eight patients were 
diagnosed in first chronic phase CML Progenitor cells were recovered directly 
either from BM or from PB in the recovery phase following high-dose 
chemotherapy using Cytarabin and Idarubicin. These progenitor cells were 
indicated as 'mobilised PB' (Table I). At the time of harvest no blast cells were 
present in the chronic phase CML samples used in this study. MononucIeated cells 
were isolated by Ficoll density gradient centrifugation (L077 g/cm2, Nycomed 
Pharma AS, Oslo, Norway), and were then cryopreserved III 10% 
dimethylsulphoxide, 20% heat-inactivated fetal calf serum (FCS) and 70% Hanks 
Balanced Salt Solution (HBSS, Gibco, Breda, The Netherlands) at -196°C as 
described27 After thawing by stepwise dilution in HBSS containing 2% FCS, cells 
were washed with HBSS containing 1% FCS and used for flow cytometric analysis 
or subset purification and inoculation into NOD/SCID mice. The viability of the 
thawed cells was determined by staining with trypan blue. 
Subset purification 
Purification of CD34+ cells was performed by positive selection using Variomacs 
Immunomagnetic Separation System as described2S (CLB, Amsterdam, The 
Netherlands). The percentage of CD34+ cells in the unseparated pool and in the 
selected CD34+ and CD34· cell fractions was determined by FACS-analysis. 
Transplantation of CML cells in immunodeficient mice 
Female, specific pathogen-free (SPF) CB-17 scidlscid mice (SCID), 6 to 9 weeks 
of age, were obtained from Harlan, CPB, Austerlitz, The Netherlands. Non obese 
diabetic SCID NODILtSz-scidiscid (NOD/SCID) mice were purchased from 
Jackson Laboratories, Bar Harbour, MA. The mice were housed under SPF 
conditions in a laminar air flow unit and supplied with sterile food and acidified 
drinking water containing 100 mg/l ciprofloxacine (Bayer AG, Leverkusen, 
Germany) ad libitum, in accordance with institutional animal research regulations. 
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The plasma Ig level of the mice was determined with an ELISA using a sheep anti-
mouse antibody reacting with mouse IgG and IgM (Boehringer Mannheim 
Biochemica, Penzberg, Germany) and animals with plasma Ig levels over 40 I1g/mI 
were excluded. To deplete macrophages in SCID mice, one day prior to 
transplantation of hematopoietic cells, the SCID-mice were injected iv. into a 
lateral tail vein with 200 I1lliposome stock solution containing di-chloromethylene 
di-phosphonate (kindly provided by dr J.J. van Rooijen, Department of 
Biochemistry, Free University Amsterdam, The Netherlands, CL,MDP was a gift 
of Boehringer Mannheim GmbH, Germany).22. 29 In previous studies with human 
umbilical cord blood (UCB) and human acute leukemia cells, this approach 
required ten-fold fewer cells for similar levels of engraftment than conditioning 
with TBI alone22 Liposome-treated SCID mice and untreated NOD/SCID mice 
received a dose of 3.5 Gy total body irradiation (TBI), delivered by a 137Cs source 
adapted for the irradiation of mice (Gammacell, Atomic Energy of Canada, 
Ottawa, Canada), 2-4 hours before transplantation. The transplants were suspended 
in 200111 HBSS containing 0.1% BSA (Sigma, Zwijndrecht, The Netherlands) and 
injected iv. into a lateral tail vein. 
In vitro colony assay 
Mononuclear cells from patients' PB or BM and chimeric mouse BM samples were 
assayed for the presence of granulocyte-macrophage-colony forming units (GM-
CFU) and erythroid burst-forming units (BFU-E) by in vitro colony formation in 
viscous methylcellulose culture medium as previously described.3o-32 Briefly, 
patients' cells or BM cells of mice 35 days post transplantation were plated at 
concentrations of 0.5 - 4xl05/ml plated in 35 mm Petri dishes (Becton Dickinson). 
The cultures were maintained in a humidified atmosphere of 10% CO, at 37°C for 
14 days, after which the colonies were counted. Data of duplicate dishes were 
expressed as average number of colonies per 105 cells plated. After counting, 
single colonies were plucked, centrifuged on glass slides and stored at -20°C until 
fluorescent in situ hybridisation (FISH) was performed. 
Tissue collections and analysis 
After 35 days, mice were killed by CO, inhalation followed by cervical dislocation. 
From each mouse, both femurs were collected and BM cell suspensions were 
prepared by flushing with HBSS. After counting, the cells were cultured in colony 
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assays and analysed by flow cytometry to detennine tbe percentage of human 
hematopoietic cells in tbe mouse bone marrow. Cells were suspended in HESS 
containing 2% FCS, 0.05% (wt/vol) sodium azide, 2% human serum and 2% 
mouse serum and stained with tbe pan-leukocyte surface marker CD45 antibody 
conjugated witb fluorescein isotbiocyanate (FITC) and with CD33 antibody 
conjugated with R-phycoerythrin (PE), for 30', at 4°C. Positive samples were 
further analysed by incubation with FITC and PE labelled mouse monoclonal 
antibodies to human CD34, CDI9, CDI6, CDI5, CD38 (Becton Dickinson, San 
Jose, CA, USA), glycophorin A (GpA), CD3 and CD71 (Dako NS, Copenhagen, 
Denmark). Parallel samples were incubated with isorype matched control 
antibodies. Cell samples of non-transplanted mice were stained as negative 
controls. Fluorescence was measured using a FACScan flow cytometer and Lysis 
II or Cellquest software (Becton Dickinson). Dead cells were excluded from 
analysis by adding I j.lg/ml propidium iodide (PI) and gating for Pf cells in the 
FL3 channel. 
For isolation of lineage subsets, isolated BM of chimeric mice transplanted with 
CML cells and thawed cells of 3 patients were stained with FITC and PE 
conjugated antibodies against human CD15, CD33, CD19, CD34, CD71, CD45 
(Becton Dickinson) and GpA for 30' on ice in HBSS containing 2% FCS, 0.05% 
(wt/vol) sodium azide, 2% human serum and 2% mouse serum. After incubation, 
tbe cells were washed twice, resuspended in HBSS and sorted using a F ACS 
Vantage or FACS Calibur flow cytometer (Becton Dickinson). Sorted subsets were 
centrifuged on slides (500 rpm, 5'), fixed in methanol for 15' and stored at -20°C 
until FISH was perfonned. 
Fluorescent in situ hybridisation (FISH) 
FISH was perfonned as described previously9. 33. 34 In short, the BCR and ABL 
specific DNA probe were labelled with biotin-16-dUTP and digoxigenin-ll-dUTP 
(Boehringer), respectively, by nick translation. Cells were pre-treated in RNAse 
solution (200 j.lg/ml in 2xSSC buffer pH 7.0, 60' at 37°C; IxSSC is 0.15 mollL 
NaCL, 0.015 mollL sodium citrate). Pepsin treatment was perfonned by incubating 
the slides for 10' at 37°C in a HCI-Pepsin solution (50 j.ll saturated pepsin in 100 
ml 0.01 N HCI). The slides were post-fixated in a 1% fonnaldehyde solution in 
PBS containing 50 roM MgCL, for 10' at room temperature and dehydrated in an 
etbanol series. The BCR and ABL probes (5 j.lg/ml) were denaturated for 4' at 
noc. After denaturation and dehydration tbe cells were hybridised overnight at 
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3TC in a humidified atmosphere. The slides were incubated for 30' at 37°C with 
avidin-FITC (2 j.lg/ml, Vector Laboratories, Burlingame CA, USA) in 4xSSC 
containing 5% non-fat dry milk (NFD-milk) (protifar, Nutricia, Zoetermeer, The 
Netherlands). The fluorescence intensity was amplified using subsequent layers of 
sheep anti-Dig-Rhodamine (Boehringer), diluted to I j.lg/ml in Boehringer milk to 
block unspecific binding, anti-avidin (Brunschwig chemie; 2.5 j.lg/ml in 
Boehringer milk), for 30' at 3TC in a humidified atmosphere. After washing, the 
cells were incubated with donkey anti-sheep Texas Red (Jackson Immunoresearch 
Lab; 6.8 j.lg/ml in Boehringer milk) and avidin-FITC (2 j.lg/ml in Boehringer milk) 
for 30' at 37°C in a humidified atmosphere. After washing, the cells were stained 
for total DNA with 4, 6-diamidino-2-phenyl-indole.2HCI (DAPI; 0.1 j.lg/ml Sigma, 
Zwijndrecht, The Netherlands) in 2.3% Vectashield (Vector Laboratory). The 
slides were analysed using a fluorescent microscope equipped with a triple band 
pass filter for simultaneous excitation of FITC, Texas Red and DAPI. A random 
sample of at least 100 complete, non-overlapping nuclei was scored for green and 
red fluorescent spots and the frequency of Philadelphia chromosomes was 
determined. A cell was scored Ph- if two distinct red and two distinct green signals 
were visible within a nucleus. A cell was scored Ph + if it contained one distinct red 
signal, one distinct green signal and one distinct yellow signal representing the 
coincidence of a red and green signal or if it contained two distinct red signals and 
two green signals with one red and one green signal in close juxtaposition. As a 
positive control cytospin slides prepared from selected CD34- cells from a patient 
with established accelerated CML were used. Cytogenetic evaluation of these 
CD34+ cells yielded 100% Ph + metaphases (30/30) without additional cytogenetic 
abnormalities and evaluation by FISH yielded positivity for bcr/abl of 97±2% 
(n=8). Normal PB or BM samples were used as negative controls in which 98±! % 
(n=8) cells were scored as Ph-. Individual FISH experiments were considered of 
sufficient quality if positive and negative controls yielded a percentage of more 
than 95% and less than 5%, respectively. 
Results 
Chimeric bon.e marrow analysis 
Low density CML cells were injected into parallel groups of scm mice 
conditioned with TBI and macrophage depletion and in NOD/SClD mice 
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conditioned with TBI alone. The level of chimerism in the mouse BM was 
assessed by flow cytometry 35 days after transplantation. The percentage CD45+ 
cells was used as a measure for engraftment of human cells. Mice with >1% 
CD45- cells were considered to be engrafted. A representative result of chimeric 
BM stained with CD45-FITC vs. CD33-PE is shown in Figure IA The presence of 
CD45+CD33+ and CD45+CD33· cells demonstrated that human myeloid as well as 
non-myeloid cells were present. 
The ability of the scm and NOD/SCm mice to support outgrowth of CML cells 
was compared in 4 separate experiments with samples of 3 patients (Figure 2). 
After transplantation with 107 to 3xl07 unfractionated cells, scm mice 
preconditioned by macrophage-depletion and 3.5 Gy TBI displayed human cells in 
only 8 of 24 mice transplanted at average levels of 5.9 ± 8.1 %. NOD/SCID mice 
preconditioned with TBI alone showed higher levels of chimerism in 19 of 23 mice 
transplanted i.e., 14.0 ± 13.5%. These results demonstrated that NOD/SCm mice 
provide better support for chronic phase CML cells with fewer graft failures than 
scm mice do. All further experiments were therefore performed with NOD/SCID 
lIDce. 
As shown in Table I, transplantation of low-density cells (l - 3x107) from 5 of 8 
patients with chronic phase CML resulted in high levels of engraftment in 24 of 27 
NOD/SCm mice. The percentage chimerism in the engrafted mice varied among 
the different patient samples, ranging from 2.5 to 22%. Patients I and 2 were also 
transplanted with purified CD34+ and CD34· grafts. Engraftment was obtained in 4 
of 5 mice transplanted with -O.2xl 06 CD34- cells. Ten million transplanted CD34· 
cells from patient I did show low levels of chimerism in 5 of 5 mice, which may 
be attributed to contaminating CD34+ cells in the graft (3.86% CD34- cells) and 
the large number of cells transplanted. Engraftment levels of purified CD34~ cells 
of patient I were significantly lower than those obtained with low density cells 
which can be attributed to the 6-7-fold lower number of CD34- cells transplanted 
as compared to the number of CD34+ cells present in the low density fraction. In 
patient 2, chimerism obtained with 0.15x106 CD34+ cells was similar to that 
obtained with 65-fold more low-density cells, which contained an equivalent 
number of CD34- cells, whereas none of 4 mice transplanted with 107 CD34- cells 
from patient 2 engrafted. The results demonstrated, at least for patient 2, that the 
huma."1 cells produced in the NOD/SCm BM were derived exclusively from small 
numbers of immature progenitors and not from surviving mature cells or from 
CD34· cells with in vivo hematopoietic ability. 
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Figure 1. Flow cytometric analysis of chimeric mouse bone marrow stained with CD45-
FITC vs. CD33-PE CAl. Positive staining for any of these markers was not found in non-
transplanted mice CB). demonstrating the specificity of the antibodies for human cells. 
Multilineage outgrowth of CML cells 
The composition of the human cell population in the BM of mice with sufficiently 
high levels of chimerism, i.e .• those transplanted with cells from patients I - 4 in 
Table I, was studied by flow cytometry using a panel of lineage specific markers. 
The percentage of cells in each subset identified was expressed relative to the 
number of cells that stained with the pan-leukocyte marker CD45 (Figure 3). Mice 
transplanted with 15 - 20x106 CML cells from patients I (Figure 3A), 2 (Figure 
3B) and 3 (Figure 3C) showed multilineage outgrowth, although the relative 
frequencies of the various cell types were variable. The most prominent population 
in mice transplanted with cells from patients I to 3 was the myeloid subset (79 ± 
24% of the human CD45" cells, n=IS) which consisted of CDIS'CD33" immature 
monomyeloid cells, mature CDI5+CD33+ monocytes and CD I 5-CD3T/' 
granulocytes. Cells of the erythroid lineage (15 ± 22%, n= 15) consisted of 
GpA+CD71+ erythroblasts and more mature GpA+CD7r erythroid cells. The GpA 
CD71 + subset (27 ± 22%, n=14) probably consisted of early erythroid cells, as well 
as activated cells of other lineages. CD20+ B cells and, occasionally, CD56+ or 
CD 16+ NK cells and CD4" or CDS+ cells were present in the mouse BM at low 
numbers. Most of the CD4+ or CDS" cells did not express CD3, and probably 
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consisted of monocytes that express CD4 at low to intermediate levels. Myeloid, 
erythroid or B-lymphoid cells were not found in BM of mice engrafted with low 
frequencies of human cells (4%) after transplantation with 20xl06 10w density cells 
from patient 4 (Figure 3D). In these mice only CD3S+ cells which were CD4-
and/or CDS- were detected, indicating that these mice were engrafted with 
activated mature T -lymphocytes. FISH analysis of these cells with BCR and ABL 
specific probes revealed that virtually all of these T cells were Ph', probably 
derived from expanding mature non malignant T cells (data not shown). 
Table 1. Engraftment of CML cells in NOD/SCID mice 
Phase Soun:e Grnft Cen CD34+ cells Cbimericmicel %Chimerism CD341 Expansion fuctor 
numl:<:r ingmt! injecteJ' (CD4S cells)§ mouseBM* CD34-
xI06 x106 x106 
CP PB(m) 1Dtl! 22 1.0 9& 21.7=15.S 3.5±39 3.5±3.S 
CD34 02 0.16 415 1.7±OS O.2±O3 1Ad.8 
CD34' 10 0.19 515 3.9±3.7 0 0 
CP PB(m) 1Dtl! 10 0.14 515 S.I±6.6 0.6±O.4 4A±26 
CD34+ 0.15 0.14 414 9.0±24 0.8±OA 6.00.1 
CD34 10 ODS 0/4 0 0 0 
CP PB(m) 1DtlI 20 O.S 515 IS.4=99 0.8±O.S 1.0±09 
CP BM 1DtlI 30 0.12 3/4 6$o6A 0 0 
CP PB(m) 1DtlI 20 IS 214 2.5±03 0 0 
CP PB(m) 1DtlI 20 03 014 0 0 0 
CP PB(m) 1Dtl! 20 0.14 015 0 0 0 
CP BM 1DtlI 20 O.lS QI3 0 0 0 
BC PB 1Dtl! 50 133 5/5 71.9±Ii.4 113=143 1.4±1.7 
BC PB 1Dtl! 50 15.S 616 51.1±8.8 39=13 025±O.I 
* CD34' BM cells, calculated on the assumption that I femur represents 8.5% of all 
BM cells 35 
# mice are considered chimeric at > I % CD45+ cells 
§ mean ± SD of chimeric mice 
CP = chronic phase, BC = blast crisis 
A total: low density cells 
(m) mobilised PB 
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Figure 2. Engrafunent levels of 3 different CML samples in scm and NOD/scm mice. 
The percentages human CD45+ cells are shown for individual scm mice preconditioned 
with TBI and CI,MDP-liposomes CO) and NOD/SCm mice preconditioned with TEl alone 
ce). Data were obtained in 4 separate experiments; cells of patient I were examined twice. 
Only results for engrafted mice C> 1 % CD45l are shown. 
FISH analysis on sorted hematopoietic subsets 
Human CD45- cells were purified from chimeric mouse BM by F ACS sorting in 
order to examine the contribution of normal and leukemic cells to engraftment of 
human cells in NOD/SCm mice. In addition, myeloid, erythroid, B-Iymphoid and 
immature cells were purified from mouse BM, using the markers and sort regions 
shown in Figure 4. The relative contribution ofPh+ and Ph· cells to engraftment of 
these subsets was evaluated by FISH analysis using BCR and ABL specific probes. 
To examine to what extent outgrowth of normal and malignant cells in the mice 
reflects the mosaicism of Ph+ and Ph· cells in the patient, the frequencies of Ph" 
cells in the subsets sorted from the chimeric mouse BM were compared to the 
frequencies in corresponding subsets sorted directly from cryopreserved patient 
BM cells. (Table 2). 
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Ph + as well as Ph- cells were present in sorted cell populations for all three patients 
tested. Sorted CD45- cells obtained directly from cryopreserved PB samples of 
these patients contained similar numbers of Ph-cells as compared to the CD45-
cells recovered from the mice. The frequencies ofPh+ and Ph- cells in the immature 
CD34+ subset and in the monocyte. granulocyte. and erythroid populations did not 
differ from the cells isolated directly from the patient samples and from the 
engrafted NOD/SCID mice. Ph+ as well as Ph- B-Iymphocytes were detectable in 
primary cells from patient I and 2 and in BM of chimeric mice transplanted with 
cells from these patients. The Ph-frequency of B-cells isolated from the mouse 
BM were higher as compared to the Ph- frequency in patients I and 2 (2-fold and 
3-fold, respectively), suggesting selective outgrowth of Ph+ B-cells in the 
NOD/SCID mice. All B-cells detected in primary cell samples from patient 3 and 
in chimeric BM of mice transplanted with cells of this patient were Ph- (Table 2). 
These results demonstrated that both normal and malignant cells obtained from 
individual CML patients engraft the BM of sublethally irradiated NOD/SCID mice 
and contribute to multilineage outgrowth of human cells. Moreover, the Ph-
distribution pattern of immature cells and cells of the myeloid and erythroid 
lineages present in the graft is recovered unchanged after transplantation, without 
selective outgrowth of either normal or malignant cells. The frequency of Ph + cells 
in the PB of all 3 patients examined and in the BM of the engrafted mice was much 
lower than can be expected for chronic phase CML patients. However, 
morphological analysis of cells of these patients revealed relatively large 
frequencies (34%, 9% and 33%, respectively) of immature myeloid precursors and 
relatively few mature granulocytes (2%, 3% and 5%, respectively). The relative 
low number of mature Ph- granulocytes and predominance of Ph-CD34+ cells in 
the patients' PB samples as well as in chimeric mouse BM were consistent with the 
relatively strong contribution of Ph- precursor cells to the circulating cell 
population after mobilising chemotherapy in chronic phase CML patients36-3S 
Maintenance afprimitive cells in NOD/SCID mice 
In addition to mature cells, BM of mice repopulated with cells from patients 1, 2 
and 3 also contained immature CD34- cells, in frequency ranging from 0.2 to 27% 
(Figure 3). Comparison of the absolute number of CD34+ cells in these mice to the 
number of CD34+ cells in the grafts showed that CD34+ cell numbers were 
maintained or increased up to 6-fold during the 35 days engraftment period (Table 
I). 
102 
CD4/CD8+-o~ 
9P:\CD71 +-o~ Gj)ACD71+ ...... ~ 
GjlA+CD71' .. -
C020+ .. -I 
clH~: 
CDI6 
CDI5+CD33"'-
CDl5+CD3r ....... ~ 
C015+C033- ....... -"-CD3S+ ....... - ................. ----I 
CD34+ ..... --1 
CD45+ .......................... . 
o 25 50 
CD4/CD8+~=== 8PA'8Bn:~' ............ ~ 
GjlA+CD71' 
CD20+ 
CD3- nd 
CD56~ 
CDI6 
CDI5"CD33+ 
75 100 
A 
C 
E8 l~:E8~r1: :~:~: :~:~:~: :~:~ ..~.~. '~'~'~;:::::::3 §B~~:i··························-
CD45+-f;;;;' .;;;;; .. ;;;;; ..~ .. ;;;; .. ;;;;.;;;;; ..~ ..;;;; .. ;;; .. ;;;.~ .. ;;;;; ..;;;; ..~. __ 
o 25 50 75 100 
~, 
......... --1. 
p~ 
nd 
nd 
•••••• -I 
•••••••••• ----I 
OJ, 
Chapter 3 
B 
.......................... -I 
o 25 50 75 100 
D 
nd 
o 25 50 75 100 
Percentage positive related to %CD45'" cells 
Figure 3. Immunophenotyping of chimeric mouse BM. BM cells were stained with a panel 
of antibodies specific against different human blood ceUlineages to assess the composition 
of the human cell population. Results for mice transplanted with cells from patients 1 (A), 2 
(B), 3 (C) and 4 (D), respectively. The percentage of cells in each subset, relative to the 
%CD45+ cells present in the BM of each mouse, is expressed as average = SD for 4, 5, and 
5 mice in (A-C), respectively, and as average of2 mice in (D). The chimerism in individual 
mice ranged between 8 and 32% for the data shown in A, between 8 and 18% for those 
shown in (B) and (C), and between 2.4 and 4% for the data shown in (D). Note that CD4 
and CD8 expression were assessed simultaneously. nd ~ not determined 
CD34-CD3S- cells were not found in the chimeric BM, suggesting there was no 
maintenance of this primitive cell population in the engrafted NOD/SCm mice 
(data not shown). Clonogenic myelomonocytic and erythroid progenitors, i.e., GM-
CFU and BFU-E, were identified in engrafted mouse BM but generally in numbers 
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lower than the GM-CFU numbers injected (Table 3). GM-CFU numbers had 
increased 1.5 to 5.6-fold relative to input numbers in only 5 of 14 mice 
transplanted with low density or purified CD34+ cells. BFU-E were also detected in 
engrafted mice, but in most mice BFU-E numbers were lower than in the graft 
(Table 3). The low and variable recovery of clonogenic human progenitors could 
be attributed to the absence of detectable Ph+ progenitors among the human 
progenitors cultured from chimeric mouse BM (Table 4). In contrast to the results 
obtained with the human cell subsets sorted directly from the chimeric BM, BFU-E 
and GM-CFU colonies grown from chimeric mouse BM were Ph-, whereas a 
significant number of colonies grown directly from the patient samples did contain 
the Ph-chromosome. These results suggested that malignant progenitors with in 
vitro clonogenic ability were maintained less efficiently in mice than their normal 
counterparts. 
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M q 
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Figure 4. Chimeric mouse BM of patient I, 2 and 3 were stalled with the human myeloid 
markers CDI5-FlTC and CD33-PE (A), with the erythroid markers glycophorin A-FlTC 
and CD71-PE (B), with the B cell marker CDI9-FlTC and with CD34-PE for immature 
progenitor and precursor cells (C). Cells expressing the different markers were sorted 
according to the windows shown and centrifuged on glass slides for FISH analysis. 
Representative dot plots are shown for BM cells of mice transplanted with cells of patient 
1. 
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Engrajtment ojNODISCID mice with cells from CMLpatients in blast crisis 
PB cells of 2 CML patients (no. 9 and 10) in blast crisis were transplanted into 
NOD/SCID mice in order to compare the engraftment characteristics of these cells 
to those of chronic phase CML. Transplantation with 5xl07 low density cells 
resulted in high levels of chimerism (patient 9: 72 ± 6%, n=5; patient 10: 51 ± 9, 
n=6) in all mice injected (Table 1). Immunophenotyping of the human cells 
produced in mice transplanted with cells from patient 9, showed that most cells co-
expressed CD34 and CD 19 which was similar to the phenotype of the blast cells in 
the graft and indicated that the engrafting cells were mainly derived from a 
leukemic B-cell precursor. CD33 was also expressed on -40% of the cells (Figure 
5A), demonstrating that the mice were engrafted with cells with mixed phenotype, 
a feature frequently observed with lymphoid blast crisis.39 
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Figure 5. Immunophenotype ofBM of a representable cillmeric mouse after transplantation 
of5xl07 blast crisis CML cells of patients 9 (Al and 10 (Bl. BM of mice transplanted with 
cells of patient 9 (3 mice 1 or of patient 10 (2 mice 1 was stained with a panel of lineage 
specific markers to assess the composition of the human CD45· cells present in the mouse 
BM 35 days post transplantation. The percentage of cells in each subset is expressed 
relative to the %CD45+ cells in the mouse. For patient 9 the chimerism ranged betv.reen 63 
and 78%, and for patient 10 between 41 and 61 %. 
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Cells produced in the mice as well as in the graft of patient 10, mostly expressed 
myeloid markers (CDlS, CD33) (Figure SB), indicating that the engrafting cells 
were mainly derived from a leukemic myeloid precursor. A large proportion of 
engrafted cells were Ph+ , i.e., 82 ± 3% for patient 9 and 87 ± 4% for patient 10. A 
similar frequency of Ph + cells was also detected in the grafts. The frequency of 10-
20% Ph- cells was significantly higher than the frequency of 'false negative' Ph-
cells, i.e. 2 ± I %, measured by FISH analysis of uniformly Ph + cells. These results 
suggest that residual non-malignant cells with in vitro repopulating potential can be 
detected in NOD/SCID mice transplanted with cells from blast crisis CML 
patients. 
Table 2. Ph-chromosome freguenc), in sorted subsets 
Patient 1 Patient 2 Patient 3 
Lineage Subset Patient MouseBM Patient MouseBM Patient MouseB:M 
Leukocyte CD45+ 32 34 25 10 39 41 
Immature CD34+ 38 30 24 3 40 42 
::v1yeloid CDI5+CD33· ?--, 18 38 nd 43 58 
CDI5+CD33+ 48 37 48 34 61 53 
CDI5TD33+ 25 27 54 56 55 48 
Lymphoid CDI9+CD34- 19 47 3 11 0 0 
erythroid GpA+CD71- 36 nd 34 nd nd nd 
GpA+CD71+ 45 50 33 nd 36 37 
GpACD71+ 30 nd 46 nd 38 nd 
nd not determined; insufficient cells were available for FISH analysis 
Discussion 
The present study shows that both normal and malignant progenitor cells from 
CML patients can be transplanted successfully into NOD/SCm mice with 
production of granulocytes, monocytes, erythroid cells, B-Iymphocytes and 
immature, CD34+ progenitors. In addition, levels of Ph+lPh- mosaicism of sorted 
subsets recovered after engraftment reflected the degree of mosaicism before 
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transplantation. Engraftrnent of cells from chronic phase CML patients in 
NOD/SCm mice conditioned with 3.5 Gy TBI was more prominent than in scm 
mice preconditioned with TBl supplemented with the injection of CLzMDP 
liposomes. This is in contrast to studies with human UCB, in which engraftrnent 
levels of unfractionated as well as purified CD34' and CD34TD3S· cells in 
macrophage-depleted scm mice and NOD/SCID mice preconditioned with TBI 
alone were similar15 and suggests that the additional NK cell and macrophage 
defects of NOD/SCm mice are necessary to achieve engraftrnent of normal and 
malignant cells from CML PB. 
Table 3. Number of human OM-CFU and BFU-E in chimeric mouse BM 
Human OM-CFU HumanBFU-E 
Patient Graft In graft In mouse Fold In graft In mouse Fold 
ID BM* expansion BM* expansion 
x103 xlO3 xlO3 xlO3 
total 261.6 126.1 0.5 687 73.4 0.1 
83.6 0.3 50.2 0.1 
CD34+ 4.1 22.9 5.6 91.6 25.7 OJ 
0 0 4.2 0 
2 total 14.4 70.2 4.9 20 21.3 1.1 
24.7 1.7 5.9 0.3 
CD34+ 20.5 35.2 1.7 42 8.8 0.2 
31.1 1.5 0.3 0 
2.6 0.1 0 0 
0.6 0 0 0 
3 total 276 15.3 0.1 924 13.8 0 
12.4 0 6.2 0 
6.1 0 8.8 0 
10.9 0 0-•. j 0 
* Colony numbers in BM of individual engrafted mice, calculated on the assumption 
that I femur represents 8.5% of all BM cells35 
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Preferably, a useful animal model for chronic phase CML should support and 
maintain the outgrowth of normal and malignant progenitors, because chronic 
phase CML is clinically characterised by a mosaicism of Ph + and Ph- progenitors. 
In addition, only NOD/SCm mice with a stable mosaicism which reflects the 
relative frequencies of Ph-and Ph- cells in the patients' blood and BM may allow 
the evaluation of treatment strategies aimed at a selective outgrowth of normal as 
opposed to malignant cells. It was, therefore, important to evaluate the capacity of 
normal and leukemic cells from individual patients for engraftment and subsequent 
outgrowth in NOD/SCm mice. FISH analysis of sorted subsets demonstrated that 
the distribution of the Ph chromosome in all human cell subsets remained in the 
same order of magnitude in all human subsets isolated from chimeric mouse BM as 
compared to the same subsets isolated directly from BM or PB from these patients. 
These results demonstrated that both normal and malignant progenitor cells 
proliferate and differentiate in BM of transplanted NOD/SCID mice, resulting in 
production of human cell populations in mice, which display a similar Ph 
distribution as the cells in the original graft. The percentages Ph + leukocytes as 
presented in Table 2 appeared low as compared to what can be expected for patients in 
fIrst chronic phase CML. However, the patients used in our study were treated with 
intensive chemotherapy including ldarubicin and Cytarabin and the cell samples 
used for NOD/SCm mouse transplantation were obtained in the recovery phase. It 
is known that Ph- precursor cells can effectively be mobilised into the peripheral 
blood following intensive chemotherapy and that peripheral blood stem cell 
harvests may even be largely devoid of malignant precursors, as demonstrated by 
cytogenetic analysis37. 38 
In previous studies we have analysed the maintenance of Ph+ and Ph- progenitors 
of purified subsets of CD34+ cells in LTC and CAFC assays, supported by the 
FBMD-l stromal cell line9 . 10 The results of a large group of patients, including 
one which was tested in NOD/SCID mice in the present study (patient 3), showed 
that Ph+ and Ph- cells are produced with similar efficiency in long-term cultures. 
The frequency of 41- 42% Ph+ human CD45- and CD34+ cells detected in the BM 
of mice which were engrafted with CD34+ cells of patient 3 (Table 2) was almost 
identical to the frequency of 42% Ph+ nucleated human cells produced after 5 
weeks oflong-term culture of highly purified CD34+CD3S- cells from this patient 
(patient 3 in reference 9). Since only the small CD34+CD3S- population of normal 
hematopoietic cells has previously been shown to engraft NOD/SCID micel4• 15. 
40-42 and also contains the highest frequencies of both Ph + and Ph- CML PB and 
BM cells identifiable in long-term cultures9 . 43, 44, it is very likely that the Ph+ and 
108 
Chapter 3 
Ph' human cells detected in engrafted NOD/SCID mice were not derived from 
relatively mature progenitors, but from very immature cells which are relevant for 
in vivo hematopoiesis. 
Table 4. Clonogenic human progenitors from engrafted mouse BM are Ph-
Colony patient I patient 2 
graft mouse BM graft mouse BM 
GM-CFU 
BFU-E 
5/13* 
3/5 
0/6 
0/5 
ne 
3/4 
* 
ne 
number of Ph + colonies I number of colonies analysed 
slides were not evaluable 
0/6 
0/8 
The production ofPh+ and Ph' myeloid, B-lymphoid and erythroid cells as well as 
immature CD34- cells in the NOD/SClD mice clearly demonstrates that 
multilineage progenitors and not exclusively myeloid progenitors were responsible 
for in vivo engraftment. However, analysis of the clonal origin of the engrafted 
cells, e.g., using retroviral-mediated gene marking, will be needed to definitively 
establish the relative contribution of multipotent as compared to committed 
progenitors to in vivo engrafment. 
In recent studies, analysis of Ph + and Ph' colonies, grown from human cells under 
conditions that permit outgrowth of human but not of murine progenitors, 
recovered from NOD/SClD mice demonstrated production of normal as well as 
leukemic colony-forming cells in engrafted mice as examined by analysis of 
metaphase chromosomes25. 26, whereas in an earlier study in SCID mice normal 
progenitors made up the majority (70%) of the human hematopoietic cells 
present. 24 Since in those studies no comparison was made with the relative 
frequencies ofPh+ and Ph' progenitors in the graft, it is difficult to assess whether 
the different results reflected a more efficient maintenance of Ph T progenitors in 
NOD/SCID as compared to SClD mice, or were caused by variations between 
individual patients with respect to the relative number of Ph T and Ph' 
progenitors24. 26 In our study, all human monomyeloid and erythroid colonies 
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grown from chimeric mouse BM were Ph-. This was in contrast to the mosaicism 
of Ph + and Ph- cells observed for the noncultured human cell subsets isolated 
directly from patients' PB and chimeric mouse BM, and for the monomyeloid and 
erythroid progenitors grown directly from the graft. Explanations for the 
discrepancy between the Ph + cell frequencies of clonogenic progenitors and sorted 
human cell subsets may include qualitative differences between the ability of Ph" 
and Ph- NOD/SCm engrafting cells to maintain or produce clonogenic progenitor 
cells in vivo. In particular, the mouse microenvironment may provide less effective 
support for maintenance or production of immature Ph + progenitors with in vitro 
clonogenic ability than for normal immature cells. Alternatively, the malignant 
progenitors may have a shorter transit time than their normal counterparts in a 
mouse microenvironment, accounting for a lower Ph" progenitor frequency while 
maintaining relatively large numbers of more mature offspring. In any case, the 
absolute number of colony-forming cells recovered from the chimeric mouse BM 
was low, with large variations between individual mice (Table 3). As shown in this 
study phenotypically identified subsets of human cells can be isolated from the BM 
of engrafted mice in sufficiently large cell numbers for reproducible FISH analysis, 
and thus provide more quantitative information about engrafrment of normal and 
leukemic cells than can be obtained by analysis of individual colonies. 
In our study, no evidence was found for the maintenance of immature 
CD34+CD3S- CML or normal cells in engrafted NOD/SCID mice or for significant 
amplification of either normal or leukemic CD34+ cells and clonogenic progenitors 
in vivo. This contrasts to our previous study using UCB cells, which also did not 
require exogenous human growth factor support, but which showed significant 
expansion of CD34+ cells and clonogenic progenitors. IS In that study, we noted 
independent control of immature CD34"CD3S- cell expansion and mature cell 
outgrowth, the former requiring support by CD34+ accessory cells present in the 
graft. Therefore, from the present study we speculate that CML cells and their 
progeny may similarly require accessory cell and/or growth factor support to 
display their full potential for immature cell amplification and outgrowth in the 
NOD/SCm environment. In recent studies, injection of stem cell factor (SCF), 
granulocyte colony"stimulating factor (G-CSF), granulocyte-macrophage colony-
stimulating factor (GM-CSF) and PIXY321 (fusion protein of IL-3 and GM-CSF) 
failed to improve the overall engrafrment levels, suggesting that the stimuli 
provided by the mouse microenvironment are sufficient for outgrowth of human 
cells24. 25 Treatment with SCF, but not GM-CSF or G-CSF selectively promoted 
the engrafrment and proliferation of leukemic cells in viv025, suggesting that 
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exogenous GF support can change the balance between Ph + and Ph- progenitors 
that are produced in vivo_ It remains to be established as to whether exogenous GF 
support can also promote the maintenance and expansion of immature 
CD34+CD3S- cells in vivo_ If such conditions can be developed it will be possible 
to use the NOD/SCID mouse transplantation assay not only to study outgrowth of 
normal and malignant cells, but also to test stimuli that can differentially promote 
the maintenance or expansion of normal cells and elimination of leukemic stem 
cells in vivo_ 
Cells from BC patients engrafted to much higher levels with less variation of 
engraftment levels in individual mice than cells from chronic phase CML patients. 
The engraftment potential of CML BC cells thus resembles that of leukemic blasts 
from AML patients, which also engraft efficiently in immunodeficient mice19•21 , 
whereas the much lower and less reproducible engraftment of chronic phase CML 
cells is more similar to that obtained with normal human BM or mobilised PB 
cells4 1. 45 The variable engraftment obtained with different human cell types may 
reflect difference in requirements for cytokines or stromal factors, or in the ability 
of engrafting cells from different sources to home to the mouse BM. 
In conclusion, the present study provides evidence for multilineage outgrowth of 
chronic phase and blast crisis CML in transplanted NOD/SCID mice. Levels of 
Ph + !Ph- mosaicism did not differ before and after transplantation. Thereby the 
model will in principle be useful to examine the feasibility of cell fractionation 
approaches and other ex vivo manipulations to eliminate transplantable malignant 
stem cells from auto grafts and to evaluate the differential effects of growth factors. 
inhibitory cytokines or cytotoxic drugs on the survival and differentiation of 
normal vs. leukemic stem cells. In addition, mice engrafted with chronic phase 
CML cells may be exploited to study the development of CML from chronic phase 
towards acceleration and blast crisis and to test treatment strategies to prevent this 
process. 
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Abstract 
Purified CD34~ and CD34+CD3S- human umbilical cord blood (UCB) cells were 
transduced with the recombinant variant of Moloney murine leukemia virus 
(MoML V) MFG-EGFP or with SF-EGFP in which EGFP expression is driven by a 
hybrid promoter of the spleen focus-forming virus (SFFV) and the murine 
embryonic stem cell virus (MESV). Infectious MFG-EGFP virus was produced by 
an amphotropic virus producer cell line (GP+envAmI2). SF-EGFP was produced 
in the PG 13 cell line pseudotyped for the gibbon ape leukemia virus (GaL V) 
envelope proteins. Using a 2 day growth factor prestimulation, followed by a 2 day, 
fibronectin fragment CH-296 supported, transduction, CD34+ and CD34-CD38-
UCB subsets were efficiently transduced using either vector. The use of the SF-
EGFPIPG!3 retroviral packaging cell combination consistently resulted in 2-fold 
higher levels of EGFP-expressing cells than the MFG-EGFP/AmI2 combination_ 
Transplantation of 10' input equivalent transduced CD34+ or 5xl03 input 
equivalent CD34-CD38" UCB cells in NOD/SCID mice resulted in median 
engraftment percentages of 8% and 5%, respectively, which showed that the in vivo 
repopulating ability of the cells had been retained. In addition, mice engrafted after 
transplantation of transduced CD34+ cells using the MFG-EGFP/AmI2 or the SF-
EGFPIPGl3 combination expressed EGFP with median values of2% and 23% of 
human CD45+ cells, respectively, which demonstrated that the NOD/SCID 
repopulating cells were successfully transduced. EGFP+ cells were found in all 
human hematopoietic lineages produced in NOD/SCID mice including human 
progenitors with in vitro clonogenic ability. EGFP expressing cells were also 
detected in the human Cobblestone Area Forming Cell (CAFC) assay at 2-6 weeks 
of culture on the murine stromal cell line FBMD-l. During the transduction 
procedure the absolute numbers of CAFC week 6 increased 5- to 10-fold. The 
transduction efficiency of this progenitor cell subset was similar to the fraction of 
EGFP- human cells in the bone marrow (BM) of the NOD/SCID mice transplanted 
with MFG-EGFP/AmI2 or SF-EGFPIPG13 transduced CD34+ cells, i.e., 6% and 
27%, respectively. The study thus demonstrates that purified CD34+ and highly 
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purified CD34-CD3S- UCB cells can be transduced efficiently with preservation of 
repopulating ability. The SF-EGFPIPG13 vector/packaging cell combination was 
much more effective in transducing repopulating cells than the MFG-EGFP/Am12 
combination. 
Introduction 
Efficient procedutes for gene transfer into human immatute hematopoietic cells 
with repopulating capacities following transplantation may in principle open new 
avenues for the treatment of a variety of hereditary and acquired diseases. 
Retroviral mediated gene transfer to such cells, which is attractive by its simplicity 
and efficiency, has however met with considerable difficulty, which is only partly 
understood.l. 2 The availability of a rapid selectable marker, such as the green 
fluorescent protein (GFP), is thought to be of pivotal importance to study major 
variables influencing the efficiency of gene transfer, as well as to track the progeny 
of transduced cells following transplantation. In the present study we evaluated the 
use of the enhanced (E) recombinant variant of GFP to label immatute human 
umbilical cord blood cells, using outgrowth in NOD/SCm micel. 3. 4 as well as 
cobblestone area forming cells (CAFC)5. 6 as assays for immatute cells with 
considerable hematopoietic reconstitution capacity. 
The CAFC assay and the Long-Term Cultute-Initiating Cell (LTC-IC) assay allow 
for frequency analysis of cells capable of long-term repopulation ill vitro5 , 7 
Murine studies have shown that the CAFC scored at week 2 are related to CFU-S 
day 12, while CAFC week 5 strongly correlate with long-term repopulating cells il1 
vivo. 6• 8 In human hematopoiesis the rare population with the primitive phenotype 
of CD34+CD3S- is highly enriched for CAFC week 6_ The primitive natute of 
CAFC week 6 is further illustrated by enrichment following incubation with 5-
Fluoroutacil (5-FU), a drug cytotoxic for proliferating cells. The CAFC week 2 
however, are absent in the CD34+CD3S- population and more than 1 log reduced 
after 5-FU treatment. Based on these results the CAFC week 6 have been proposed 
to be representative for cells with long-term repopulating ability il1 vivo in the 
human situation9 On this basis, this assay is considered suitable to assess the effect 
of manipulation of human hematopoietic progenitor cell populations, such as by 
gene transfer protocols. 1 O. 11 
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The efficiency of gene transfer to stem cells is limited by the inability of most 
retroviral vectors to integrate DNA into the cellular genome of quiescent cells.n -15 
Stimulation of stem cell cycling with hematopoietic growth factors (HGF) such as 
IL-3, IL-6, stem cell factor (SCF) or Flt3-Ll6 prior to and during virus exposure 
would seem to be essential to promote transduction17. 18 but may result in loss of 
repopulating ability of transduced cells as a result of differentiation16. 19 In 
addition, colocalisation of target cells and virus on dishes coated with the 
recombinant fibronectin-fragment CH-296 has been shown to furtber increase gene 
transfer efficiency20. 21 
For transduction of human hematopoietic cells murine retroviruses based on the 
MoML V are most commonly used. However, expression of functional receptors 
for the MoML V envelope protein is presumably low and pseudotyping the vector 
with the GaL V envelope protein resulted in higher transduction efficiencies in 
hematopoietic progenitor cells22-24, which has been attributed to a higher 
expression of functional pseudotyped GaLV receptor (Pit-I) by the immature 
hematopoietic cells22. 24 than the amphotropic retroviral receptor (Pit_2)24-28 A 
study in which CD34T cells were transduced by the GaLV-pseudotyped retroviral 
vector revealed that CD34+ cells were efficiently transduced (21-33% transduction) 
as determined by culture in a colony-forming cell assay2 It is not known to what 
extent the relative transduction inefficiency of the MoML V type viruses is caused 
by a low Pit-2 expression on immature stem cells or by inefficient activation and 
provirus integration in quiescent cells. Transplantation of CD34+ or CD34+CD38' 
transduced cells in immunodeficient beige/nude/xid (bnx) mice showed that 8 of 10 
mice transplanted with CD34+ transduced cells contained the retrovirally 
transduced bacterial neomycin phosphotransferase resistance (neo) gene whereas 
only 2 of 14 mice that had received CD34+CD3S- cells contained low levels of 
transduced cells2 The ability to engraft the BM of NOD/SCID mice and provide 
multilineage outgrowth, which resides exclusively in the CD34+CD38'population3, 
has been described as unsuccessful, in contrast to the LTC-IC or CAFC week 6 
which were transduced with efficiencies ranging between 10 to 70%.1 These 
differences led to the suggestion that NOD/SCID repopulating cells are distinct 
from the LTC-IC or CAFC week 61 However, recent data obtained with vectors 
that contained the neo-gene show that transplantation of retrovirally transduced 
CD34T DCB cells in NOD/SCID mice result in transduced human hematopoiesis in 
the NOD/SCID BM with transduction levels similar to those obtained for LTC-
IC29 
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Figure 1. Flow cytometric profile used to define and sort the CD34+CD3S- cell population 
(A). The window R3 was used to define CD34+CD38- cells for sorting and contains 5% of 
the CD34+ population (as defined by window R2) with the lowest CD38 antigen 
expression. Re-analysis of the sorted cells is sbown in (8). 
Use of the green fluorescent protein (GFP) gene from the jellyfish Aequorea 
victoria as a retrovirally transduced marker allows rapid identification of 
transduced cells by fluorescence microscopy, flow cytometry or culture in real time 
without additional staining steps in contrast to other genetic markers such as the 
neo_gene30-32 and the bacterial B-galactosidase gene (LacZ)33-36 As wtGFP 
produces a weak (but stable) green fluorescence signal, several GFP variants, such 
as EGFP, have been created which are better suited for detection of expression by 
fluorescence microscopy and flow cytometry37, 38 Studies with murine cells have 
shown that cells with the ability of in vivo reconstitution can be transduced with 
EGFP 39 Our ongoing studies show that high expression levels of EGFP could be 
detected in mouse BM, peripheral blood, spleen and thymus for a current 
observation period of 6 months after transplantation and were retained in secondary 
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reCIpIent mice, indicating that long-term repopulating stem cells can be 
successfully transduced40 Human cell lines and purified CD34+ cells were also 
transduced using EGFP containing vectors28 Therefore, retroviral vectors 
containing EGFP genes can be used to transduce a variety of cells which can then 
be easily detected in vitro as well as in vivo. 
To initiate an analysis directed at optimal vectors and transduction procedures, the 
MFG-EGFP retroviral vector produced by an amphotropic packaging cell line and 
the SF-EGFP vector pseudotyped for the GaL V envelope protein were used to 
transduce immature cell subsets in human UCB. The potential of these 
vector/packaging cell combinations for transduction of purified CD34+ and 
CD34TD38" UCB subsets were compared by assessing the ability of transduced 
cells to produce EGFP-positive cobblestone areas in the CAFC assay and to 
contribute to multilineage human hematopoiesis in NOD/SCm mice. 
Materials and methods 
Human umbilical cord blood cells 
UCB samples were obtained from placentas of full-term normal pregnancies after 
informed consent in conformity with legal regulations in The Netherlands. 
Mononuc1eated cells were isolated by Ficoll density gradient centrifugation (1.077 
g/cm", Nycomed Pharma AS, Oslo, Norway), and were cryopreserved in 10% 
dimethylsulphoxide, 20% heat-inactivated fetal calf serum (FCS) and 70% Hanks 
Balanced Salt Solution (HBSS, Gibco, Breda, The Netherlands) at _196°C as 
described41 before use. After thawing by stepwise dilution in HBSS containing 2% 
FCS, the cells were washed with HBSS containing 1 % FCS and used for gene 
transduction experiments. 
Viral vectors and packaging cell lines 
The amphotropic retroviral producer cell line, MFG-EGFP, was obtained by a 20 
hour incubation of GP+envAm12 under standard culture conditions with 
supernatants containing ecotropic retrovirus from the GP+E-86!MFG-EGFP cell 
line and hexadimethrine bromide at 4 flg/ml (Sigma, St. Louis, MO) as 
EGFP expression in umbilical cord blood stem cells 
described38 The pseudotyped retroviral producer cell line PG l3/EGFP7 was 
developed by transducing the PG 13 packaging cell line (kindly provided by D. 
Miller, Fred Hutchinson Cancer Research Center, Seattle, W A) with 0.45 ~m 
filtered supernatant from P A3l7IEGFP cell cultures28 EGFP expression was 
analysed by flow cytometry and bright single cells were sorted on 96-well plates by 
using an EPICS Elite ESP flow cytometer coupled to an autoclone device (both 
from Coulter, Miami, FL, USA). Single clones were cultured as previously 
described.28 The sorted clones were additionally selected for high virus titer. The 
viral titer of both the amphotropic and the pseudotyped producer cell line was in 
the order of 10' infectious particles per ml as detennined by supernatant titration 
on cultured murine NIH 3T3 cells and human HeLa cells, respectively. Absence of 
replication-competent virus was verified by failure to transfer GFP-expression 
from a transduced cell population to a secondary population. Additionally, for the 
SF-EGFPIPG 13 vector/packaging cell combination pseudotransduction was tested 
on HeLa cells and found absent. 
Subset purification 
Purification of CD34- cells was perfonned by positive selection using Variomacs 
Immunomagnetic Separation System as described42 (CLB, Amsterdam, The 
Netherlands). The percentage of CD34- cells in the unseparated population (low 
density UCB) and in the purified CD34·· and CD34· fractions was detennined by 
FACS-analysis. For isolation of CD34-CD38· subsets, purified CD34+ cells were 
stained with fluorescein isothiocyanate (FITC) and R-phycoerythrin (PE) 
conjugated antibodies against human CD34 and CD3S (CD34-FITC, CD38-PE, 
Becton Dickinson) for 30', on ice in HBBS, supplemented with 2% (vol/vol) 
bovine serum albumine (BSA; Sigma), 0.05% (wtlvol) sodium-azide (Merck, 
Darmstadt, Gennany) and 2% (vol/vol) nonnal human serum (NHS). After 
incubation, the cells were washed twice, resuspended in HBSS and CD34+CD3S· 
cells, the window set at 5% of the CD34- population with the lowest CD38 
expression levels (Figure 1) were sorted using a FACS Vantage flow cytometer 
(Becton Dickinson, San Jose, CA). 
Retroviral transduction ofUeE subsets 
Supernatants containing recombinant retrovirus were generated by culturing 
approximately 80% confluent producer cells for 12 hours in culture medium 
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conslstmg of a serum-free enriched version of Dulbecco's modified Eagle's 
medium (DMEM, Gibco, Gaithersburg, MD)3, 39, 43 Media for all cultures 
routinely included 100 U/ml of penicillin and 100 fig/ml of streptomycin. The 
cultures were maintained at 37°C with 10% C02 (measured every 15' with read-
outs between 9.5% and 10%) in a humidified atmosphere, The culture supernatant 
was subsequently procured and passed through a 0,45 fim filter. To enhance the 
transfection efficiency, Falcon 1008 (35 mm) bacteriological culture dishes were 
coated with the recombinant fibronectin fragment CH-296 (Takara Shuzo, Otsu, 
Japan) at a concentration of 10 fig/cmo as described previously,44 UCB subsets 
(CD34" or CD34TD38') were prestimulated for 2 days in either medium 
consisting of enriched Dulbecco's medium (Gibco, Gaithersburg, MD), or 
CellGro®SCGM (Boehringer Ingelheim, Heidelberg, Germany), Different 
combinations of human recombinant HGF were added to the culture medium; IL-3 
(20 ng/ml; Gist-brocades NV, Delft, The Netherlands), IL-6 (100 ng/ml; Ares-
Serono SA, Geneve, Switzerland, thrombopoietin (TPO; 10 ng/ml, kindly provided 
by Genentech, South San Francisco, CA, USA), stem cell factor (SCF; 100 ng/ml 
and Flt3-L (50 ng/ml, the latter two kindly provided by Amgen, Thousand Oaks, 
CA, USA), The HGF combination Flt3-L, TPO, IL-6 and SCF was used during the 
transduction procedure; in some initial experiments, as indicated in the legend of 
the figures and tables, the IL-3, IL-6, SCF combination was used, Before adding 
purified cord blood subsets to the fibronectin-coated dishes, the CH-296 
fibronectin fragment was preincubated with supernatant containing the 
amphotropic MFG-EGFP or the pseudotyped SP-EGFP vector for I hour at 
37°C21, 45 Subsequently, nucleated cells were resuspended in the vector-
containing supernatant supplemented with hematopoietic growth factors, and added 
to the dishes. Over a period of 2 days, culture supernatant was once replaced 
completely by resuspending nonadherent cells into fresh retrovirus supernatant and 
HGF. Finally the cells were harvested and used for FACS analysis, human 
granulocyte-macrophage colony forming units (GM-CFU) and erythroid burst-
forming units (BFU-E) assays, CAFC assay, and transplantation into NOD/SCID 
ll1lce. 
Flow cytometry 
Cell samples were analysed using a F ACSCalibur flow cytometer (Becton 
Dickinson) as previously described38, 39 Immunophenotyping ofEGFP-transduced 
cells was performed by staining with peridinin chlorophyll protein (PercP) labeled 
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anti-CD45 and cyanin-5-conjugated anti-CD34 (CYs; Amersham, 
Buckinghamshire, tJK) or PE conjugated monoclonal antibodies against CD38, 
CD2, CD4, CDS, CD19, CD20, CD56, CD33 (Becton Dickinson 
Immunocytometry Systems, San Jose, CA, USA). Mice were considered engrafted 
if the percentage CD45- cells exceeded 1%. 
Transplantation of transduced UCB subsets in immunodefiCient mice 
Specific pathogen-free (SPF) NODlLtSz-scidlscid (NOD/SCID) mice, 6 to 9 weeks 
of age, were bred and housed under SPF conditions in a laminar air flow unit and 
supplied with sterile food and acidified drinking water containing 100 mg/I 
ciprofloxacine (Bayer AG, Leverkusen, Germany) ad libitum. Housing, care and all 
animal experimentation were done in conformity with legal regulations in The 
Netherlands, which include approval by a local ethical committee. All mice 
received total body irradiation (TBI) at 3.5 Gy, delivered by a 137 Cs source adapted 
for the irradiation of mice (Gammacell, Atomic Energy of Canada, Ottawa, 
Canada), 2-4 hours before transplantation. The transplants were suspended in 200 
).II HBSS containing 0.1 % BSA and injected iv. into a lateral tail vein. Transplanted 
cell numbers were 105 CD34+ cells and 5xl03 CD34+CD3S' cells. 35 Days after 
transplantation the mice were killed by CO, inhalation followed by cervical 
dislocation, both femurs isolated and BM cell suspensions prepared by flushing. 
After counting, the cells were cultured in colony assays and analysed by flow 
cytometry to determine the percentage of human EGFP+ cells in the mouse BM. 
In vitro colony assay 
Purified UCB cells, EGFP-transduced cells and chimeric mouse BM samples were 
assayed for the presence of human GM-CFU and BFU-E by in vitro colony 
formation in viscous methylcellulose culture medium as previously described3 . 43, 
46. 47 The number of colonies was determined after 14 days of culture in a 
humidified atmosphere of 10% CO, at 37°C, EGFP- colonies were scored under 
excitation by ultraviolet light. 
Stromalfeeders and Cobblestone area forming cell (CAFC) assay 
The contact inhibited FBMD-I murine stromal cell line was used as described 
before.6 After seven to ten days of culture at 33°C and 10% CO, the stromal layers 
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had reached confluence and were overlaid with non-transduced or transduced 
CD34+ or CD34+CD3S' UCB cells within the subsequent week. Confluent stromal 
layers of FBMD-I cells in flat-bottom 96-wells plates were overlaid with UCB 
cells in a limiting dilution set-up. Input values of the CD34-CD3S' population and 
the CD34+ were 25 nucleated cells and 500 nucleated cells per well in the first 
dilution, respectively. Twelve two-fold serial dilutions were used for each sample 
with 15 replicate wells per dilution. The cells were cultured at 33°C and 10% CO2 
for six weeks with weekly half-medium changes. The percentage of wells with at 
least one phase-dark hematopoietic clone of at least five cells (i.e., a cobblestone 
area) beneath the stromal layer was determined weekly with an inverted 
microscope. Green fluorescent cobblestone areas were screened in the same way 
but with an UV-light excitation source. Frequencies of total and green-fluorescent 
CAFC were calculated by using Poisson statistics as described previously,6 During 
the period of culture no transfer of the EGFP gene to the stromal underlayer has 
been observed. 
Statistical analysis 
Data are expressed as median (range). Statistical comparisons were performed 
according to Mann Whitney U-test. P values of <0.05, two tailed, were considered 
significant. 
Results 
Transduction efficiencies in purified cells with MFG-EGFP and SF-EGFP vectors. 
Purified CD34+ and CD34+CD3S' UCB cells (Figure 1.) were prestimulated for two 
days and subsequently transduced with either the MFG-EGFPlAmI2 or the SF-
EGFPIPG 13 vector/packaging cell combination, during two days of exposure to 
virus-containing supernatants in fibronectin fragment-coated bacterial dishes. 
Transduction efficiencies obtained by infection using the amphotropic MFG-EGFP 
producer cell line were compared to those obtained with the pseudotyped SF -EGFP 
cell line. 
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Table 1. EGFP expression ofUCB subsets 
VectorlPackaging Purified P- CD34+CD3S· P-
cell line CD34+ Value population within Value 
cells purified CD34+ 
MFG-EGFP/AmI2 30 (S-51) >.05 25 (15-55) >.05 
(n~13) (n~9) 
SF-EGFPIPG 13 75 (53-84) >.05 66 (58-81) >.05 
(F7) (n~5) 
p-value'l' 0.0001 0.003 
. 
Purified 
CD34+CD3S· 
19(8-21) 
(n~) 
62 (21-71) 
(n~) 
0.02 
Results are expressed as percentages ofEGFP+ cells and depicted as median (range). 
For statistical analysis the Mann-Whitney U-test has been used. 
P-
Value# 
0.02 
0.12 
* comparison of the median of purified CD34+ cells and CD34+CD38· subset within the 
purified CD34- population. 
A comparison of the median of CD34TD38· subset within the purified CD34- popUlation 
and purified CD34+CD3S- cells. 
Ii comparison of the median of purified CD34+ cells and purified CD34+CD3S- cells. 
~ comparison ofMFG-EGFP and SF-EGFP transduced cells. 
The percentage EGFP+ cells was assessed by flow cytometry (Figure 2). The 
percentage EGFP+ cells of the purified CD34+ population transduced with the SF-
EGFPIPG 13 vector/packaging cell combination (median 75% EGFPl was more 
than 2-fold higher as compared to MFG-EGFP/AmI2 transduced CD34+ cells 
(median 30%) (Table I). Sorted CD34-CD3S- cells were also transduced at a 
higher frequency using the SF-EGFPIPGI3 combination (62%) than after 
transduction with the MFG-EGFP/AmI2 combination (19%). On average, 
transduction frequencies were lower in the purified CD34+CD38· cells than in the 
CD34+ cell fraction, but only for the MFG-EGFP/Am12 transduced cells the 
difference was statistically significant. The level of transduction of the 
CD34+CD38· subset within the purified CD34+ popUlation obtained with the SF-
EGFPIPG 13 vector/packaging cell combination was more than 2.5 fold higher than 
with the MFG-EGFP/AmI2 combination. The differences in transduction 
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efficiency between the two vector/packaging cell combinations in these cell 
populations were significant (p<0.025). 
Transduction efficiency of cobblestone area forming cell subsets. 
The ability of transduced cells to form cobblestone areas was evaluated in long-
term culture supported by FBMD-I stromal cells. EGFP+ cobblestone areas were 
identified by fluorescence microscopy (Figure 3). The absolute numbers of CAFC 
at different culture periods increased as a result of the transduction procedure 
without significant differences between the target cells and vector used (Table 2). 
The absolute number of CAFC week 2 in the MFG-EGFP/AmI2 transduced 
CD34+ UCB cells increased S-fold, for the SF-EGFPIPG13 transduced CD34+ 
UCB cells the increase was 7-fold. The CAFC week 6 expanded lO-fold and 5-
fold, respectively. For the CD34+CD3W UCB cells, similar results were obtained, 
6-fold and 10-fold ofCAFC week 6 after MFG-EGFP/AmI2 and SF-EGFPIPGI3 
transduction, respectively. Consistent with the immaturity of the CD34+CD38· cell 
population, CAFC week 2 could not be detected in the CD34-CD38- cell fraction 
prior to transduction_ These data show that the transduction protocol that has been 
used causes a modest expansion of both CAFC week 2 and week 6. The 
transduction efficiency of the CAFC week 2 in MFG-EGFPI Aml2 transduced 
CD34- cells ranged between 23 and 30% with a median value of 26% and in SF-
EGFPIPG13 transduced CD34+ cells the median value was 60% (46-74%) (Table 
2). The transduction efficiency of the CAFC week 6 in MFG-EGFP/AmI2 
transduced CD34- cells ranged between 0% and 11 % with a median of 6% EFGP+ 
cobblestone areas. CAFC week 6 in SF-EGFPIPGI3 transduced CD34+ cells 
showed as high as 27% transduction_ 
CAFC week 6 in SF-EGFPIPG13 transduced CD34+CD3W cells showed a similar 
level of 25% transduction efficiency. Notably, highly purified CD34+CD38- cells 
transduced with the amphotropic cell line did not produce EGFP- cobblestone areas 
week 6. These experiments clearly demonstrated the superiority of SF-EGFPIPG 13 
over MFG-EGFP/AmI2 in transducing late appearing CAFC, in concordance with 
the results obtained in phenotypically identified immature CD34+ subsets. 
Repopulation of transduced subsets in NODISCID mice. 
In parallel with analysis of cobblestone formation the ability of transduced cells to 
reconstitute hematopoiesis in vivo was examined by transplantation of the 
129 
EGFP expression in umbilical cord blood stem cells 
equivalent of 105 non-cultured CD34" cells into sublethally irradiated NOD/SCm 
mice. After 35 days the level of chimerism and the percentage of EGFP+ cells in 
mouse bone marrow were detennined by flow cytometry (Table 3). Similar levels 
of engraftment were found in mice transplanted with non-cultured or cultured 
CD34+ cells. 
in CD34+ gate 
" 
00 
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Figure 2. Flow cytornetric analysis of a representative transfection of purified CD34 + cells 
with the amphotropic MFG-EGFP retroviral vector after 2 days prestirnulation and 2 days 
supernatant infection in the presence of IL-3. IL-6 and SCF. This particular transduction 
resulted in efficiencies of 30% within the CD34 + population (Al. In (El CD34+ cells were 
gated and the CD38 distribution of the EGFP-transduced cells was studied. Also 
CD34+CD3S- cells expressed the EGFP gene with efficiencies sintilar to the total CD34 + 
population (30% EGFPl. 
Following transplantation of non-cultured CD34- cells human cells were detected 
in all mice (n=ll) (median: 54% (6-64%) CD45" cells). EGFP+ cells were found in 
6 of 10 repopulated chimeric mice transplanted with MFG-EGFPlAmI2-
transduced CD34" cells with a median percentage of EGFP+ cells of 2% (Table 3). 
CD34+ cells transduced using the SF-EGFPIPG13 vector produced higher levels of 
EGFP+ cells (median: 23%) in the human population in all 4 mice transplanted. 
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Figure 3. Fluorescence microscopic image of a representative EGFP+ cobblestone area. The 
bright green cells are the mature cells on top of the stromal layer and the dim green cells 
represent the EGFP+ cobblestone area. 
These data demonstrated that the repopulating cells in the CD34" population can be 
transduced effectively and produce EGFP+ progeny in transplanted NOD/SCm 
mice. In addition, SF-EGFPIPG 13 was much more efficient in transducing the 
repopulating cells than MFG-EGFPI Am12. 
Transplantation of non-cultured CD34+CD38- cells and transduced CD34+CD38-
resulted in chimerism levels of median 10% (6-29%) for the non-cultured cells and 
5% (1-24%) and 6% (4-9%) for tbe MFG-EGFP/AmI2 or SF-EGFPIPGI3 
transduced cells, respectively. In contrast to tbe results with purified CD34+ cells, 
CD34+CD3S- cells transduced with MFG-EGFP/AmI2 were not able to repopulate 
mouse BM with EGFP-expressing cells, altbough all 4 mice engrafted with human 
cells (Table 2); this parallels the absence of EGFP expressing CAFC week 6 in 
CD34+CD3S- cells transduced with MFG-EGFP/AmI2. Only 1 of3 mice engrafted 
with SF-EGFPIPG13 transduced CD34-CD3S- cells. EGFP+ could only be detected 
in 3% of the CD45+ cells produced. This is in contrast to the results witb the CD34+ 
cells in that apparently most repopulating cells in the highly purified CD34+CD3S-
subset were not transduced efficiently or the transduced cells displayed a 
significant reduction in their engraftment potential compared to the cells which 
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were not transduced during the procedure. Nevertheless, SF-EGFPJPGI3 was also 
in these experiments apparently more efficient than MFG-EGFP/AmI2. 
Table 2. Absolute numbers of CAFC week 2 and week 6 and percentages of green 
fluorescent cobblestone areas after transduction of 10' selected UCB CD34+ cells or 35x\O' 
CD34+CD3S- cells with the vectors MFG-EGFP or SF-EGFP. 
CAFCwkl CAFCwk6 
CD3r % CD34TD3S- % 
Non-transduced nd 4 xlO' 
AmI2IMFG-EGFP 21S x103• 26 15 41 x103• 6 
PGI3/SF-EGFP 24 
% percentage of green fluorescent cobblestone areas expressed as median. 
nd not detectable. 
* n=2 
# n=1 
Multilineage outgrowth of EGFP -transduced CD34+ cells. 
0.3 xl03 
nd 
25 
The composition of the EGFP- human cell population in 2 mice was assessed by 
flow cytometry using a panel oflineage specific markers (Figure 4). EGFP+ cells of 
the myeloid lineage (CD33; 31-39%, CDllb+; 20-25%, CD4; 30-45%), T 
lymphoid (CD2; 20-22%), B-lymphoid (CD20; 16-23%), and NK cells (CD56; 
1 %) were found in mice transplanted with EGFP-transduced CD34+ cells. Also 
immature EGFP+CD34+ cells were present in the mouse BM (1.1-6.8%) (Figure 5). 
Transduced cells and chimeric mice BM were also cultured in standard 
methy1cellulose medium under conditions which selectively favour the outgrowth 
of human monomyeloid and erythroid progenitors and fail to stimulate mouse 
progenitors. In both the graft and the chimeric mice BM, EGFP+ GM-CFU (15/39 
in the graft and 3123 in the mouse BM) and BFU-E (23/40 in the graft and 5/25 in 
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the mouse BM) were identified by flow cytometry of isolated colonies or 
fluorescence microscopy of whole cultures. 
------.... ~ Green fluorescence 
Figure 4. Representative immunophenotyping of chimeric NOD/SCm mouse BM 35 days 
after transplantation of MFG-EGFP/AmI2 transduced, IL-3, IL-6, SCF-stimulated CD34+ 
DCB cells. BM (>10% CD451 was stained with a panel of antibodies specific against 
different human blood cell lineages and CD45 as a marker for human cells. Figure A shows 
the bright green autofluorescence on the X-axes vs. CD45. The window represents all 
human, CD45~ cells. The other dotplots shown, are gated cells in this CD45 + window 
representing only human cells. Representative examples are shown for EGFP vs. CD34 (B), 
EGFP VS. CD33 (C) EGFP vs. CDllb, (D), EGFP vs. CD2 (El, EGFP VS. CD4 (Fl, EGFP 
VS. CD20 (Gl and EGFP vs. CD56 (H). 
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Discussion 
The versatile use of EGFP as a selectable marker of retroviral-mediated gene 
tra.'1sfer in hematopoietic cells provides a basis to further optimise retroviral gene 
transfer to human repopulating stem cells and to evaluate the role of hematopoietic 
growth factors in activation and expansion of immature hematopoietic cells. This 
study focused on the development of optimal conditions for gene transfer to human 
CD34+ and CD34+CD3S- UCB cells with the ability to reconstitute hematopoiesis 
in NOD/SCID mice and produce cobblestone areas for prolonged periods in 
stroma-supported long-term cultures. 
Comparison of transduction frequencies of immunophenotypically characterised 
immature cells and those of SCID repopulating cells and CAFC may both 
demonstrate the relationship of these cell types as well as point to essential 
differences. In general, there was concordance between these assays, in that the 
GaLV-pseudotyped retroviral vector (SF-EGFP) transduction was much more 
efficient than the amphotropic retroviral vector (MFG-EGFP) transduction. Also, 
transduction frequencies of the immature CD34+CD3S- subset within the CD34+ 
population related well to those obtained following transplantation of NOD/SCm 
mice and CAFC week 6. In addition, the study revealed that repopulating cells in 
the highly purified CD34+CD3S- cells were resistant to transduction in the absence 
of the CD3S+ subset, particularly notable for MFG-EGFP/AmI2 as demonstrated 
by the finding that the EGFP transduced CD34+CD3S- subset in general failed to 
produce EGFP- progeny in NOD/SCm mice. One mouse transplanted with SF-
EGFPIPGl3 transduced sorted CD34+CD3S- cells displayed 3% human EGFP+ 
cells, one order of magnitude less than the frequency of EGFP+ CAFC week 6 in 
the same sample. 
The more prominent transduction efficiency of the green fluorescent protein gene 
into purified and highly purified immature UCB cells with the GaLV-pseudotyped 
SF-EGFP compared to the MFG-EGFP/ Aml2 retroviral packaging cell 
combination, is consistent with earlier studies where transduction of human 
hematopoietic progenitors was more efficient with a retroviral vector that uses the 
GaL V receptor23-26 The lower transduction percentage obtained with the 
amphotropic vector may thus be primarily attributed to the low or absent 
expression of the amphotropic envelope-receptor on the target cells4S. 49 This was 
particularly corroborated by the absence ofEGFP expression in MFG-EGFP/AmI2 
transduced sorted CD34+CD3S- cells, both in the week 6 CAFC assay and 
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following transplantation into NOD/SCm mice, Alternatively, UCB cells may be 
more efficiently transduced by tbe SF-EGFPIPG13 vector/packaging cell 
combination due to tbe use of tbe SFFV IMESV hybrid promoter which has been 
designed to overcome transcriptional inefficiency and silencing associated witb 
retroviral gene transfer into myeloid progenitors and hematopoietic stem cells, 50 
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Figure 5, Representative chimerism (0 ) and EGFP expression levels ( IZI ) in chimeric 
NOD/SClD mouse BM 35 days after transplantation of nontransduced (A) and transduced 
(B) CD34+ VCB cells, relative to the numbers of human (CD45-) cells found, 
Other variables tbat obviously need to be further analysed include differences in 
titer and the ability and efficiency of the vectors to transduce EGFP in 
hematopoietic cells, The titers of tbe two vectors used were comparable, but tested 
in different assays, The colocalisation of vector and cells during transduction, using 
tbe CH-296 fibronectin fragment21 , makes it unlikely tbat differences in titer did 
heavily influence the results, This is tbe more so since preparative experiments (not 
shown) witb the MFG-EGFP/AMI2 retroviral vector revealed that additional 
charges of the virus supernatant in the transduction protocol did not result in higher 
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transduction frequencies, which indicated that the transduction system is 
sufficiently saturated with virus. Also Hanenberg et al. concluded that the amount 
of retroviral particles present in the supernatant was not a limiting factor for 
transduction of CD34+ BM cells on CH-296-coated plates 51 The higher efficiency 
of the SF-EGFPIPG13 combination when compared to the MFG-EGFP/AMI2 
combination should therefore not be considered as being due to supernatant virus 
titer differences. 
Table 3. Repopulation of EGFP transduced VCB subsets in NOD/SCID mice and CAFC 
assay 
VectorlPackagillg 
cell line 
DCB subset Transduction EGFP+I Chimerism % EGFP" CAFC wk 
efficiency chimeric mice* NOD/SCID on CD4, 6 
%EGFP %CD45 
AmI2IMFG-EGFP CD34- '31 (29-51) 6/10 12 (2-65) 
PG 13/SF-EGFP CD34+ '66 4/4 8 (3-12) 
?value >.05 
AmI2IMFG-EGFP CD34+CD38· '5 0/4 5 (1-24) 
PG13/SF-EGFP CD34+CD38· '21 1/3 6 (4-9) 
Pvalue >.05 
Results are depicted as median (range) of 2 or 3 experiments. 
For statistical analysis the Mann-Whitney V-test has been used 
nd not detectable. 
, insufficient data to perform statistical analysis. 
* all transplanted mice engrafted with> 1% CD4S+ cells. 
cells %EGFP 
2(0-18) 6 (0-11) 
23 (2-41) 27 (26-27) 
0.032 0.12 
0 nd 
3 ~5 
>.05 
The observation that repopulating cells in the CD34+ population can be transduced 
efficiently and produce transduced multilineage progeny in transplanted 
NOD/SCID mice, whereas repopulating cells in the highly purified CD34+CD3S· 
subset are either not transduced effectively or do not develOp in vivo is of 
considerable interest for elucidation of mechanisms involved in successful 
transduction of immature hematopoietic cells. The transduction efficiency of the 
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CD34+CD3S- tended to be lower than that of the CD34+ cells2, and was 
significantly so for the MFG-EGFP/AmI2 combination, which may be related to 
the low or absent expression of the amphotropic receptor. Since repopulating cells 
are exclusively present in the small CD34+CD3S- population, and CD34+CD3S+ 
cells do not effectively engraft, the low levels of gene expression in the chimeric 
NOD/SCm BM after transplantation of transduced CD34+CD3S- cells may 
indicate that the growth factors used during prestimulation and virus infection were 
not sufficiently effective for activation and stable virus integration of the 
NOD/SCm repopulating cells. The much higber frequency of EGFP expressing 
cells in the BM of NOD/scm mice after transplantation of transduced stem cells 
from the less pure CD34- fraction may indicate that stimuli provided by accessory 
CD34+ cells were responsible for the more efficient transduction of repopulating 
CD34+CD3S- within the CD34+ cell fraction. Alternatively, these accessory cells 
may be needed to maintain the repopulating ability of stem cells during the 
transduction procedure of 4 days, e.g. by preventing differentiation, or to promote 
the expansion and outgrowth of transduced stem cells after transplantation. We 
speculate that these accessory cells may be related to the accessory CD34+CD3S+ 
cells which are involved in the maintenance and expansion of CD34+CD3S- cells in 
immunodeficient mice transplanted with non-transduced human UCB subsets3 
Further identification of these accessory CD34+ cells and elucidation of the active 
principle may therefore be both relevant for stem cell expansion physiology and for 
the design of successful gene transfer strategies for immature hematopoietic cells. 
The absolute numbers of CAFC produced after week 2 and week 6 of culture show 
a modest increase after transduction with the MFG-EGFP or SF-EGFP vectors. The 
frequency of EGFP+CAFC week 6 in SF-EGFP or MFG-EGFP transduced CD34+ 
UCB cells was similar to levels of EGFP+CD45+ cells found in NOD/SCm mice. 
The reason for the 10-fold discrepancy between the levels of transduction of the 
CAFC week 6 and the very low numbers of EGFP+CD45+ in NOD/SCm BM after 
transplantation of the SF-EGFPIPG l3 transduced CD34+CD38- population is not 
clear. Studies with the murine ADA vector similarly yielded very low numbers of 
gene-marked human cells in the NOD/SCm mouse BM, in contrast to higher 
numbers of transduced LTC-IC and colony forming cells (CFC), which was 
interpreted as evidence that the latter cell types are functionally distinct from 
NOD/SCID repopulating cells. 1 However, this distinction might be artificial if 
effectively transduced CD34+CD38- require the described CD34- accessory cells 
for in vivo maintenance and expansion but not for in vitro cobblestone area forming 
ability. 
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We conclude that retroviral mediated EGFP transduction in umbilical cord blood 
cells, in combination with functional assays for repopulating cells, is a rapid tool to 
study essential gene transfer variables such as vector tropism and transduction 
conditions. In addition, the use of the GaLV-pseudotyped retroviral vector SF-
EGFP resulted in highly efficient gene transfer in both late CAFC and NOD/SCm 
repopulating cells, the latter presently the most immature subset of human 
CD34-CD3S' cells that can be approached by a functional assay. These results 
justifY the expectation, that the imminent analysis of variables promoting genetic 
marking of primitive, transplantable hematopoietic cells, such as further optimised 
transduction conditions and vector constructs, lead to protocols for clinically 
relevant levels of therapeutic gene transfer. 
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Abstract 
Retrovirus mediated gene transfer in hematopoietic stem cells of large outbred 
species including humans has met with considerable difficulty, with only low 
numbers of transplantable stem cells successfully transduced and a significant loss 
of repopulating capacity. We analysed the relative importance of variables 
determining the efficiency of gene transfer, using the gene encoding an enhanced 
version of the green fluorescent protein (EGFP) as a marker. Fibronectin fragment 
CH-296 supported supernatant transduction of CD34" umbilical cord blood (UCB) 
or rhesus monkey bone marrow (RhBM) cells in serum free cultures stimulated 
with Flt3 ligand (FL), stem cell factor (SCF) and thrombopoietin (TPO) was done 
with a virus pseudotyped for the gibbon ape leukemia virus (GAL V). The EGFP 
gene was driven by the SF promoter, composed of elements of the spleen focus 
forming virus, SFFV, and the murine embryonic stem cell virus, MESV. The data 
revealed a substantial dependence of the CH-296 supported transduction on virus 
titer. Selection of high titer sub clones of the virus producer cell line resulted in 
transduction efficiencies of more than 90% in CD34+ RhBM cells and UCB cells. 
Prior cryopreservation of RhBM cells was essential for high transduction levels. 
Transplantation into NOD/SCm mice of UCB cells confmned the validity of the 
optimal conditions for scm repopulating cells (SRC' s). The results revealed a 
threshold for transduction of SRC's relative to CD34 - cells and demonstrated that 
transduction efficiencies of SRC's of -80% can be obtained with retrovirus vectors 
under optimal conditions that transduce> 90% of the primary CD34+ cells. 
Introductiou 
Stable retrovirus mediated gene transfer into human hematopoietic CD34+ cells 
with repopulating capacity has large potential for the treatment of a variety of 
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hereditary and acquired diseases and as an adjuvant in the treatment of tumors. The 
promise of clinical gene transfer has recently been highlighted by treatment of 
SCID-XI disease, in which the transgene confers a selective advantage to 
transduced lymphoid progenitorsl, and in an initial study directed at transfer of the 
multidrug resistance I (MDR-I) gene, where a selective pressure can be exercised 
in vivo. 2 These successes were reached with relatively conventional retrovirus 
vectors and moderate transduction efficiency of the transplanted CD34+ cells, 
which are amenable to further improvement required for many other clinical 
conditions that can potentially be cured by gene therapy. Despite these recent 
achievements, retrovirus mediated gene transfer is still problematic and its clinical 
application limited by low transduction frequencies in long term repopulating stem 
cells3 
Several improvements have been made recently which include new insights into 
the growth factors required to induce cell cycling of immature. transplantable stem 
cells4-6, alternative viral receptors7. 8, improved retroviruses9-l2. as well as 
methods to co-localise virus and cells. especially by the recombinant fibronectin 
fragment CH-296. In addition, the development of selectable reporter molecules 
such as the enhanced green fluorescent protein (EGFP) speeded up the analysis of 
transduction procedures, enabled viable selection of the transduced cells by flow 
cytometry, and provided a tool for rapid monitoring of the fate of the transduced 
cells and their progeny after transplantation. l3-l7 
The low frequency of hematopoietic stem cells in most target populations and the 
inherent resistance to transduction due to their quiescent state likely are major 
limiting factors for transduction. Hence, the use of purified cell populations and 
induction of cell cycling without promoting excessive differentiation and, thereby, 
loss of repopulating capacity, are essential features of retrovirus mediated 
transduction procedures. Recently, the combination of Flt-3 ligand (FL), stem cell 
factor (SCF) and thrombopoietin has been identified as a minimum growth factor 
requirement to stimulate stem cells while preserving repopulating capacity18-2l 
Adding growth factors such as IL-3 or IL-ll to this combination resulted in a 
dramatic decline of repopulating capacity in short term serum free cultures with no 
difference being apparent in transduction efficiency2l, consistent with the 
detrimental effect ofIL-3 on repopulating capacity reported earlier22 
Facilitation of retrovirus cell transductions by colocalisation of cells and virus 
using a human fibronectin fragment (CH_296)23-25 increases the transduction of 
CD34~ cells substantially, enabled efficient supernatant transduction procedures 
that replaced the cumbersome co-cultivation of virus producing cells and target 
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cells23, 25, and was subsequently also shown to be effective for cells repopulating 
nonhuman primate bone marrow.26 
Retrovirus vector design aims at viruses that are better suited to transduce 
hematopoietic stem cells than the classical Moloney virus derived vectors27 and 
display increased gene expression and reduced silencing. Several improvements 
have been made, including the development of vectors based on the 
myeloproliferative sarcoma virus!! and the Friend spleen focus-forming virus 
(SFFV)9. 28 Combination of the U3 region of the SFFV and a permissive leader 
from the murine embryonic stem cell virus generates viruses that give superior 
gene expression in CD34+CD3S- cells12 Using such a GAL V-pseudotyped SF 
virus and the EGFP reporter gene, we previously showed much higher transduction 
frequencies than those that could be achieved with the Moloney virus based 
amphotropic MFG-EGFP virus in UCB cells, able to reconstitute hematopoiesis in 
NOD/SCID mice and to produce cobblestone areas for prolonged periods in 
stroma-supported long-term cultures16 This was consistent with earlier studies 
which showed that replacing the conventional amphotropic packaging cell lines 
with the packaging cell line PG 13, which generates virus, pseudotyped for the 
gibbon ape leukemia virus (GAL V) envelope protein, results in higher transduction 
levels of transplantable immature hematopoietic cells,9. 29-35 as well as with the 
characteristics of the SF virus used.36 The comparatively low efficiency37-42 of 
amphotropic retrovirus vectors is attributed to a lower expression level of the 
amphotropic retrovirus receptor (Pit-2) than the GALV receptor (GLVR-l, Pit-I) 
on immature hematopoietic.!6. 29, 30. 43-48 On the basis of these results we 
postulated that the further analysis of variables influencing transduction frequency 
should lead to much higher levels, bringing gene transfer within reach for disease 
entities in which a selective advantage of the transduced cells would be relatively 
sma1l49-52 or not be expected. 
To meet this aim, the present study focuses on finding residual relevant variables to 
promote retrovirus mediated gene transfer in human umbilical cord blood and 
rhesus monkey immature hematopoietic cells. Briefly, we used the PGl3 
packaging cellline30 for GAL V pseudotyping and the SF-EGFP virus43 in serum 
free cultures53-55 supported by the fibronectin fragment CH-296.23 The growth 
factors used were restricted to FL, SCF and TPO. Further variables studied 
included multiplicity of infection (i.e., virus titer versus cell concentration) and 
prior cryopreservation. Although the study was primarily aimed at rhesus monkey 
immature cells, the general applicability of the results was further verified in 
human UCB cells, using a rapid read-out for repopulating capacity of EGFP 
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transduced CD34+ UCB cells by transplantation of CD34+ cells into NOD/SCID 
mice56, 57, to measure content of "SCID-repopulating cells" (SRC's)58 and to 
assess tbe multilineage nature of tbe transduced cells, 
Material and methods 
Human umbilical cord blood and rhesus bone marrow cells 
Human umbilical cord blood (UCB) samples were obtained after informed consent 
in conformity witb legal regulations in The Netberlands from placentas of full-term 
normal pregnancies, Normal rhesus BM (RhBM) samples were obtained as 
described59 from purpose-bred healtby rhesus monkeys (Macaca mulatta) housed 
in stainless steel cages in rooms equipped witb a reverse filtered air barrier, 
provided witb daylight rhythm, and conditioned to 20°C witb a relative humidity of 
70%, Animals were given free access to commercially available primate chow, 
fresh fruits, and acidified water, All animals were free of intestinal parasites and 
seronegative for herpes B, simian T-Iymphotrophic viruses (STLV), and simian 
immunodeficiency virus (SIV), An ethics committee operating in conformity witb 
legal regulations in The Netberlands approved housing, experiments and all otber 
conditions, In a number of experiments, rhesus monkey BM was obtained 
following priming ("mobilisation") witb 100 flgikg G-CSF (Neupogen; Amgen Inc, 
Thousand Oaks, CA) for 4 consecutive days. UCB and RhBM mononuc1eated cells 
were isolated by Ficoll density gradient centrifugation (1.077 g/cm2, Nycomed 
Pharma AS, Oslo, Norway), and were cryopreserved in 10% dimethylsulphoxide, 
20% heat-inactivated fetal calf serum (FCS) and 70% Hepes-buffered Hanks 
Balanced Salt Solution (H+H, Gibco, Breda, The Netberlands) at -196°C as 
described,60 After tbawing by stepwise dilution in H+H containing 2% FCS, the 
cells were washed with H+H containing 1% FCS and subsequently suspended into 
the serum free transduction medium, 
Subset purification 
Purification of CD34+ UCB cells was performed by posItIve selection using 
Variomacs Immunomagnetic Separation System6! (CLB, Amsterdam, The 
Netberlands), RhBM CD34+ cells were purified by positive selection usmg 
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Dynalbeads (Dynal, Oslo, Norway).62 Briefly, low-density cells were incubated 
with an IgG2A antibody against CD34 (mAb 561; from G. Gaudernack and T. 
Egeland, Rikshospitalet, Oslo, Norway) that was covalently linked to rat anti-
mouse IgG2A beads. CD34" cells devoid of the CD34-antibody were recovered 
using a polyclonal antibody against the Fab part of the CD34 antibody 
(Detachabead, Dynal). The percentage CD34+ cells in the unseparated population 
and in the purified CD34+ and CD34- fractions was determined by flow cytometric-
analysis (FACS Calibur, Becton Dickinson, San Jose, USA) 
Viral vector and packaging eel/line 
The pseudotyped retrovirus producer cell line PG 13/SF-EGFP7 was kindly 
provided by J. Barquinero (Institut de Recerca Oncologica, Barcelona. Spain). The 
cell line was developed by transducing the PG 13 packaging cell line 7 (kindly 
provided by D. Miller, Fred Hutchinson Cancer Research Center. Seattle, W A) 
with 0.45 I1ill filtered supernatant from PA317!EGFP cell cultures.43 Expression of 
the enhanced green fluorescent protein (EGFP) was analysed by flow cytometry 
and bright single cells were sorted on 96-well plates by using an EPICS Elite ESP 
flow cytometer coupled to an autoclone device (both from Coulter, Miami, FL, 
USA). Single clones were cultured as previously described.43 The PG 13!EGFP7 
cell line was subsequently subcloned by diluting the cells to 1 cell per well of a 96-
well plate. Single subclones were cultured in culture medium consisting of an 
enriched version of Dulbecco's modified Eagle's medium (DMEM, Gibco, 
Gaithersburg, MD)14. 54 supplemented with 10% fetal calf serum (FCS) and kept at 
37°C with 10% CO, in a humidified atmosphere. The subclones were analysed for 
transduction efficiency on rhesus BM and UCB CD34- cells. The viral titer of the 
cell lines used for further experiments (original and subclones) was in the order of 
10' - 106 infectious particles per ml as determined by supernatant titration on 
cultured human HeLa cells and Rat-2 cells. Absence of replication-competent virus 
was verified by failure to transfer EGFP-expression from transduced Rat-2 cells to 
a secondary Rat-2 cell population. 
Retrovirus mediated transduction 
Supernatants containing recombinant retrovirus were generated by culturing 
approximately 80% confluent producer cells for 12 hours in culture medium 
consisting of serum-free enriched version53. 54 of Dulbecco's modified Eagle's 
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medium (DMEM, Gibco, Gaithersburg, MD), further modified with equimolar 
concentrations of cholesterol and linoleic acid. 55 Media for all cultures routinely 
included 100 U/ml of penicillin and 100 flg/ml of streptomycin. The cultures were 
maintained at 37°C with 10% CO2 (measured every 15' with read-outs between 
9.5% and 10%) in a humidified atmosphere. The culture supernatant was 
subsequently produced and passed through a 0.45 flm filter. To enhance the 
transduction efficiency, Falcon 1008 (35 mm) bacteriological culture dishes were 
coated with the recombinant fibronectin fragment CH-296 (Takara Shuzo, Otsu, 
Japan) at a concentration of 10 flg/cm2 as described previously.25 
Table 1. Repopulation ofEGFP-transduced CD34+ DCB cells in NOD/SCm mice 
Virus producer Transduction EGFP+I Chimerism in %EGFP+ in CD45+ 
efficiency chimeric NOD/SCm cells ± SD (range) 
%EGFP mice %CD45 
PG13/SF-EGFP7 66 4/4 8 (3-12) 23 ± 17 (2-41) 
PG 13/SF -EGFP7.1 85 5/5 3 (1-6) 63 ± 17 (38-80)* 
* p<0.009 
CD34-selected UCB and normal RhBM cells were prestimulated for 2 days in 
enriched DMEM with the human recombinant growth factors (GF) frns-like 
tyrosine kinase-ligand (Flt3-L, 50 ng/ml, kindly provided by Immunex, Seattle, 
WA, USA), thrombopoietin (huTPO or RbTPO, 10 ngiml, kindly provided by 
Genentech, South San Francisco, CA, USA) and stem cell factor (SCF, 100 ng/ml). 
Before adding purified subsets to the fibronectin-coated dishes, the CH-296 
fibronectin fragment was preincubated with supernatant containing the 
pseudotyped vector for I hour at 37°C23. 25 Subsequently, nucleated cells were 
resuspended in the vector-containing supernatant supplemented with the GF 
cocktail, and added to the dishes. Over a period of 2 days, culture supernatant was 
replaced completely by resuspending non-adherent cells into fresh retrovirus 
supernatant and GFs. The standard cell number used in transduction experiments 
was 10' cells/mL For cell titration experiments the cell concentration varied from 
3x106/ml to 101/mL The producer cell line was routinely cultured in T75 cm2 flasks 
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filled with 10 ml serum-free culture medium until 80% confluence. During the 
transduction, the virus supernatant was refreshed once. After 2 days of 
prestimulation and 2 days of supernatant infection in the presence of SCF, TPO and 
Flt3-L, the cells were harvested and the transduction efficiency was determined by 
visualising EGFP transduced cells by flow cytometry. The cells were 
counterstained with a monoclonal antibody against CD34 (566, G. Gaudernack and 
T. Egeland, Rikshospitalet, Oslo, Norway) that had been conjugated with the Cy-5 
fluorochrome. 
Transplantation of transduced UCB cells into NODISCID mice 
Male, specified pathogen-free (SPF) NODlLtSz-scidiscid mice (NOD/SCID) were 
bred and housed under SPF conditions and supplied with sterile food and drinking 
water containing 100 mg/I ciprofloxacine (Bayer AG, Leverkusen, Germany) ad 
libitum. Housing, care and all animal experimentation were done in conformity 
with legal regulations in The Netherlands, which include approval by a local 
ethical committee. All mice received total body irradiation (TBI) at 3.5 Gy, 
delivered by a l37Cs source adapted for the irradiation of mice (Gammacell, Atomic 
Energy of Canada, Ottawa, Canada), 2-4 hours before transplantation. The 
transplants were suspended in 200 III H+H and injected iv. into a lateral tail vein. 
Transplanted cell numbers were 2x105 CD34' UCB cells. At day 35 after 
transplantation, the mice were killed by CO, inhalation followed by cervical 
dislocation, both femurs and the spleen were isolated and BM suspensions were 
prepared by flushing. After counting, BM cells were analysed by flow cytometry to 
determine the percentage human EGFP+ cells in the mouse BM and cultured in 
colony assays as described53-55• 57 to measure the transduction of colony forming 
units-granulocyte/monocyte (GM-CFU) and burst forming units-erythrocyte (BFU-
E). 
Statistics 
Data were expressed as median (range). Statistical comparisons were performed 
according to Mann Whitney U-test. Two tailed P values of <0.05, were considered 
significant. Actual significance levels are indicated in the Tables and Figures. 
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Figure I. Titration of cryopreserved CD34-se1ected RhBM cells (panels A + B) and UCB 
(panels C + D) during transduction using the pseudotyped PG 13/SF-EGFP7 packaging 
cell/vector combination. 
Results 
Decreasing cell numbers result in higher transduction efficiencies 
The efficiency of transduction in cryopreserved purified CD34- cells using TPO, 
Flt3-L and SCF stimulation, appeared to be highly dependent on the number of 
target cells per culture (Figure 1). Cell numbers of 3xlO6 CD34-selected rhesus 
monkey BM (RhBM)/ml resulted in very low levels of transduction of the CD34 
cells, i.e., -5% EGFP+ cells. (Figure IA+B). The transduction efficiency using the 
virus supernatant produced by the PG13/SF-EGFP7 cell line increased 3 to 6-fold 
with decreased cell numbers/m!. The maximum transduction levels were -35% for 
RhBM cells at a concentration of 105 cells/m!. Decreasing the cell concentration to 
103 cells/ml did not increase the transduction efficiency further. Transduction of 
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graded numbers of purified CD34" UCB cells (Figure I C+D) showed the same 
effect. Low frequencies of EGFP+CD34+ cells (-20%) were found at cell numbers 
of 3x106/ml, whereas frequencies of transduced cells increased to -75% at target 
cell concentrations below 5xl05 cells/m!. The maximum transduction efficiency of 
UCB cells was more than 2-fold higher than the transduction efficiency of RhBM 
cells. Also, the apparent saturation occurred for RhBM at 5-fold lower 
concentrations than for UCB cells, suggesting a difference in GAL V receptor 
density andlor affinity. All further experiments were performed using a cell 
concentration of lOs RhBM cells or 5x105 UCB cells. 
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Figure 2. Transduction efficiency of RhBM CD34+ cells of 5 subclones derived from the 
parental packaging cell/vector combination PG 13/SF -EGFP7 (A). Transduction efficiencies 
of recloned producers I, 2 and 5 are shown in B. 
High titer clones of PG 13ISF-EGFP resulted in high transduction efficiencies 
Single cell culture of the PG 13/SF-EGFP7 packaging cell/vector combination by 
limiting dilution resulted in five PG 13/SF-EGFP subclones. The virus titers were 
determined by supernatant titration on human HeLa cells and Rat-2 cells. Subclone 
I (PG 13/SF -EGFP7.1) showed the highest titer of 5x105 infectious particles per ml, 
which was 2 times higher than the virus titer of the parental cell line (PG 13/SF-
EGFP7) (data not shown) whereas subclone 5 (PG13/SF-EGFP7.5) showed a titer 
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which was considerably lower than the parental PG 13/SF-EGFP7 packaging 
celllvector combination (l04 infectious particles/ml). Therefore, the serial passage 
of the producer cell line had produced a significant heterogeneity, affecting virus 
titer. 
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Figure 3_ Titration of cryopreserved CD34-selected RhBM cells during transduction using 
the pseudotyped PG 13/SF -EGFP7 packaging cell/vector combination and the subclone 
PGl3/SF-EGFP7.1. 
The transduction efficiency of the subclones was tested using cryopreserved CD34-
selected RhBM cells (Figure 2). Clones with a higher virus titer (PG 13/SF-
EGFP7.1 and 7.2) resulted consistently in high transduction efficiencies in the 
order of magnitude of -90% to be compared with the -50% efficiency of the 
parental PG 13/SF-EGFP7 cell line in the same experiment. The low titer sub clone, 
PG 13/SF-EGFP7.5, transduced the CD34- RhBM cells with a low efficiency of 
-5%. Recloning the subclones I, 2 and 5 transduced rhesus BM and UCB cells 
with the same efficiency as their parental sUbclones, demonstrating that these were 
homogeneous and stable (Figure 2B). Using the most efficient sub clone 7.1, we 
examined the dependence of transduction efficiency on cell concentration in 
comparison to that obtained with the parental clone. Figure 3 demonstrates the 
difference in both the plateau level reached and the lack of dependence on cell 
concentration in the range studied when using the high titer sub clone. This 
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demonstrated that the low level transduction of RhBM cells is not due to the 
presence of receptors on only a subset of CD34+ cells63 and that the maximum 
transduction can be achieved at higher cell concentrations by increasing the 
multiplicity of infection (m.oj.). Consequently, there was a direct relationship 
between the virus titers and CD34+ transduction efficiencies (Figure 4). The 
saturation level of the virus titer is 4xlOs particles/ml, corresponding to a m.oj. -4, 
above which the transduction levels did not increase further. 
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Figure 4. Virus titer related to efficiency of transduction of CD34' selected RhBM cells. 
The virus titer was determined on HeLa cells C+) and on Rat-2 cells CIII). 
Transduction of cryopreserved vs fresh hematopoietic cells 
Cryopreservation of normal or G~CSF primed rhesus BM resulted in 3-fold 
increased transduction levels compared to fresh cells (Figure 5). Transduction of 
fresh G-CSF primed RhBM with subclone 7.1 resulted in 30% ± 24% EGFP+ cells 
(n=8), whereas frozen BM samples of G-CSF primed monkeys were transduced 
with significantly (p<0.01) higher numbers of 70% ± 10% EGFP" cells (n=4). A 
significant difference was not found between the transduction efficiency of frozen 
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G-CSF primed cells, frozen normal RhBM (70% ± 16% EGFP+ cells, n=7) and 
frozen UCB cells (80% ± 12%, n=13). 
Transduction efficiency o/NOD/SeID repopulating cells (SRCs) 
To determine the effect of the optimised transduction conditions on repopulating 
ability, transduced UCB CD34+ cells were transplanted into NOD/SCID mice. 
Using the virus of the parental PG 13/SF-EGFP cell line, 10' CD34+ UCB cells 
were transduced with an efficiency of 66%. Injection of these transduced cells into 
4 NOD/SCm mice resulted on average in 23% EGFP positive cells within the 
CD45+ population. 16 Transplantation of CD34- UCB cells using the high titer virus 
producing subclone PG 13/SF-EGFP7.1 (77% and 93% EGFP- cells, respectively in 
2 experiments) resulted in 63 ± 17%, EGFP+CD45+ cells in the BM of engrafted 
mice (Table 1). The %EGFP+ cells in these mice was significantly higher than 
those obtained previously with 105 CD34+ cells (66% EGFPj transduced with 
virus produced by the parental PG 13/SF-EGFP virus producing cell line, i.e., 23% 
CD45+ cells after transplantation with 105 CD34- cells (p < 0.009). 
Table 2. Human CFU-GM and BFU-E in the chimeric NOD/SCm mouse BM 35 days after 
infusion 
Graft #CD45- # CD34+ CFU-GMI CFU-GMll05 BFU-E/femur BFU-EIl05 
cells/femur cells/femur femur human cells human cells 
x106 xl0' 
Day 0* 4.2 ± 3.0 6.6 ± 5.4 8997009762 332±316 10762 ± 14674 290 ± 275 
Day 4* 0.5 ± 0.24 LOOo LO 1180 ± 1150 25300135 1605±2319 293 ± 294 
* n=5 
Immunophenotyping of the human cells that were present in the mouse BM 
revealed that high levels of EGFP were expressed in all human hematopoietic 
lineages assessed, i.e., CD56+ NK cells, CD20+ B-lymphocytes, CD4+ or CDS+ T-
cells and CDllb+ and CD33+ monomyeloid cells, and immature CD34+ cells 
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(Figure 6). The numbers of CD45+ and CD34+ cells as well as human progenitor 
cells, i.e., GM-CFU and BFU-E, present in the BM of mice transplanted with 
EGFP transduced CD34+ cells were on average lower than those of mice injected 
with day 0 CD34" cells (Table 2), suggesting 0.5-1 log loss of SRC's under the 
conditions used, which is similar to data obtained in mice using similar 
transduction conditions and a quantitative transplantation assay21 Since these 
differences are not apparent in GM-CFU and BFU-E per 10' human cells (Table 2), 
the results point to an adequate preservation of repopulating capacity of the SRC's 
after transduction. Low numbers (0.4%) of human CD45- cells were found in the 
spleen of the mice, approximately 92% of these cells expressed the EGFP gene 
(data not shown). 
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Since only a small subset of CD34+ cells has the capacity to produce offspring after 
transplantationS7. 64, it was thought to be of interest to relate EGFP expression 
frequencies of CD45+ cells in the engrafted NOD/SCID mice witb tbe frequency of 
EGFP+ cells in the transplanted CD34- cells (Figure 7). This analysis revealed a 
tbreshold of transduction ofSRC's relative to the CD34+ cells, which explains why 
substantial transduction frequencies in CD34+ cells do not necessarily result in 
similar frequencies following transplantation, and also demonstrated that witb the 
optimised procedure up to 80% of tbe SRC' s should express the transgene. 
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Figure 6. Chimerism and EGFP expression levels in a chimeric NOD/SCm mouse BM 35 
days after transplantation of 105 CD34+ VCB cells of which 93% expressed the EGFP gene. 
The bright green autofluorescence on the X-axes vs. CD45 on the Y-axes clearly shows that 
almost all human (CD45+) cells (80%) express the EGFP. The right panel shows the 
distribution of EGFP- ( 0 ) and EGFP- cells (\;l ) in all hematopoietic lineages assessed. 
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Discussiou 
In this study, the fibronectin-based retrovirus mediated transduction protocol was 
further optimised, which resulted in high level transductions of >90% in CD34-
selected umbilical cord blood (DCB) and rhesus monkey adult BM cells. 
Transplantation of the transduced UCB cells into NOD/SCm mice resulted in up to 
80% EGFP+ human cells in the mouse BM 35 days after transplantation, 
demonstrating efficient transduction of cells capable of multilineage reconstitution 
following transplantation. 
Initially surprising, the cell concentration of the CD34- RhBM or UCB cells 
appeared to be of critical importance for the efficiency of the fibronectin-supported 
transduction procedure at limiting virus titers. Decreasing numbers of human and 
rhesus monkey progenitor cells resulted in increased percentages of EGFP-gene 
transduction. Hanenberg et al., demonstrated that the use of the fibronectin 
fragment during the transduction allowed large numbers of cells to be efficiently 
transduced on small surfaces coated with the CH-296 fragment and that the 
quantity of retroviral particles in the supernatant was not a limiting factor for the 
transduction of primary human cionogenic cells24, using a virus titer of >3xl06 
cfulml corresponding to an m.o.i. of 4.8 in the highest concentration used. The 
virus titer of the parental virus producer cell line used in our studies was -3x105 
/ml and the optimal concentration of CD34" UCB or RhBM cells used was 5xl05 
and 105 celis/mI, respectively, resulting in a m.o.i. of -1. This explains the negative 
effect of increasing cell concentration on the transduction efficiency and 
demonstrates that for optimal transduction efficiencies the cell concentration of the 
target cells should be carefully balanced with the virus titer. 
The highest transduction levels in RhBM using the PG 13/SF-EGFP7 combination 
was found at a cell concentration of 104 to 5xl04 cells/ml, which was 2 to 10-fold 
lower compared to UCB cells transduced under the same conditions of limiting 
virus titers with a maximum efficiency at cell numbers of 105 cells/m!. A likely 
explanation for this discrepancy between RhBM and UCB might be differences in 
virus receptor-expression of both cell types. This is corroborated by studies that 
compared the susceptibility of CD34+ BM progenitors from four non-human 
primate species (pigtail macaques, rhesus monkeys, cynomolgus macaques and 
baboons) and humans to transduction with amphotropic retrovirus vectors, which 
showed differences in transduction efficiency65 Semiquantitative RTIPCR analysis 
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suggested these differences due to different expression levels of the amphotropic 
receptor, Pit-2 in the different species. 
The pseudotyped PG 13/SF-EGFP producer cell line transduced human UCB cells 
with NOD/SCm repopulating ability with higher efficiency than the amphotropic 
ArnI2IMFG-EGFP packaging cell line/vector combination16 After several 
transduction experiments using RhBM and UCB with variable results, variability in 
the results prompted an analysis of the producer cell line by flow cytometry. 
Although the PG13/SF-EGFP cell line was initially cloned by single cell sor-t43, the 
expression of EGFP was heterogeneous, ranging from no expression to very high 
expression (up to 4 logs). The most likely explanation for the heterogeneity is 
silencing of expression of the EGFP gene and the packaging sequences during 
serial passage. Subcloning of the vector/packaging cell line by limiting dilution 
resulted in high titer clones (5 to 10-fold the titer of the parental PG13/SF-EGFP7 
packaging cell line/vector combination) which were able to transduce UCB and 
RhBM cells more efficiently. Use of the selected high titer producer cells and 
transduction of graded numbers of CD34-selected RhBM or UCB cells did not 
reveal the dependence on cell concentration encountered with the PG13/SF-EGFP 
in the range of cell concentrations examined and resulted in expression levels of 
>90% of both UCB and RhBM CD34+ cells. 
Transplantation of the UCB cells into NOD/SCID mice resulted in high 
frequencies of EGFP+ human cells 35 days. Compared to previous studies in which 
the parental clone was used to transduce NOD/SCm grafts16, the sub clone resulted 
in 2- to 4-fold higher engraftrnent levels of transduced SRC's, with a mean value of 
63 ± 17%, similarly expressed in all hematopoietic lineages examined. This 
demonstrates, fIrstly, the validity of the optimisation for transplantable 
hematopoietic stern cells and, secondly, that those cells can be transduced under 
optimal conditions with frequencies up to 80%. Relating the frequency of EGFP 
expressing cells in NOD/SCm mice to that of the primary transplanted CD34+ 
cells displayed a marked threshold of the SRC's relative to the CD34+ cells, with 
virtually nO engraftrnent of transduced cells at transduction frequencies of CD34+ 
cells < -30%. This might relate to a lower virus receptor expression at the small 
subset of repopUlating cells and is a phenomenon to bear in mind for clinical gene 
therapy protocols necessarily utilising CD34+ transduction frequencies for quality 
control. However, we do not exclude that the threshold is a purely numerical 
phenomenon attributable to the low seeding efficiency of human stern cells 
transplanted into the mouse environrnent. 16, 57, 66 
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Figure 7. Percentage of EGFP positive CD45+ cells in NOD/SCID mice 35 days after 
transplantation related to the percentage of primary EGFP positive CD34+ cells 
transplanted. (~) AMI2IMFG-EGFP transductions; (0) PG 13/SF-EGFP transductions. 
The amphotropic data were taken from reference 16, the other data points represent the 
individual data summarised in Table 1. The regression line of the data without the 
amphotrophic transductions is identical to that shown of all data pooled. 
When reanalysing data from all experiments, we noted that cryopreserved RhBM 
cells and DCB cells consistently gave higher transduction efficiencies when 
compared to fresh rhesus monkey BM used for transplantation purposes 
(manuscript in preparation), which prompted a systematic survey of freshly 
harvested versus cryopreserved RhBM cells. Cryopreservation of the target cells 
appeared to have an increasing effect on the transduction efficiency using the 
pseudotyped PG l3/SF-EGFP packaging cell/vector combination. This has not been 
earlier described for this virus receptor type, but is consistent with the increase in 
mRNA expression of the amphotropic receptor found in cord blood samples after 
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cryopreservation67-69 The expression of the GALV receptor (Pit-I) might be 
similarly upregulated after cryopreservation. The exact mechanism involved is not 
clear yet. A recent study described that CD34+ hematopoietic cells extend long, 
thin podia with adbesion receptors that are known to play important roles in blood-
cell migration and adbesion, including CD34, L-selectin and CD4SJO It is not 
unlikely that these podia also are the membrane location of other receptors and, due 
to their fragile nature, are damaged by cryopreservation, requiring upregulation of 
receptor expression after thawing. The expression of L-selectin, which is involved 
in migration and adbesion of primitive hematopoietic cells, is indeed decreased by 
the freezing procedure and restored after overnight incubation of the thawed cells 
in culture medium71, 72 All experiments with VCB cells were done after 
cryopreservation; initial experiments revealed no difference between fresh and 
cryopreserved VCB cells (data not shown), suggesting that receptor expression is 
already optimal in fresh VCB cells. 
The high transduction levels achieved in repopulating cells likely result from the 
use of the fibronectin fragment mediated co-localisation of virus and cells, the 
selection of a minimum combination of hematopoietic growth factors capable of 
preserving repopulating capacity while efficiently inducing cell cycling, complex 
serum free media to support the cells during culture and the use of pseudotyped 
retrovirus to overcome the low expression levels of the previously used 
amphotropic receptor on immature repopulating cells. 
The results shown in this study thus enable a reproducible, highly efficient 
retrovirus mediated method of gene transfer into hematopoietic cells with 
repopulating ability. We chose to test the repopUlating capacity of the transduced 
cells by using VCB cells transplanted into NOD/SCm recipients, rather than the 
much more laborious and time-consuming rhesus monkey recipients. The ongoing 
preclinical nonhuman primate experiments are directed at its clinical development 
using further improved, high titer SF type retroviruses. We conclude that, taking 
these optimal conditions into account, clinically applicable retrovirus mediated 
gene transfer of therapeutic genes that do not necessarily confer a growth 
advantage to transplantable hematopoietic stem cells is now within short-term 
reach. 
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Abstract 
A single dose of 0.3 fig recombinant human thrombopoietin (TPO) was injected 
into sublethally irradiated NOD/SCm mice immediately after transplantation of 
1.5xl05 purified CD34+ umbilical cord blood (UCB) cells. Bone marrow (BM) was 
analysed at day 35 for human cells by immunophenotyping and colony culture. 
TPO-treatment resulted in a 3 to 4-fold increase in the frequency and number of 
human CD45+ cells; mouse type cells were not influenced. The lineage 
distributions among the human cells were essentially similar irrespective of TPO 
treatment, however, with a lower frequency of myeloid CD33+ cells in the TPO 
treated mice and a prominent increase in the total number of erythroid and 
megakaryocytic cells. An impressive increase was observed in CD71"GpA' cells, 
reflecting the proliferative stimulus provided by TPO administration. Also the 
frequency of immature CD34+, CD34+CD38" cells and of human GM-CFU and 
BFU-E in TPO-treated mice was similar to that of untreated mice, but their total 
number had increased proportional to the increase of human cells. The results 
demonstrate that human TPO is a major limiting factor for multilineage outgrowth 
of human UCB cells in NOD/SCm mice and can be conveniently supplemented by 
single dose treatment immediately after transplantation. The findings in this study 
make the NOD/SCID mouse a more efficient assay for human hematopoietic stem 
cells and provide a new basis for further studies on human stem cell regulation 
using immunodeficient mouse models. In addition, immunodeficient mice 
transplanted with human UCB cells yield a suitable assay for the development of 
novel human c-mpl agonists. 
Introduction 
Xenotransplantation into immunodeficient mice is a major tool to study the 
properties of normal and malignant hematopoietic stem cells l -3, as well as the 
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development of ex vivo expansion4 and gene transfer5 Following the development 
of the severe combined-immunodeficient (SCID) mouse6, various crosses with 
other deficient mutants 7 have been explored, with more recently the non-obese 
diabetic (NOD)/SCm mouseS as a versatile recipient for these purposes9 -11 Some 
obvious disadvantages are the limited mature end cell production and the low 
seeding efficiency of the human cells in the mouse environmentl2, necessitating 
the use of large quantities of human cells, which could be partly attributed to 
accessory CD34-CD3S+ cells. 13 Supplementation of human growth factors such as 
interleukin-3 (IL-3) and granulocyte/macrophage-colony stimulating factor (GM-
CSF)14, stem cell factor (SCF) andlor PIXY321 (a fusion of IL-3 and GM-SCF) 
andlor erythropoietin (EPO) I 5. 16 or fins-like tyrosine kinase3-ligand (Flt3-L) 
andlor IL-717 has been used to augment the outgrowth of human cells in the mouse 
environment, or, more simply, addition of large quantities of irradiated human 
cellsl6, of which the role is not fully clear. Recent novel crosses of mutants, such 
as the NODlRagl nUll or the NOD/SCID/f32microglobulinnull mouselS. 19, require 
lower numbers of human cells, suggesting that residual immune functions in the 
NOD/SCm mouse contribute to the relative inefficiency of the NOD/SCm mouse. 
Also, species barriers may exist for hematopoietic growth factors, murine growth 
factors not necessarily being optimal or suited to stimulate the human cells. Since 
thrombopoietin (TPO) is an essential physiologic factor for stem cell maintenance 
and proliferation20, apart from its functions in platelet production and activation21 , 
in the present study we sought to explore the option of using human TPO to 
stimulate outgrowth of human cells in NOD/SCID murine recipients. 
TPO is the ligand for the receptor c_mpI22, which is expressed on megakaryocytes, 
platelets and their precursors and also on pluripotent hematopoietic progenitor 
cells. TPO was first isolated and cloned in 199423-25 and consists of a highly 
conserved amino-terminal domain that is related to EP021 TPO is constitutively 
produced, mainly in the liver, and its levels are regulated by c-mpl-mediated 
clearance by platelets26 and megakaryocytes27 As a consequence, exogenous TPO 
needs to saturate the c-mpl mediated clearance mechanism to be optimally active. 
Similar to many growth factors, TPO displays multiple biological activities and 
acts within the specific megakaryocytic lineage to produce platelets, has a role in 
platelet activation21 and stimulates immature hematopoietic stem cells.20 
Therefore, TPO may play an important role in in vivo and ex vivo expansion of 
hematopoietic cells with repopUlating ability. 
Ex vivo culture of CD34-selected UCB cells for up to 10 weeks using stroma-free 
culture conditions containing 10% human plasma plus TPO and Flt3-L resulted in a 
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large amplification of CD34+ cells, colony-forming cells, long-term culture-
initiating cells (LTC-IC) and NOD/SCm repopulating cells4 Cultures of murine 
BM using TPO as a single exogenous GF could be maintained for 3 to 4 months 
without apparent loss of the primitive phenotype and with sustained high-level 
production of both megakaryocytic and non megakaryocytic cells able to 
reconstitute hematopoiesis in lethally irradiated mice28 Furthermore, knock-out 
mice lacking TPO or c-mpl expression are not only thrombocytopenic and show 
80% to 90% reduction in megakaryocytes and platelets, are also seriously deficient 
in stem cell numbers, as was determined by serial transplantation experiments29 
Further evidence for the stimulatory action of TPO on immature hematopoietic 
cells was provided by studies of in vivo hematopoietic recovery after BM 
suppression as a result of total body irradiation (TBI) and/or chemotherapy30, 31 
Treatroent of mice32-35 or non-human primates without BM suppression36-38 
resulted usually only in a platelet response, whereas in myelosuppressed animals 
the response was convincingly multilineage in nature39-44 Administration of TPO 
to animals after chemotherapy or radiation shortened the interval to platelet 
recovery3L 45 One single intravenous (iv.) dose of TPO in non-human primates 
shortly after intensive cytoreductive treatroent was sufficient to significantly 
alleviate the course of thrombocytopenia46, consistent with the results in mice,47. 
48 and, in addition, accelerated BM CD34+ cell reconstitution, thereby potentiating 
the action of concomitant G-CSF or GM-CSF treatroent. TPO treatroent in 
myelosuppressed individuals did not result in adverse effects49 
This study focussed on the effect of a single dose of recombinant human TPO on 
the efficiency of engraftment of CD34+ UCB cells in NOD/SCm mice. Previous 
studies in which the use of immunodeficient NOD/SCID mice for transplantation 
assays with purified human UCB subsets was demonstrated, provided evidence for 
differential regulation of the expansion of immature human hematopoietic stem 
cells13, and opened an experimental approach to examine the effects of various 
GFs such as TPO. Briefly, CD34+ cells, isolated from UCB samples, were iv. 
transplanted into sublethally irradiated NOD/SCID mice, immediately followed by 
a single intraperitoneal (ip.) injection of 0.3 j.lg TPO. The dose used is sufficiently 
high to overcome initial c-mpl mediated clearance50, but found to be insufficient to 
stimulate the mouse type cells. After 5 weeks, the mice were sacrificed and the BM 
of the mice was analysed for human (CD45+) cells, lineage specific phenotypes and 
human colony-forming cells. 
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Material and methods 
Human umbilical cord blood cells 
UCB samples were obtained from placentas offull-tenn pregnancies after infonned 
consent in conformity with legal regulations in The Netherlands. Mononucleated 
cells were isolated by Ficoll density gradient centrifugation (l.077g/cm", Nycomed 
Pharrna AS, Oslo, Norway), and were cryopreserved in 10% dimethylsulphoxide, 
20% heat-inactivated foetal calf serum (FCS) and 70% Hanks Balanced Salt 
Solution (HBSS, Gibco, Breda, The Netherlands) at -196°C as described5l before 
use. After thawing by stepwise dilution in HBSS containing 2% FCS, the cells 
were washed with HBSS containing 1% FCS and used for transplantation into 
NOD/SCID mice. 
Subset purification 
Purification of CD34+ cells was perfonned by positive selection using Variomacs 
Irnrnunomagnetic Separation System as described52 (CLB, Amsterdam, The 
Netherlands). The percentage of CD34+ cells in the unseparated population (low 
density UCB) and in the purified CD34+ and CD34- fractions was determined by 
FACS-analysis. The CD34- subset used for transplantation contained 75% to 95% 
CD34+ cells after purification. 
Transplantation ofUeB subsets in immunodeficient mice 
Specific pathogen-free (SPF) NODlLtSz-scidiscid (NOD/SCID) mice, 6 to 9 weeks 
of age, were bred (experiment I) or obtained from Bornboltgard Breeding & 
Research Centre AlS, Denmark) (experiment 2) and The Jackson Laboratory (Bar 
Harbor, MA) (experiment 3), housed under SPF conditions in a micro-isolator and 
supplied with sterile food and acidified drinking water containing 100 mg/I 
ciprofloxacine (Bayer AG, Leverkusen, Gennany) ad libitum. Housing, care and all 
animal experimentation were done in confonnity with legal regulations in The 
Netherlands, which include approval by a local ethical committee. All mice 
received total body irradiation (TBI) at 3.5 Gy, delivered by a 137CS source adapted 
for the irradiation of mice (Garnrnacell, Atomic Energy of Canada, Ottawa, 
Canada), 2-4 hours before transplantation. The transplants were suspended in 200 
fLl HBSS containing 0.1 % BSA and injected iv. into a lateral tail vein. Transplanted 
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cell numbers were 1.5xl05 CD34+ cells. The group receiving human TPO was 
injected ip. with 0.3 fig full length recombinant human TPO (Genentech Inc., 
South San Francisco, CA) per mouse directly after transplantation. 35 Days after 
transplantation the mice were sacrificed by CO, inhalation followed by cervical 
dislocation, both femurs and spleen were isolated and cell suspensions prepared. 
After counting, the cells were cultured in colony assays and analysed by flow 
cytometry to determine the percentage and the distribution of human cells in the 
mouse BM. In total 32 mice were transplanted of which 16 received TPO 
injections. The survival of TPO-treated mice after transplantation was 11 (-70%), 
whereas only 7 mice of the 16 (-45%) transplanted without TPO treatment 
survived. 
Flow cytometry 
Cell samples were analysed using a F ACSCalibur flow cytometer (Becton 
Dickinson) as previously described. 13 Immunophenotyping of engrafted cells was 
performed by staining with preidinin chlorophyll protein (PercP) labeled anti-
CD45 and cyanin-S-conjugated anti-CD34 (CyS, Amersham, Buckinghamshire, 
UK) or PE conjugated monoclonal antibodies against lineage markers CD38, CD4, 
CD8, CD19, CD20, CD56, CD33 (Becton Dickinson Immunocytometry Systems, 
San Jose, CA, USA). Mice were considered engrafted if the percentage CD4S+ 
cells exceeded 1%. 
In vitro colony assay 
Purified UCB subsets and chimeric mouse BM samples were assayed for the 
presence of human GM-CFU and BFU-E by in vitro colony formation in viscous 
methykellulose culture medium as previously described. 13. 53-55 The number of 
colonies was determined after 14 days of culture in a humidified atmosphere of 
10% CO, at 37°C. 
Statistical analysis 
Data are expressed as median (range) or mean ± standard deviation (SD). 
Statistical comparisons were performed according to a two-tailed Mann-Whitney 
U-test. P values of <0.05 considered as statistically significant. 
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Table 1. Engraftment analysis of the BM after transplantation with 1.5xlO' CD34+ DCB 
cells. mean values ± standard deviation (SD) 
Exp TPO % #CD45 % #CD34 % # CD34CD38 # mouse 
CD45 cells / femur CD45CD34 cells/femur CD34CD38 Ifcmur cells/femur 
xlO6 xlO5 xlO3 xlO6 
~ (n""") 52 ± 19 6.5 = 3.3 27±9 20 ± 14 nd* nd 5.5 ± 1.7 
- (n~3) 29 ± 18 2.4 == 2.5 13 ± S 4.3 ± 6.0 nd nd 4.4 ± 1.0 
2 ~ (F5) 25 ± 14 3.1=2.4 11 ± 7 3.4 = 3.0 1.2 ± 0.9 2.2:i 1.3 7.9 = 1.6 
- (n~2) 6-8 0.6 -1.0 7 (n~I)A 0.5 (n~l) 1.6(n~l) 0.75 (Fl) 10 - 12 
3 + (F2) 20-55 5.7 - 6.3 10 - 21 6.4 - 12 0.2 - 1.5 1.0-18.7 5.2 -23 
- (n~2) 3-9 0.4 - 0.7 15 - 19 0.07 - 1.3 0.6 - 4.1 0.72-2.7 13 
Exp: experiment. #: number, * nd: not done, A (n=l) as the cell number of one of the mice 
was insufficient for analysis 
Results 
Chimerism ana(vsis 
Purified CD34+ UCB cells were transplanted into NOD/SCID mice with or without 
IP administration of 0.3 "g TPO. Chimerism levels were obtained 35 days later by 
staining the cells with the human pan-leukocyte antibody CD45. The results are 
showu in Figure lAo The percentage CD45* cells obtained in the mouse BM 
without addition ofTPO was on average 29% ± 18% (n=3) in the first experiment, 
6% and 8% (n=2) in the second experiment. and 3% and 9% (n=2) in the third 
experiment. Injection ofTPOresultedina2-to 6-fold higher level ofengraftment; 
i.e., 52% ± 19% (n=3), 25% ± 14% (n=5), and 20-55 (n=2), respectively (Figure 
IB, Table 1). These differences are statistically highly significantly (p<0.001) as 
showu in Table 2. 
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Figure 1. Levels of chimerism in NOD/SCID mice transplanted with 1.5xlO' CD3r VCB 
cells in 3 seperate experiments (A). In each experiment transplanted mice were either 
injected with 0.3 ).lg TPO (+, black symbol) or not (control, open symbol). Percentage 
CD45 was used as a measure for the level of chimerism. Numbers ofCD45+ cells per femur 
(B) were measured in individual mice that where injected with TPO (+) or no TPO 
(control). The number of mouse cells per femur in the NOD/SCID mouse BM is shown in 
Figure C. 
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The absolute numbers of human cells produced in the mouse BM after 
transplantation were 3 to 6-fold higher in TPO treated mice than those of the 
controls (Figure IB), whereas the number of mouse cells in the BM was not 
influenced by the injection of TPO (Figure I C, Table 2). Thus, the TPO 
administration had selectively expanded human cells and did not stimulate or 
negatively affect mouse hematopoietic cells during repopulation. Frequencies of 
CD45+CD34+ cells and CD34+CD3S- cells did not differ significantly with or 
without TPO treatment, but the absolute numbers of CD34+ cells and CD34+CD3S-
cells per femur were, proportional to the larger number of CD45+ cells, higher in 
the TPO treated mice than in the controls (Table I). 
Multilineage outgrowth is similar with or without TPO injection 
The lineage distribution among the human cells was assessed by flow- cytometry 
using a panel of specific markers (Figure 2). TPO-treated mice produced human 
cells of the myeloid lineage (CD33+; 24% ± 15%, CD33"CDIS-; 11% ± 6%; 
CD33+CDI5\ 14% ± 6%; CD33-CDl5\ 6% ± 2%, CDllb+; 21 % ± 11%, CD4"; 
. . 
IS% ± 14%), NK cells (CD56+; 1%), B lymphoid (CD20+; 10% ± 6%), T lymphoid 
(CDS+; 0.1 % ± 0.2%), and erythroid lineage (CD71+GpA+; 6% ± 2%, CD71++GpA 
; 1% ± 1%, CD7I'GPA+; 0.1% ± 0_02%). Also CD34+ cells (16% ± 10%) and the 
highly immature CD34+CD3S- subset (1%) were present in the human cell 
population (Figure 2A). The control mice displayed an essentially similar pattern of 
phenotype frequencies. However, CD71-GpA- cells were significantly more 
frequent in the TPO treated mice, whereas CD20+, CD33+ and CD56+ cells were 
significantly less frequent. In absolute numbers of cells produced per femur (Figure 
2B) the differences between TPO-treated and untreated mice were more profound. 
All phenotypes were increased in the TPO treated mice, most prominently so the 
CD41+ and the CD71+GpA+ cells, reflecting the megakaryoctic and erythropoietic 
lineages, and the CD71 +GPA cells, reflecting proliferating cells and thereby the 
proliferative stimulus provided by the TPO administration. 
Chimeric BM was cultured in standard methykellulose medium under conditions 
that selectively favor the outgrowth of human monomyeloid and erythroid 
progenitors and fail to stimulate mouse progenitors. In both TPO treated and 
untreated mice, GM-CFU and BFU-E were detectable at similar, approximately 
normal frequencies. The total number of colony-forming cells was considerably 
higher in the TPO treated mice than in the controls and proportional to the 
expansion of CD45- cells observed (Table 3). 
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Table 2. Statistical analysis of chimerism levels 
Analysis +TPO -TPO 
Number of mice transplanted 16 16 
Survival after transplantation 11 7 
Number of CD45" cells / femur 
Mean 4.9xl06 1.4xlO' 
Median 3.8xlO6 0.68xl06 
Standard error O.88x106 0.65xl06 
Standard deviation 2.9xlO6 1.7xl06 
P (two tailed)* <0.01 
Number of mouse cells / femur 
Mean 8.1xl06 7.9xlO' 
Median 7.3xl06 6.9xl06 
Standard error 1.6xl06 1.5xl06 
Standard deviation 5.2x106 3.8x106 
P(two tailed)* <0.9 
* for statistical analysis the Mann-Withney U-test has been used 
Discussion 
The results presented, provide new insight into the factors limiting the outgrowth 
of human cells in the murine environment and emphasise the importance of TPO in 
the regulation of immature cells with multilineage reconstitution capacity. Since it 
has been previously established that the NOD/SCm repopulating cells reside 
exclusively in the CD34-CD38" subsetl3. 56, the data can be interpreted as evidence 
for a direct action of TPO on these immature cells. The single dose TPO treatment 
apparently resulted in a sustained effect in that all differentiation lineages 
examined had expanded grossly similar 5 weeks after administration. 
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Table 3. Colony-fonning cells after transplantation into NOD/SClD mice 
Exp CFU-GM BFU-E TPO CFU-GMlI05 human* CFU- BFU-EIlO' human* 
injected injected human cells in GM inmouse human cells in BFU-E in 
mouseBM BM mouseBM mouse BM 
xl0" xlO4 
2.1xl0' 3.8xl04 + (n=4) 129 ± 46 7.9 ± 1.4 50±32 3.1 ± 1.4 
- (F3) 117" 131 2.4 ± 1.2 62±42 1.8± 0.4 
2 1.7xl04 4.4xl03 + (n=5) 123 ± 97 3.9 ± 3.9 55 ± 38 2.3 ± 0.3 
- (n=J) 255 1.9 138 1.0 
3 1.3xl04 2.6xl0' -i- (n=2) 272 - 910 21 - 65 234 - 1280 18 - 91 
- (n~2) 424-847 3.6-4.5 390-1075 3.3 -5.6 
* calculated on the assumption that I femur represents 8.5% of all BM cells 59 
TPO treatment did not essentially influence the lineage distribution among the 
human cells, although it cannot be entirely excluded that the slight, but significant 
decrease in frequency of myeloid CD33+ cells is the result of preferential 
expansion of other cells types, notably erythroid and megakaryocytic cells. Even 
so, the action of TPO is remarkably neutral with respect to expansion of all major 
lineages of hematopoietic cells compared to the controls. 
Administration of human growth factors, such as combinations of IL-3, GM-
CSFI4, SCF, PIXY321, EPOI5. 16 or Flt3-L and IL_717 by multiple injections or 
osmotic pumps, has previously been attempted to augment the outgrowth of small 
numbers of human cells in transplantation assays using immunodeficient mice. 
Obviously, the effect of a single administration of TPO is much more prominent 
than that of each, or combinations of these growth factors. Therefore, this study 
identifies human TPO as a major limiting factor for the proliferation and outgrowth 
of human hematopoietic cells in a mouse environment. 
The administration of human TPO did not noticeably influence the number of 
mouse cells per femur. This observation is consistent with the dose ofTPO chosen, 
which in normal mice does not exert a stimulatory effect, and is remarkable in that 
the TPO induced expansion is not accompanied by a proportional reduction of 
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Figure 2. Immunophenotyping of chimeric NOD/SCm mouse BM 35 days after 
transplantation of CD34-selected VCB cells. BM was stained with a panel of antibodies 
specific for different human blood cell lineages using CD45 as a marker for human cells. 
Results for 6 mice that where not treated with TPO are shown in the dark grey columns. the 
10 mice that were injected with TPO are sho\Vil in the light grey columns. The percentage 
of cells in each subset, relative to the %CD45- cells present in the BM is expressed as mean 
± standard deviation CAl. In figure B the number oflineage specific cells present per femur 
is calculated and expressed as mean ± standard deviation. Results of CD41 and CD71/GpA 
stainings are based on 3 mice treated with TPO and 3 untreated mice. Note the difference in 
X-axes scale used to express frequency and absolute numbers of the CD45 subset and other 
panels. The results of statistical analysis are represented as * for p<O.05, ** for p<O.Ol, and 
*** forp<O.OOl. 
185 
The effect ofTPOon the engraftment ofUCB cells 
Dose and dose schedule of TPO were derived from a previous study, in which it 
was shown that the dose of TPO should exceed saturation of the platelet c-mpl 
clearance mechanism to exert an optimal effect, and that there is a short critical 
time interval for optimal multilineage efficacy, delay of administration resulting in 
a reduced effect that was predominantly along the platelet lineage50 The critical 
time interval was related to increased survival and proliferation of multilineage 
repopulating cells at the expense of more immature precursor cells. The large 
effects presented here in the NOD/SCm recipients of human CD34+ cells may 
suggest that these observations also apply here, which, however, needs to be 
explored further, while also the pharmacokinetics of human TPO in a mouse 
environment need to be assessed. Since a 10- to 30-fold higher dose of human TPO 
is fully capable of stimulating mouse platelet production (unpublished 
observation), advantage was taken of the affinity difference between mouse and 
human TPO for the mouse receptor to achieve selective outgrowth of human cells. 
This also implies that the 0.3 >Lg human TPO is sufficiently high to overcome the 
threshold of initial c-mpl mediated clearance. 
The results are at variance with those obtained previously in lethally irradiated 
rhesus monkey recipients of limiting numbers of autologous bone marrow derived 
CD34+ cells, where TPO was largely ineffective. 57. 58 In contrast, TPO was highly 
effective in 5 myelosuppressed monkeys after the midlethal dose of 5 Oy TBI42, 
both models yielding an identical hematopoietic reconstitution rate in the placebo 
controls. So far, the possible reasons for this discrepancy (reviewed elsewhere57) 
have not been fully elucidated. The present study shows that it is not the transplant 
situation per se that makes cells unresponsive to exogenous TPO. 
Although the frequencies of the various differentiation lineages were hardly 
influenced by TPO treatment, in absolute numbers a clear shift was noticeable in 
that megakaryocytic and erythroid cells were more prominently expanded in the 
TPO treated mice than in the controls, apparently at the relative expense of myeloid 
CD33+ cells. This phenomenon is consistent with the known range of actions of 
TPO and with previous observations in myelosuppressed rhesus monkeys. 
Treatment of the latter with TPO alone demonstrated accelerated reconstitution 
along the platelet and red cell lineages, whereas the TPO potentiated expansion and 
terminal maturation of the neutrophil/monocyte lineage required additional 
stimulation with exogenous growth factors such as O-CSF or OM-CSF. Compared 
to the observed shift in favor of erythroid and megakaryocytic cells at the expense 
of other lineages, the TPO-induced expansion of immature CD34+CD38+ cells and 
CD34- cells is neutral and of the same order as the expansion of all human cells in 
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the NOD/SCID bone marrow. It remains to be explored as to whether TPO is 
capable to replace the accessory cells important for expansion of immature 
CD34+CD3S+ cells described previously. 13 
The findings in this study clearly will make the NOD/SCID mouse a more efficient 
assay for human hematopoietic stem cell and provide a new basis for further 
studies on the effects of growth factors and other regulatory mechanisms involved 
in human stem cell regulation and differentiation. In addition, the NOD/SCID 
mouse transplanted with human DCB cells will provide a suitable assay for the 
development of novel genetically engineered, high-affinity c-mpl agonists and/or c-
mplligand mimetic substances designed to circumvent the disadvantages of protein 
agonists. 
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Introduction 
The hematopoietic system is derived from stem cells that have an extensive 
capacity to proliferate, differentiate and self-renew enabling repopulation of 
recipients after transplantation. The development of the hematopoietic system is 
tightly regulated by a combination of intrinsic factors and external stimuli such as 
hematopoietic growth factors (GFs) and contact with stroma in the 
microenvironment of the bone marrow. Disorders of the hematopoietic system such 
as leukemia, may result in dysregulation of hematopoiesis. Treatment of these 
diseases often involves chemotherapy or irradiation. Hematopoietic recovery after 
radiation exposure (therapeutic or accidental) or chemotherapy might be promoted 
by bone marrow transplantation (BMT), administration of GF or transplantation of 
in vitro stimulated stem cells. Understanding the cellular and molecular factors that 
regulate the development of normal stem cells and those that initiate proliferative 
diseases such as leukemia is, next to increasing the fundamental knowledge on 
hematopoiesis, essential for the design of therapeutic regimens, including gene 
therapy. 
The conceptual framework of stem cell characterisation has changed in time. Forty 
years ago stem cells were quantitatively assayed using the spleen colony forming 
assay (CFU-S) and were defined as cells that are capable of homing to the spleen 
of irradiated mice 8-14 days after transplantation and form spleen colonies. l Since 
then, in vivo and in vitro assays have been developed to measure and characterise 
the small population of hematopoietic stem cells, all demonstrating the complexity 
and heterogeneity of this subset. Magli et aZ2 demonstrated that the CFU-S was 
more complicated than thought by showing that day 8 and day 12 spleen colonies 
originated from different cell types, which implied that the repopulating stem cell 
population is heterogeneous. In addition, heterogeneity of stem cells is observed in 
studies in which BM is serially passaged in reconstitute lethally irradiated mice.3 
Results indicate the presence of at least two phases of engraftment, which appear to 
be associated with progenitors at different stages of differentiation. Early 
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hematopoietic recovery is procured by an initial, unsustained engraftment phase 
produced by short-term repopulating cells, followed by a second sustained phase 
for which pluripotent stem cells are responsible. The presence of diverse subsets 
within the hematopoietic stem cell hierarchy is also expressed in the difference in 
radiosensitivity4. 5 Less primitive colony forming cells (CFU-C) and early 
cobblestone area forming cell (CAFC) are relatively radiation resistant, CFU-S day 
7 and CAFC day 10-14 became more sensitive, whereas with increasing 
primitiveness of the hematopoietic stem cell subsets (CFU-S day 12 and marrow 
repopulating ability (MRA» the radioresistance is greater5 
Apart from the difference in long and short term repopulating ability and in 
radiosensitivity, the distribution of phenotypic markers and growth factor receptors 
may also illustrate stem cell heterogeneity. The CD34+CD3S' immunophenotype 
defines a primitive subpopulation of human progenitor cells which is present in 
foetal liver, foetal and adult bone marrow (BM) and umbilical cord blood (UCB)6-
9 Although these cells all express CD34 without co expression of CD3S, at least 2 
functionally distinct subpopulations exist within this population, i.e., those able to 
produce distinct colonies in semi-solid medium (CFU-C) within the standard long-
term culture initiating cells (LTC-IC) assay period and a more primitive, rare 
subset that begins to proliferate in culture after 8 weeks.9 CD34+ cells expressing 
Thy-l 10 or c-kit (SCF-receptor)l1 in the absence of lineage markers, HLA-DRI2, 
transferrin receptors13 and with a low uptake of rhodamine123 are categorised as 
primitive hematopoietic stem cells. 14 Recently, a novel marker, vascular 
endothelial growth factor receptor-2 (VEGFR-2, also known as KDR) was found to 
be a positive, functional marker defining stem cells and distinguishing them from 
progenitors15 KDR is present on 0.1 to 0.5% of the CD34+ cells that are positive 
for early progenitor and stem cell markers, such as CD3S-, Thy-l+, and kit1ow• 
Growth factor receptors expressed on CD34+ cells are receptors for early acting 
growth factors and include IL-3-R, IL-6-R, GM-CSF, c-kit (SCF-R) and c-mpl 
(TPO_R)16.19 Receptors for late acting GF such as EPO, G-CSF and M-CSF are 
not expressed on immature cells, but exclusively on specific, committed subsets. 
Novel techniques such as cell separation and selection methods and the (further) 
development of in vitro assays such as the LTC-IC assay20. 21 and surrogate in vivo 
transplantation assays such as transplantation of purified human hematopoietic 
cells into immunodeficient mice22. 23 or the use of non-human primates24-29 have 
helped to identifY a small subset of pluripotent stem cells that is exclusively 
capable of repopulating the bone marrow (BM) of a recipient and to proliferate and 
differentiate into all hematopoietic cells. 
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The use of human umbilical cord blood (DCB) as an additional stem cell source in 
hematopoietic stem cell transplantation has been a successful alternative for 
allogeneic BM transplantation. It has been shown in early studies that both term 
and preterm cord blood contains a significantly higher number of early and 
committed progenitor cells than adult peripheral blood30 Furthermore, 
transplantation with UCB cells results in a decreased incidence of graft versus host 
disease (GVHD) compared to BM31-33 Although it has been demonstrated that 
UCB contains sufficient numbers of hematopoietic progenitor cells to engraft 
larger size children and adults34, others have suggested that to gain sufficient 
immature cells for transplanting large adults, ex vivo manipulation of cells might be 
necessary35 For grafts containing suboptimal numbers of stem cells such as the 
average cord blood sample, expansion may result in an earlier engraftment 
following transplantation and in a reduction of the transplant-related morbidity. 
However, the composition of GF receptors and the response pattern to GF on 
repopulating stem cells is as yet insufficiently known. Thus the presently available 
GFs may either not stimulate stem cells or stimulate them to differentiate rather 
than to self-renew. The immunophenotypic and functional characterisation and 
determination of the cell cycle and growth characteristics of these most primitive 
hematopoietic progenitors are essential steps toward the identification of 
hematopoietic stem cells which are important target cells for gene transfer. Since 
only a small population of stem cells is responsible for the long-life formation of 
all blood cell lineages, hereditary and acquired hematopoietic diseases may be 
treated with gene transfer to hematopoietic stem cells. Furthermore, as peripheral 
blood cells traverse the entire organism, transduced hematopoietic cells can act as a 
delivery system for the treatment of non-hematopoietic diseases such as enzyme 
deficiencies. To reach clinically relevant levels, the transduction of the target cells 
should be highly efficient. Transduction efficiencies of 10% to 20% can be 
sufficient to cure some genetic diseases36, especially those in which expression 
levels are not of critically importance, such as enzyme-deficiencies. However, most 
diseases require transduction of long-term repopUlating cells with higher levels. 
The studies presented in this thesis focus on the quantitative use of severe 
combined immunodeficient (SCID) mice37 and non obese diabetic (NOD)/SCID 
mice38 as recipients of human normal progenitor cells (CD34" and CD34"CD3s-) 
isolated from UCB and malignant (CD34-) cells isolated from the peripheral blood 
of chronic myeloid leukemia (CML) patients to get insight into the characteristics 
of cells capable of multilineage in vivo repopulation (chapters 2 and 3). Second, by 
retroviral transduction of human stem/progenitor cells using the fluorescent 
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enhanced green fluorescent protein (EGFP) marker gene, human repopulating cells 
were marked. With this procedure, the quality of the transduced cells can be 
rapidly assessed and the cells can be selected after transduction and their fate and 
progeny tracked after transplantation (chapter 4). For quantitative analysis, stable 
and high levels of integration of the EGFP gene in the DNA of the target cell is 
required. Therefore, variables influencing the transduction efficiency were 
analysed and the transduction protocol optimised (chapter 5) to reach high-level 
transduction efficiencies of hematopoietic stem cells. To analyse stimulating or 
inhibiting factors, such as GFs or other agonists which possibly influence the 
repopulation of normal progenitor cells, the NOD/ScrD mouse assay can be 
effectively used. In chapter 6 the effect of the GF thrombopoietin (TPO) on the 
engraftment of normal CD34+ UCB cells in NOD/ScrD mice is studied. 
Requirement of accessory cells 
The study described in chapter 2 of this thesis focuses on quantitative analysis of 
the maintenance and differentiation of distinct UCB subsets with repopulating 
potential after transplantation in the (NOD) / scm mouse model. These studies 
have provided essential information that can be used to design and test conditions 
for ex vivo activation of immature hematopoietic cells, and of various experimental 
purposes such as the effect of various GFs on the self-renewal of immature 
hematopoietic cells as well as the development of efficient gene transfer protocols. 
Transplantation of 105 purified CD34+ human UCB cells into sublethally irradiated, 
macrophage-depleted scm mice or irradiated NOD/SCm mice resulted in high 
levels of multilineage chimerism, measured by flow cytometry. An equivalent 
number (5xI03) of purified CD34"CD3S· cells also engrafted efficiently with 
chimerism levels similar to those observed in studies in which the NOD/SCID mice 
were cotransplanted with irradiated non-repopulating CD34- cells and/or GF 
supported NOD/SCm mice39 The human cell population in the scm mouse BM 
consisted of prominent numbers of B-Iyrnphoid cells (25% to 50% of the human 
population), but also high levels of monocytes, granulocytes and immature 
myelomonocytic cells, erythroblasts and immature CD34+ cells were present at 5 
weeks after transplantation. Purified CD34+CD3S+ cells and CD34- UCB cells did 
not engraft, indicating that the CD34+CD3S- subset is exclusively able to 
reconstitute the BM of a recipient after transplantation. Studies analysing the 
kinetics of the engrafted cells showed that the most primitive human cell 
populations reached maximum levels at 5 weeks postrransplantation, after which 
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they declined40 At 10 weeks, most of the human cells present in the BM were 
mature (mostly CD34-CDI9l cells and at the end of the experiment at 16 weeks, 
all subsets of human cells had declined significantly40 
Transplantation of graded numbers of CD34+ UCB cells into scm mice showed a 
linear relation between the cell number transplanted and the percentage of CD4S+ 
cells produced. The percentage of CD34" cells within the human cell population 
also increased proportionally with cell dose, in contrast to the production of 
CD34"CD38- cells that showed a steeper dependence on the number ofCD34+ cells 
transplanted. This, and the fact that no CD34+CD3S- cells and IO-fold lower 
numbers of CD34+ cells were produced after transplantation of purified 
CD34+CD3S- UCB cells showed that CD34+CD38- cells can only be maintained 
with support of accessory cells among the CD34"CD38- population. This feature 
was directly demonstrated by cotransplantation of CD34+CD38- cells with 
CD34+CD38+ cells, a cell subset that itself was not capable of engrafting the mouse 
BM, but restored the propagation of CD34-CD38- cells in repopulated mice. The 
function of these CD34+CD38- cells during the repopulation of long-term 
engrafting cells remains unclear. One possible function could be that the maturing 
cells prevent elimination of the small numbers of CD34"CD3S- cells by residual 
immune reactivity of the NOD/SCm mouse. Another, more likely explanation 
could involve growth factor production as has been shown for CD34+ cells which 
can produce various GF such as IL-3 and G-CSF41 Also other stimuli may be 
assessed by the CD34+CD38+ accessory cells which are needed for self-renewal of 
the CD34+CD38- subset and are not provided by the mouse microenvironment. 
Transplantation of graded numbers CD34- G-CSF mobilised PB cells into 
NOD/SCm mice resulted in a dose-dependent increase in engraftment in BM and 
spleen.42 Compared to CD34+ UCB, higher cell numbers were needed to result in 
similar engraftment levels, probably caused by an intrinsic difference in scm-
repopulating cell (SRC) frequency or by a difference in the biological properties of 
CD34- cells derived from foetal or adult hematopoietic tissue. In contrast to UCB 
and mobilised PB cells, transplantation of human BM cells into NOD/SCm mice 
requires the addition of human growth factors to establish high-level human cell 
engraftment, suggesting that neonatal cells either respond differently to the murine 
microenviroument or provide their own cytokines in a paracrine fashion.43. 44 
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Stem cell frequency 
Ideally, all stem cells that are present in a graft home to the BM of the recipient and 
proliferate and differentiate there to fully reconstitute the BM. In reality, syngeneic 
mouse studies showed that IS-20% of the injected progenitor cells home to the BM 
and 1-10% could be found in the spleen45-47 Because BM and spleen comprises 5 
to 10% of the mouse body weighr8, and the graft is injected into the blood vein, in 
theory it is likely that 5 to 10% of a graft reaches the BM and the spleen. The other 
90-95% of the graft is then captured in other organs and eliminated. However, 
homing to spleen and BM is 30% instead of 5 to 10% which indicates specific 
homing mechanisms for hematopoietic cells to go to these 2 hematopoietic 
organs45. 47. 49 The seeding of human progenitor cells in the BM and the spleen of 
NOD/SCm mice is less efficient (1-7% to the BM and 0.2-0.9% to the spleen)50 
which should be taken into account when calculating the frequency of human cells 
with NOD/SCm repopulating activity. The frequency of CD34+CD3S- cells that 
can maintain or expand after infusion into NOD/SCm mice was estimated using 
Poisson statistics and was found to be I in 70,000 CD34+ cells. This was in the 
same order of magnitude as the frequency that was found in other studies, which 
was I in 3,500 CD34+CD3S- cells50 Taking the low seeding efficiency into 
account, the frequency of human SCm-repopulating cells is certainly 
underestimated. In addition, other factors such as the efficacy of the stimuli of the 
mouse microenviromnent and the role of accessory cells might be involved in the 
efficiency of homing and proliferation of repopulating cells. 
Apart from the quality of the donor cells, recipient properties and residual 
immunity influence the efficiency of engrafrment. Early studies in which human 
hematopoietic cells were transplanted into immunodeficient animals used the C.B.-
17-scid/scid (SCID) mouse which was highly radiosensitive, had a short life span 
due to the formation of lymphoma and showed low levels of engrafrment partly 
due to residual immune reactivity.37 When NODlLtSz-scidiscid (NOD/SCm) mice 
were used, 5 to 10-fold higher engrafrment levels were obtained38 However, 
NOD/SCm mice are very sensitive to radiation, which limits effective 
conditioning, have a short life span and become leaky with age. 51-53 Although the 
seeding efficiency is low, conditions prevailing within the microenviromnent of the 
(NOD/SCm) mouse BM are able to sustain many aspects of human 
hematopoiesis23, 54-58 Novel mouse strains, such as NODlLtSz-scidiscid j32mn,1I 
(j32mnull NOD/SCID) mice engraft with 10-fold higher levels but have a shorter life 
span compared to NOD/SCm mice59. 60 The efficiency of homing and 
proliferation of transplanted cells is much higher in this mouse strain than any 
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other immunodeficient mouse available. Engraftment of human cells in these mice 
requires IO-times less cell numbers, which obviously is useful for studies on rare 
cell populations as hematopoietic stem cells. The most recent immunodeficient 
hybrid developed is the NODlLtSz-RagI OUll mouse, which has a normal sensitivity 
to radiation and does not become leaky with age. Transplantation of human 
hematopoietic cells in these mice results in similar levels of engraftment as the 
NOD/SClD mice61 This strain would seem to be particularly useful to study 
engraftment during longer time intervals. 
Leukemic and normal engraftment of CML cells in immunodeficient mice 
A useful model for chronic phase CML should support and maintain the outgrowth 
of both normal and malignant progenitors, as CML is clinically characterised by a 
mosaicism of Philadelphia-chromosome positive (Ph -) and Ph· progenitors. Only 
models in which stable mosaicism can be reached that reflects the relative 
frequencies in the patients' blood and BM may allow the evaluation of treatment 
strategies aimed at selective outgrowth of normal cells. Early attempts to establish 
an in vivo transplantation model of chronic phase CML using SCID mice as 
recipients were not successful 49. 62 unless large numbers of cells were injected.63 
Evaluation of the engraftment of normal and leukemic cells after transplantation of 
107 unfractionated or 2xl05 purified CD34+ CML cells in NOD/SCID mice 
(Chapter 3) was performed using fluorescent in situ hybridisation (FISH) analysis 
on sorted subsets of patient samples and harvested BM of engrafted mice. Both Ph-
as Ph + cells proliferate and differentiate in the mouse BM with the same 
distribution as the cell subsets in the original graft which makes this assay useful to 
study the effect of (ex vivo) manipulations on the survival and proliferation 
capability of normal vs. malignant cells. 
Cells from CML patients in blast phase engrafted SCID mice at much higher levels 
than cells from chronic phase CML, resembling that of leukemic blasts from AML 
patients64-66 As both cells from chronic phase CML and blast crisis CML engraft 
NOD/SCID mice with different characteristics, this assay could also be exploited in 
examining the processes involved in acceleration from chronic phase CML to blast 
crisis CML and to test treatment procedures that can prevent this development. 
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Ex vivo expansion 
The integration of trans genes by retrovirus mediated gene transfer requires cell 
cycling67 To accomplish this, target cells are cultured in vitro for the duration of 
the transduction procedure. In addition, expansion of hematopoietic pluripotent 
progenitor cells in ex vivo culture may have important implications in 
transplantation, stem cell marking and gene therapy, as it may allow the use of 
stem cell sources which are available in limited quantities, such as UCB. It is of 
importance to choose the culture conditions and the use of GF or GF combinations 
in such a way that stem cells be induced to proliferate, but not differentiate, as the 
stem cells most likely loose their repopulating capability. 
In initial gene transfer experiments, hematopoietic cells were prestimulated and 
transduced in serum-free culture medium in the presence of IL-3, IL-6 and SCF 
with or without stromal support.68• 69 Moderate transduction efficiencies were 
reached but the target cells differentiated into the myeloid lineage, resulting in loss 
of the repopulating ability of the stem cells. The availability of newly cloned GF 
such as Flt3-L7o and TP071-74 in combination with SCF resulted in higher 
transduction efficiencies and maintenance of cells with an immature phenotype. 
Although extensive amplification of primitive progenitor cells assayed as colony-
forming cells (CFC) or cobblestone area-forming cells (CAFC) / long-term culture 
initiating cells (LTC-IC) has been described75-77, the repopulating activity of the 
expanded cells can only be assayed in transplantation models. During ex vivo 
culture, phenotypes of hematopoietic cells may alter, such as the downregulation of 
CD38 on maturing CD34+CD38+ cells, resulting in increasing numbers of 
CD34+CD38- cells which have the same phenotype as the rare CD34+CD38-
population that is exclusively capable of repopulating the BM of a recipient after 
transplantation. Injection of these cultured CD34+CD38- cells into NOD/SCID 
mice shows a clear dissociation between the CD34'CD38- cell surface phenotype 
and the NOD/SCID repopulating ability78 
Retrovirus mediated gene transfer 
Stable integration of high levels of the EGFP marker gene into the DNA of 
immature hematopoietic cells allows tracking of the transduced cells and their 
progeny after transplantation in a recipient This facilitates the study of the 
mechanisms that are involved in in vivo repopulation ofthe BM but also the effects 
of different agents such as GFs or (inhibitory) cytokines on the process of BM 
reconstitution. Studying the optimal conditions by which genes are integrated into 
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the DNA of the target cells with high efficiency is essential for the eventual goal of 
gene therapy. Hematopoietic stem cells are obvious targets to use in the treatment 
of hereditary hematological and non-hematological diseases. Although the quality 
of the virus particles produced by retroviral producer cell lines is not always stable, 
the integration of the vectors into the target cell DNA is. Other gene transfer 
systems such as adenovirus and liposome-based methods do not integrate genes 
stably at high frequencies. Furthermore, adenoviral vectors tend to be toxic at high 
concentrations and can be highly immunogenic.79. 80 Although lentivirus mediated 
gene transfer can transduce non-dividing cells with high efficiency, the possibility 
of mutations or recombinations which may lead to replication-competent virus with 
pathogenic potential complicates, at this time point, their choice for clinical 
applications.81 . 82 Novel lentivirus vectors are being developed with a reduced 
likelihood of recombination and pathogenesis. These vectors contain, for instance, 
genetic elements from three different viruses (simian immunodeficiency virus; 
SlY, human immunodeficiency virus-I; HIV -1, and vesicular stomatitis virus; 
VSV) which have low nucleotide homology reducing the possible recombination 
between vector elements.83 The use of self-inactivating (SlV-based) vectors that 
contain minimal virus sequences also reduces the risk both of emergence of 
replication-competent recombinants and of mobilisation of the vector in target 
cells.84 Once these safety concems are overcome, the potential for modifications of 
the human genome for therapeutic purposes using lentiviral vectors is promising81 
However, the present way of production of the lentiviruses makes it difficult to 
ensure quality control under GMP conditions, which makes these viruses, apart 
from the risks, less likely to be developed rapidly for clinical application. 
Gene marking in the studies described in this thesis (chapter 4) has been mediated 
by retroviral gene transfer, using either an amphotropic virus producing cell line 
based on the Moloney murine leukemia virus (MoML V) or a gibbon ape leukemia 
virus (GaL V) pseudotyped virus producer. Both cell lines were transfected with an 
EGFP containing vector, the amphotropic cell line with MFG-EGFP (AmI2IMFG-
EGFP)85. 86, and the pseudotyped cell line with the SF-EGFP vector (PG 13/SF-
EGFP)87 Consistent with earlier studies in which amphotropic and pseudotyped 
virus producing cell lines were compared88-91 the pseudotyped PG13/SF-EGFP 
packaging cell/vector combination transduced purified CD34+ and CD34+CD3S-
UCB cells with a higher efficiency than the amphotropic AmI2IMFG-EGFP 
possibly caused by the low or absent expression of the amphotropic envelope-
receptor (GL VR-2 or Pit-2) on the target cells92. 93 Transplantation of the EGFP-
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marked CD34- and CD34+CD38- UCB cells in NOD/SCm mice revealed that 
cells, transduced with the AmI2IMFG-EGFP combination, engrafted either with 
low levels of efficiency or did not engraft at all. Injection of CD34- and 
CD34+CD38- cells transduced with the pseudotyped virus producing cell line into 
NOD/SCID mice resulted, 35 days after transplantation, in higher levels of 
transduced human cells in the mouse BM. Periodic analysis of BM samples from 
transplanted NOD/SCID mice revealed a sustained engraftment up to 90-120 days 
post transplantation of human hematopoietic cells expressing the transgene94 
Although hematopoietic progenitor/stem cells were efficiently transduced, the 
transduction of NOD/SCm repopulating cells was low in efficiency and the 
variability between experiments was large. The retroviral transduction procedure 
appeared to be suboptimal and had to be optimised and the quality of the virus 
containing supernatant had to be stabilised (chapter 5). The gene transfer efficiency 
into imrnatnre CD34- hematopoietic cells has been significantly improved by the 
use of the human fibronectin fragment CH-29695 , the use of GAL V-pseudotyped 
vectors rather than amphotropic virus vectors, novel stem cell purification 
techniques and the use of novel growth factors (GF) such as thrombopoietin 
(TPO)71-74 and fins-like tyrosine kinase ligand (Flt3-L)70 In addition, the 
development of fluorescent markers, such as EGFP significantly speeded up the 
time required to analyse variables in the transduction procedure_ 96 
Despite the many difficulties in therapeutic gene transfer, Cavazzana-Calvo et al 
have successfully treated two infants (for at least up to 10 months) suffering from 
severe combined imuunodeficiency (SCID) using retroviral mediated gene transfer 
to CD34- cells97 The superior results of this study, as compared to previous gene 
therapy trails that treated ADA-deficient scm patients98-1 01, are partly due to the 
optimisation of the transduction conditions during the last decade. The presence of 
Flt3-L in the growth factor cocktail during the transduction procedure, the use of 
human fibronectin-coated cultnre dishes and the choice of the retroviral vector has 
resulted in higher levels of gene transduction sufficient to successfully treat two 
SCm-children. In addition, the choice of X-linked scm as a target for gene 
therapy has added to the success because this model did not need a strict control of 
expression of the gene. Second and more important, in this disease the transduced 
cells acquire a significant selective advantage over non-transduced cells as the 
product of the transduced gene delivers a proliferating signal to cells that express 
the gene. A third reason for the successful treatment is that transduced T cells 
(differentiated from purified CD34+ cells) are long-lived and may be present for 
several yearsI02 
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Despite this singular therapeutic success in SCID-patients, further optimisation of 
the transduction conditions to reach high levels of transduction and stable 
integration is necessary for long-term multilineage integration of the foreign gene. 
Viral titers of retrovirus vectors (Mo-MLV-based) are relatively low (105 to 
106/ml), and cannot infect some human cells efficientlyl03. 104 Attempts to 
concentrate retroviral vectors by physical methods such as filtration or 
ultracentrifugation have generally resulted in massive loss of infectious virus, 
presumably due to instability of the retroviral envelope protein, which is essential 
for the integration of virions with the cell surface receptor and for their entry into 
the cells105 Pseudotyping the Mo-MLV-derived retroviral vectors with the G-
protein of the vesicular stomatitis virus (VSV -G, member of the rhabdovirus 
family) results in a vector that can be concentrated to high titers (lOs_109/ml) by 
ultracentrifugation. l05 In addition, pseudotyping the Mo-MLV vector with gibbon 
ape leukemia virus (GAL V) increases the transduction of purified hematopoietic8S• 
89. 106 probably due to the different distribution of the viral receptors on the cell 
surface.89. 90. 106 Apart from high titer production, lentivirus vectors have the 
advantage of being able to infect non-dividing cells which makes these vectors, in 
spite of the safety concerns, superior for transducing quiescent hematopoietic stem 
cells. Studies using the lentivirus based gene transfer system have lead to stable 
transduction of large fragments of the human ~-globin gene to mouse BM cells. In 
addition, transplantation of syngeneic BM transduced with the human ~-globin 
gene into mice, resulted in the production of clinically relevant levels of human ~­
globin in the peripheral blood of the transplanted mice. l07 
In addition to the use of fibronectin coated dishes, the most promising GF 
combination at this time point (SCF, Flt3-L and TPO), and pseudotyped retrovirus 
vectors, the ratio virus titer - target cell concentration is of critical importance to 
get sufficient high levels of transduction (>90%). This ratio is variable between 
different target cell populations. CD34-selected DCB cells transduce highly 
efficient using a lower titer - target cell ration as compared to CD34- rhesus BM 
cells supposedly because of receptor differences between the species. 
Transplantation of CD34+ cells of which >90% expressed EGFP into sublethally 
irradiated mice resulted in high levels (40-80%) EGFV human cells in all lineages 
assessed. 
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Growth factor stimulated in vivo expansion of human cell s transplanted in 
NOD/SCID mice 
Some disadvantages of human cells transplanted into NOD/SCID mice are the 
limited mature end cell production and the low seeding efficiency of the human 
cells in the mouse environment50, necessitating the use of large quantities of 
human cells, which could be partly attributed to the described accessory 
CD34+CD3S+ cells108 Supplementation of human GFs such as IL-3 and GM-
CSF23, SCF and/or PIXY32 I (a fusion oflL-3 and GM-SCF) and/or erythropoietin 
(EPO)40,54 or Flt3-L and/or IL_7109 has been used to augment the outgrowth of 
human cells in the mouse environment, or, more simply, addition of large 
quantities of irradiated human cells40, of which the role is not fully clear, Recent 
novel crosses of mutants, such as the NODIRaglnUll or the 
NOD/SCID/j32microglobulinnun mouse60, 61, require lower numbers of human 
cells, suggesting that residual immune functions in the NOD/SCID mouse 
contribute to the relative inefficiency of the NOD/SCID mouse, Also, species 
barriers may exist for hematopoietic growth factors, murine growth factors not 
necessarily being optimal or suited to stimulate the human cells, Since 
thrombopoietin (TPO) is an essential physiologic factor for stem cell maintenance 
and proliferation110, apart from its functions in platelet production and 
activation 72, in the study described in chapter 6 we sought to explore the option of 
using human TPO to stimulate outgrowth of human cells in NOD/SCID murine 
recipients, A single dose of human TPO was injected into sublethally irradiated 
NOD/SCID mice immediately after transplantation of purified CD34+ UCB cells, 
TPO-treatment resulted in a 3 to 4-fold increase in the frequency and number of 
human CD4S+ cells in the mouse bone marrow, assessed S weeks after 
transplantation, while mouse type cells were not influenced, The lineage 
distributions among the human cells were essentially similar irrespective of TPO 
treatment, however, with a slightly lower frequency of myeloid CD3T cells in the 
TPO treated mice and a prominent increase in the total number of erythroid and 
megakaryocytic cells, An impressive increase was observed in CD71 +GpA cells, 
reflecting the proliferative stimulus provided by TPO administration, Also the 
frequency of immature CD34-, CD34+CD3S- cells and of human GM-CFU and 
BFU-E in TPO-treated mice was similar to that of untreated mice, the increase in 
their total number being proportional to the increase of human cells, The results 
demonstrate that human TPO is a major limiting factor for selective multilineage 
outgrowth of human UCB cells in NOD/SCID mice and can be conveniently 
supplemented by single dose treatment immediately after transplantation, Also, the 
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study emphasises the importance of TPO for immature hematopoietic cell 
maintenance and proliferation, in accordance with studies in myelosuppressed 
animals, which demonstrated that TPO not only accelerates platelet and red cell 
reconstitution, but also that of immature CD34- cells, thereby potentiating the 
action of growth factors such as G- and GM-CSF and alleviating neutropenia. 1 11-
113 The findings make the NOD/SCm mouse a more efficient assay for human 
hematopoietic stem cells and provide a new basis for further studies on human 
stem cell regulation using immunodeficient mouse models. In particular, synergism 
and/or antagonism of TPO and other growth factors on human stem cells can now 
be studied in the transplant setting, while also analysis of the described accessory 
cellsl08 can be approached under more optimal growth factor stimulation. In 
addition, immunodeficient mice transplanted with human UCB cells yield a 
suitable assay for the development of novel human c-mpl agonists, in particular 
non-protein substances l14, that have an easier pharmacology, can potentially be 
orally given and avoid the problem of antibody formation that has jeopardised the 
pharmaceutical development ofTPO.llS 
Final remarks 
Much of our understanding of the organisation of the cells that comprise the 
hematopoietic system and the cellular and molecular mechanisms that regulate 
their development is derived from mouse models. Studies of the human 
hematopoietic system have long been hampered by the absence of in vivo assays 
that measure their repopulation capacity. The development of methods to transplant 
normal and leukemic human hematopoietic cells into immune-deficient 
(NOD)/SCm mice provides the foundation for human stem cell assays and are 
essential to further understand and defme the characteristics of repopulating human 
stem cells. Hence, the NOD/SCID mouse assay is well known in studies of 
proliferation and differentiation of selected primitive hematopoietic cells and the 
influence of, for instance, in vitro culture conditions or GF treatment on their 
growth. However, the limitation of being able to study short-term repopulation 
only and the need for high cell numbers to be transplanted makes this assay less 
attractive. Newly developed mouse assays using the NOD/SCm ~2 microglobulin 
knockout (~2MK.O) mice or the NODlLtSz-Ragl null mouse are superior to 
NOD/SCID mice in engraftment efficiency and life span, respectively and will be 
used in the future for human cell transplantation studies. 
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Umbilical cord blood has, since the first transplant in 1989116, been used to 
successfully transplant many people of which most were children. Although UCB 
may be an enriched source of hematopoietic stem cells, the quantity of a UCB 
sample is usually too low to transplant a large adult patient with34• 117 Expansion 
of these cells is therefore essential and subject of many studies. Clinical trials in 
which the use of expanded/cultured UCB cells are studied are planned. However, 
as the use of certain GF, such as SCF, causes, next to a large expansion of the 
target cells, unacceptable adverse effects in patients, the step from bench to bed is 
not easy. To overcome this problem, there are plans to obtain BM stromal cells 
from the patient before the UCB transplant, expand the UCB cells on the BM 
stroma and harvest these together for the transplantI18 Due to the high 
proliferative potential of hematopoietic cells, stable gene transfer is a key 
requirement for stem cell characterisation as well as for clinically efficacious 
stem/progenitor cell-based gene therapy. Retroviral vectors are most commonly 
used for gene transduction of hematopoietic cells, but recently, also lentiviral 
vectors have been used to transduce progenitor/stem cells with high efficiency and 
are even found to be superior to retroviral vectors 1 19-121 
The studies described in this thesis reveal that efficient retroviral mediated gene 
transfer involves complex interactions between target cells and virus particles. 
Therefor, stabilisation of the virus production and quality of infectious, replication-
incompetent virus particles is one of the main issues to work on. Transplantation of 
transduced cells into NOD/SCID mice resulted in multilineage engraftment of cells 
expressing the transduced EGFP gene suggesting efficient transduction of 
pluripotent progenitor cells. However, as the NOD/SCm mouse assay ends at 5 
weeks after transplantation (which is too early to conclude about the transduction 
of long-term repopulating cells), it is of importance to measure repopulating 
activity of transduced cells with long-term repopulating ability in a preclinical 
setting, for instance in rhesus monkeys. Although progress made in the 
optimisation of the transduction protocol is considerable and results in high levels 
of transduced cells, transplantation of these cells into rhesus monkeys did not result 
in long-term engraftment of EGFP+ cells in the BM and PB of the animals. This 
could partly be due to the insufficient stimulation with GFs during the transduction 
procedure and/or in vivo to mobilise stem cells to the peripheral blood, by which 
stem cells are not properly stimulated or differentiate and loose their repopulating 
ability. Combining the right GFs and searching for novel GFs that influence stem 
cell activity without causing differentiation remains an issue to be studied. 
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Furthennore, virus titers could be insufficiently high to transduce enough stem 
cells. Retrovirus based transductions are most commonly used in transduction 
protocols for their stable integration into the cell's DNA, but show several major 
shortcomings, of which the most critical is the relatively low virus titer that can be 
achieved and the need for cell division for stable integration in the target cell DNA. 
Lentiviral based vectors produce very high titers of virus particles and only need 
low reverse transcriptase activity for infection. During the last few years, the 
possible hazards of using HIV -related viruses have been decreased by the reduction 
of the possibility of production of replication-competent viruses, which makes 
lentiviral vectors more attractive for the use in hematopoietic stem cell research. 
Suggestions for the near future include the development of systems for regulated 
expression that would allow on! off switching of the integrated gene when needed 
and the development of vectors which utilise specific, safe integration sites to 
avoid the possible hazard of malignancy of the transduced cells. Also targeting 
specific cell subsets for instance CD34 +, or leukemic cells could help the further 
development of safe efficient tools for gene therapy. 
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The stem cell subset is a rare population of cells mostly present in the BM and is 
able to repopulate the bone marrow (BM) of patients who have undergone BM 
depletion, for instance due to total body irradiation and/or chemotherapy. All blood 
cell types descent from these so-called totipotent stem cells which have unique 
properties that allow useful physical and biochemical characterisation and 
quantification. Many enrichment procedures such as density gradient centrifugation 
and selection methods such as immunomagnetic subset selection or fluorescent 
activated cell sorting (FACS) have been developed to isolate primitive 
hematopoietic subsets to study its features using in vitro and in vivo assays. In vitro 
experiments are used to detect hematopoietic precursor cells in different stages of 
development. However, the repopulating activity of (isolated) precursor/stem cells 
can only be studied in transplantation experiments. 
Hematopoietic stem cells are among the main targets for gene therapy as these cells 
can proliferate and differentiate into all blood cells after repopulation of the BM. 
This is essential for the treatment of hereditary or acquired diseases of the 
hematolymphoid system. Furthermore, gene transfer into stem cells makes it 
possible to mark cells with specific genes to be able to select the transduced cells 
and/or track their progeny after transplantation into a recipient, thereby gaining 
insight into the biology of stem cells. Although several gene delivery systems are 
known, up till now, retrovirus mediated gene transfer is mostly used for stable 
integration of genes into hematopoietic cells. 
The work described in this thesis focuses on the self-renewal and differentiation 
characteristics of isolated human progenitor/stem cells of normal origin (isolated 
from human umbilical cord blood) and malignant cells (isolated from patients with 
chronic myeloid leukemia, CML) by performing transplantation assays into 
immunodeficient mice (non-obese diabetic / severe combined immunodeficient; 
NOD/SCID mice). Using retrovirus mediated gene transfer, repopulating cells were 
marked by integration of a gene coding for the green fluorescent protein. Five 
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weeks after transplantation into NOD/SCID mice ( transduced) human cells can be 
traced and analysed in the BM of the mice by flow cytometry. 
The study reported in chapter 2 focuses on the in vivo expansion and multilineage 
outgrowth of immature cell subsets from UCB after transplantation into 
macrophage depleted scm mice. As measured by immunophenotyping, 
transplantation of equivalent numbers of unfractionated cells, purified immature 
CD34" and CD34+CD3S- cells resulted in similar levels of human CD45+ cells in 
the SCID mouse BM 5 weeks after infusion of the cells. However, the number of 
immature CD34"CD3S- cells produced in vivo was not proportionally to CD34-
graft size, but showed a second"order relation. In addition, mice engrafted with 
purified CD34"CD3S- cells produced IO-fold fewer CD34+ cells without detectable 
CD34+CD3S- cells. Addition of CD34+CD3S+ cells to a CD34TD3S- graft restored 
the maintenance and expansion of the immature subset. These results indicated that 
scm repopulating CD34+CD3S- cells require CD34+CD3S+ accessory cells for 
survival and expansion of immature cells, but not for the production of mature 
multilineage progeny in the scm mouse BM. 
As the development of mouse assays went on, a newly developed, more 
immunodeficient mouse strain, NOD/SCm mice became available for 
transplantation experiments. Compared to irradiated, macrophage-depleted SCID 
mice, the engraftment of cells from chronic phase CML patients, but not of UCB 
cells, in irradiated NOD/SCm mice was IO-fold higher. Chapter 3 discusses the 
ability of malignant and normal progenitors in the peripheral blood and the BM of 
CML patients in chronic phase to proliferate and produce mature progeny after 
transplantation into NOD/SCID mice. As demonstrated by fluorescent in situ 
hybridisation (FISH) analysis, purified human myeloid, B-Iymphoid, erythroid and 
CD34+ cells that were isolated from chimeric mouse BM contained Philadelphia-
chromosome (Ph)-positive cells (characteristic for CML) and Ph- cells in similar 
frequencies as primary cells from the CML patients. This demonstrates that the 
production of normal as well as malignant cells of multiple lineages were 
supported in the mouse assay with similar efficiency which is essential for a 
reliable transplantation assay. The NOD/SCm mouse assay for CML can facilitate 
the examination of differential effects of growth factors, inhibitory cytokines and 
cytotoxic drugs on the survival of normal and malignant stem cells. Furthermore, 
as cells isolated from CML blast crisis patients grew with high efficiency in the 
NOD/SCID mouse BM, this assay can also be useful to study the progression of 
chronic phase CML towards blast crisis. 
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Hematopoietic stem cells are targets for gene transfer because of their ability to 
permanently reconstitute the hematopoietic system after transplantation. Gene 
marking of cells with repopulating ability using genes that code for a fluorescent 
protein such as the green fluorescent protein (GFP) gene, facilitates easy analysis 
of transduced cells and their progeny after transplantation in real time without 
additional steps. In chapter 4 the transduction efficiency of the recombinant valiant 
of the Moloney leukemia virus (MoML V), (Arn12IMFG-EGFP) was compared to 
the gibbon ape leukemia virus (GAL V) pseudotyped PG 13/SF-EGFP combination. 
Purified CD34+ and CD34+CD38' UCB cells were efficient transduced using either 
cell line after a 2-day growth factor prestimulation, followed by a 2-day fibronectin 
fragment (CH-296)-supported transduction. Transduction efficiencies using the 
PG13/SF-EGFP were consistently 2-fold higher as compared to the AmI2IMFG-
EGFP combination. Transplantation of the EGFP transduced CD34+ or 
CD34-CD38' UCB cells into NOD/SCID mice resulted in EGFP levels of 2% and 
23% of the engrafted cells, transduced with the ArnI2IMFG-EGFP and PG13/SF-
EGFP, respectively. 
Although EGFP-transduced cells repopulated NOD/SCID mice BM, the 
transduction protocol used needed to be optimised to gain stable high transduction 
levels with clinical relevance in hematopoietic stem cells. In chapter 5, the steep 
correlation between transduction efficiency and cell concentration (RhBM and 
UCB cells) using the PG l3/SF-EGFP packaging cell/vector combination is 
described, Subcloning of this virus producer resulted in 2 high titer clones with 
transduction efficiencies in hematopoietic progenitor cells up to 90%. In addition, 
cryopreservation of the target cells resulted in a 2-fold higher efficiency of 
transduction. NOD/SCm mouse transplantation of CD34+ UCB cells transduced 
with the fibronectin-based supernatant infection method using the high level clone 
at the optimal cell concentration using GF combinations including SCF, TPO and 
Flt3-L, resulted in high levels of 40% to 80% EGFP+ human cells in all 
hematopoietic lineages assessed. 
The use of GFs to stimulate immature cells into cell cycle and/or to expand cell 
samples that are too small to use for transplantation has been extensively studied 
by several groups. Several GF combinations are known to stimulate the 
differentiation of stem cells (combinations including IL-3), maintenance and 
proliferation of inunature cells, however, is much more difficult to achieve. Newly 
cloned GFs such as TPO and Flt3-L are known, at least in vitro, to stimulate the 
proliferation of immature cells in order to expand the cells with an immature 
phenotype. In vivo administration of GFs such as G-CSF, is usually done to 
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mobilise hematopoietic stem cells into the peripheral blood to use as graft. 
Expansion of hematopoietic stem cells in vivo following transplantation of limited 
numbers of BM cells or of highly purified stem cells might be efficienty 
accomplished by administration of GFs directly after transplantation. Injection of 
one single dose of rHuTPO after transplantation of purified CD34+ VCB cells into 
irradiated NOD/SCm mice resulted in an accelerated engraftment and higher 
percentages and numbers of human cells in the mouse BM. (chapter 6) 
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De hematopoietische stamcelpopulatie is een zeldzame populatie cellen die 
voomamelijk aanwezig is in het beemnerg (BM) waar ze (in volwassen 
zoogdieren) gedurende het hele leven voortdurend verantwoordelijk is voor de 
vorming van aile typen gedifferentieerde bloedcellen. Dit proces wordt 
hematopoiese genoemd. Naast differentiatie zijn stamcellen in staat dochtercellen 
te produceren die aile eigenschappen van de stamcellen behouden (self-renewal) 
wat de continulteit van de hematopoiese waarborgt. Stamcellen kunnen het BM van 
ontvangers repopuleren na BM depietie ten gevolge van bestraling enJof 
chemotherapie. Alle celtypen die aanwezig zijn in het bloed stammen af van deze 
zogenaamde totipotente stamcellen die, door hun unieke eigenschappen, fysisch en 
biochemisch te karakteriseren en te k-wantificeren zijn. Om de mechanismen van 
stamcelproliferatie en -differentiatie naar mature bloedcellen te hmnen bestuderen, 
is het noodzakelijk deze immature cellen te isoleren. Hiervoor zijn een aantai 
verrijkingsprocedures ontwikkeld zoals dichtheidsgradient centrifugatie en 
selectiemethoden waaronder immunomagnetische seiectie of flow cytometrie 
(FACS). Met in vitro experimenten kan de aanwezigheid van hematopoietische 
voorlopercellen in diverse stadia van ontwikkeling worden aangetoond. Bchter, 
aileen door het uitvoeren van transplantatie experimenten wordt inzicht verkregen 
in de repopulerende activiteit van de (gelsoleerde) voorloper/stamcellen. 
Omdat hematopoietische stamcellen kunnen uitrijpen in aile celtypen aanwezig in 
het bloed, zijn deze cellen uiterst geschikt voor het transduceren van genen met als 
doel onder meer gentherapie voor de behande1ing van erfelijke of verkregen 
ziekten. Daamaast kan gentransfer een middel zijn waarmee cellen gemarkeerd 
kunnen worden met een specifiek marker gen, bijvoorbeeld een fluorescerend gen, 
die vervolgens na transplantatie in een ontvanger gevolgd kunnen worden. Hoewel 
een aantal systemen bekend is waarmee genen kunnen worden gelntroduceerd in 
een eel, wordt transductie middels retrovimssen het meest gebmikt. Retrovirale 
gentransfer geeft de mogelijkheid van stabiele integratie van genen in 
hematopoietische cellen. 
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In het hier beschreven onderzoek zijn experimenten uitgevoerd met het doel meer 
inzicht te krijgen in de karakteristieken van hematopoietische stam- en 
voorlopercellen. Hiervoor zijn normale en maligne CD34+ voorlopercellen 
gelsoleerd uit humaan navelstrengbloed en uit beenmerg van patienten met 
chronische myeloide leukemie (CML) en vervolgens getransplanteerd in 
immuundeficiente muizen (non-obese diabetic / severe combined immunodeficient, 
NOD/SCID muizen). Door de afwezigheid van specifieke afweer cellen (T en B-
lymfocyten) in de muis wordt het transplantaat met menselijke cell en niet 
afgestoten maar kan het prolifereren en differentieren in alle bloedceltypen 
inc1usief de immature populatie in het beenmerg. Met retrovirale gentransductie 
zijn cellen gemarkeerd met een gen dat codeert voor het groen fluorescerende eiwit 
(EGFP). Na transplantatie van getransduceerde cell en in NOD/SCID muizen is, 
met behulp van flow cytometrie of fluorescentie microscopie op eenvoudige wijze, 
de uitgroei van menselijke, EGFP+ cellen in het muizenbeenmerg te analyseren. 
De studie die besproken wordt in hoofdstuk 2 belicht de in vivo expansie en de 
multilineage uitgroei van immature sub-populaties die gelsoleerd zijn uit 
navelstrengbloed na transplantatie in macrofaag-gedepleteerde SCID muizen. 
Cellen die afkomstig zijn van het menselijk navelstrengbloed kunnen worden 
onderscheiden van muizencellen door het beenmerg te isoleren uit de muis en de 
cell en te kleuren met een CD45 antilichaam gekoppeld aan een fluorchroom. CD45 
is een specifiek antigeen dat aanwezig is op alle menselijke leukocyten, maar niet 
op muiscellen. Transplantatie van equivalente aantallen ongefractioneerde cellen, 
CD34- of CD34+CD3S- cellen resulteerde in identieke percentages humane cellen 5 
weken na transplantatie. Echter, in tegenstelling tot transplantatie van CD34+ 
cellen, nam het aantal immature CD34+CD3S- cel1en dat geproduceerd werd in vivo 
niet proportioneel toe met de grootte van het CD34-CD38- transplantaat, maar 
verliep volgens een tweede-orde relatie. Transplantatie van gelsoleerde 
CD34+CD38- cellen resulteert in IO-voudig lagere aantallen CD34- cellen, 
waaronder geen CD34+CD3S- cellen te detecteren waren in het muizenbeenmerg. 
Het toevoegen van CD34+CD3S+ cellen aan het CD34+CD38-- transplantaat 
herstelde het behoud en de expansie van de immature sub-populatie wat impliceert 
dat SCID repopulerende CD34+CD3S- cellen CD34+CD3S+ accessoire cellen nodig 
hebben voor overleving en expansie van deze immature populatie. 
Met de ontwikkeling van nieuwe muisstammen kwam de NOD/SCID muis tot onze 
beschikking. Deze muisstam heeft, naast de specifieke afweer ook een deficiente a-
specifieke afweer en is daarom nog beter toepasbaar voor stamcel onderzoek. 
Hoofdstuk 3 beschrijft het gebruik van NOD/SCID muizen in het onderzoek naar 
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de uitgroei van nonnale en kwaadaardige voorlopercellen afkomstig van patienten 
met cbronische myeloide leukemie (CML). Met fiuorescente in situ hybridisatie 
(FISH) analyse is aangetoond dat uit chimeer muizenbeemnerg gezuiverde 
myeloide, B-lymfoide, erytbroide en CD34+ cellen het voor CML karakteristieke 
Philadelphia (Ph) cbromosoom bezitten in dezelfde frequenties als de primaire 
cellen van de CML patienten. Dit geeft aan dat de productie van nonnale als ook 
maligne cellen voorkomt met dezelfde efficientie in het NOD/SCID muis 
beemnerg. Met deze proefopzet voor CML is het mogelijk de effecten van 
verschillende groeifactoren, remmende cytokines en cytotoxische stoffen op de 
overleving en uitgroei van nonnale en maligne cellen te onderzoeken. Omdat 
cellen die gelsoleerd zijn uit patienten met CML blasten crisis met hoge efficientie 
uitgroeien in het NOD/SCm muis beemnerg, kan deze test ook gebruikt worden 
om de progressie van cbronische fase CML naar blasten crisis te bestuderen. 
Hematopoietische cellen zijn evidente doelcellen voor gentransfer dankzij de 
mogelijkheid na transplantatie het hematopoietisch systeem volledig te 
repopuleren. Het markeren van cellen met repopulerende activiteit met genen die 
coderen voor bijvoorbeeld het groen fiuorescente eiwit (GFP) gen, maakt 
eenvoudige, snelle analyse van de getransduceerde cellen en hun dochtercellen na 
transplantatie mogelijk. In hoofdstuk 4 wordt de efficientie waannee gezuiverde 
sub-populaties navelsrengbloed cellen getransduceerd worden met een 'verbeterd' 
Genhanced) GFP (EGFP) gen gemeten. Daarbij is gebruik gemaakt van !wee virus 
producerende cellijnen met daarin !wee verschillende vectoren die het EGFP gen 
bevatten, AmI2IMFG-EGFP en PG13/SF-EGFP, respectievelijk. De Aml2 cellijn 
is een amfotrope cellijn die aan de Pit-2 receptor ofwel gibbon ape leukemia virus-
receptor-2 (GL VR-2) kan binden. De PG 13 cellijn is gepseudotypeerd voor het 
gibbon ape leukemia virus (GAL V) en bindt aan een andere receptor, GL VR-l 
ofwel Pit-I. Gezuiverde CD34+ en CD34+CD3S· navelstrengbloed populaties 
worden efficient getransduceerd met beide cellijnen na een !wee dagen durende 
groeifactor stimulatie met TPO, SCF en Flt3-L gevolgd door een !wee dagen 
durende periode met virus bevattend supernatant. Hierbij wordt gebruik gemaakt 
van een methode waarbij een humaan fibronectine fragment (CH-296) coating 
zorgt voor een efficientere transductie. De percentages EGFP na transductie met de 
gepseudotypeerde PG13/SF-EGFP cellijn waren hoger vergeleken met de 
amphotrope AmI2IMFG-EGFP cellijn. Transplantatie van getransduceerde, CD34+ 
geselecteerde navelstrengbloed cellen in NOD/SCm muizen resulteerde in 
percentages EGFP+ cellen van 23% en 2%, respectievelijk. 
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Hoewel EGFp-getransduceerde cellen het BM van de NOD/SCID muizen 
repopuleren, bleek het noodzakelijk het transductie protocol te optimaliseren om zo 
een stabiele, klinisch relevante expressie van het getransduceerde gen te krijgen. 
Hoofdstuk 5 beschrijft ondermeer de relatie tussen transductie efficientie en cel 
concentratie (rhesus aap BM en navelstrengbloed cellen) bij gebruik van de 
PG13/SF-EGFP virus producerende cellijn. Subcloneren van deze cellijn 
resulteerde in subclones met een hogere virus titer die in staat waren de transductie 
percentages te verhogen naar 90%. Daarnaast bleek cryopreservatie van RhBM 
cell en de transductie efficientie te verhogen. Omdat uitsluitend transplantatie 
experimenten inzicht kunnen geven in de mate van transductie in repopulerende 
cellen, zijn getransduceerde voorlopercellen uit navelstrengbloed in NOD/SCID 
muizen getransplanteerd. Dit resulteerde in 2 tot 4-voudig hogere percentages van 
gerepopuleerde EGFP- cellen dan na transductie onder suboptimale condities. 
Hematopoietische groeifactoren worden gebruikt om immature cellen te 
stimuleren en/of om BM of bloed afuarnes die te klein zijn voor transplantatie te 
expanderen. Het effect van diverse combinaties groeifactoren op de groei van BM 
en bloed in kweek is uitgebreid bestudeerd in vitro. Van bepaalde combinaties is 
het bijvoorbeeld bekend dat ze de differentiatie van de cellen stimuleren 
(combinaties met IL-3), het behoud en proliferatie van immature cellen echter, is 
moeilijker te realiseren. Recent gecloneerde groeifactoren als thrombopoietine 
(TPO) en fins-like tyrosine kinase3 ligand (Flt3-L), stimuleren de proliferatie van 
immature cellen in elk geval in vitro, waardoor deze groeifactoren vee1belovend 
zijn in de expansie van starn cellen. In vivo toediening van groeifactoren 
(bijvoorbeeld granulocyte colony-stimulating factor (G-CSF)) wordt vaak 
toegepast om starncellen uit het beenmerg naar het perifere bloed te mobiliseren, 
waarna grote hoeveelheden eenvoudig kunnen worden verzameld. Expansie van 
hematopoietische stamcellen in vivo na transplantatie van gelimiteerde 
hoeveelheden beenmergcellen of gezuiverde stamcellen kan wellicht efficient 
gestimuleerd worden door middel van het toedienen van groeifactoren direct na 
transplantatie. Injectie van een enkele dosis rHuTPO direct na transplantatie van 
gezuiverde CD34- cellen uit navelstrengbloed in bestraalde NOD/SCID muizen 
resulteerde in een hoger percentage en absoluut celaantal van humane cellen in het 
muizenbeenmerg. (Hoofdstuk 6). 
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Hemato1ogie van de Erasmus Universiteit Rotterdam onder leiding van dr G. Wagemaker. 
N u werk! ze als postdoc in de proj ectgroep van dr G. Wagemaker. 
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Bedankt! 
Zo aan het einde van dit boekje wil ik traditiegetrouw een aantal mensen bedanken. 
Terugkijkend op mijn A.LO periode besefik dat promoveren naast hard werken. vooral een 
hele leulee tijd kan zijn. Voor mij is dat in elk geval waar. 
Professor Lowenberg, mijn promotor, wil ik bedanken voor zijn steun en het kritisch 
doorlezen van dit proefschrift. Professor Hagenbeek en professor Dzierzak. leden van de 
kleine commissie, oak u wil ik bedanken voor de moeite die u genomen heeft om dit 
proefschrift te bestuderen. 
Gerard, veel heb ik van je geleerd. Met name op gebied van het presenteren van data in 
zowel mondelinge presentaties als publicaties heb je me vaak op het goede spoor gezet. lk 
vind het fantastisch dat ik nog even in je lab mag blijven werken. 
Bert. jouw enorme kennis over al1erlei onderwerpen, bewonder ik enonn. Bedanl.1: voor je 
begeleiding, je correcties op mijn schrijfv..rerk en je ideeen voor nieuwe proeven. Ik hoop 
datje het naar je zin hebt in Vancouver. 
Trui, mensen als jij zijn onbetaalbaar! Ik wil je bij deze bedanken voor aIle overgedragen 
kennis met name op het gebied van kweken. Daarnaast ook voor alle gezeUige momenten 
waaronder je poging onS wat zingen bij te brengen,je altijd luisterend en objectief oor en de 
heerlijke herrie in het lab. 
Yvonne, Saskia, Dorinde, Hannie en Astrid, van jullie heb ik. met name in het begin van 
mijn project, veel geleerd. Bedankt voor jullie hulp en gezelligheid. Wati, bedankt voor al 
die vreselijke FISH glaasjes! Het ga je goed in lndonesie! Mechteld, het was kort, maar het 
was leuk metje samen te werken. 
Karen en Marg, jullie gingen mij voor in het in elkaar draaien van een proefschrift. 
Bedankt voor aIle tips en adviezen. Marg, ik vond het bijzonder je paranimfte mogen zijn. 
Marti. voortbordurend op jouw uitzoekwerk met betrekking tot efficiente EGFP 
producerende cellijnen is een groot deel van dit werk tot stand kunnen komen. Bedankt 
voor je introductie in de gentransfer! 
Sandra. Fatima, Jessica, Silla en Allard, als student in onze groep kan ik me voorstellen dat 
je denkt; '·Waar kom ik nu toch weer in terecht! ! .. Het liep altijd goed af. en ik vond het 
leule deel(lje) uit te maken vanjullie opleiding. 
Federica, you are a crazy girl! Ne1l'attesa di riverderti ti invio molti cordiali saluti!! We'll 
keep in touch! 
Simone, heel veel succes in het ziekenhuis en natuurlijk veel geluk bij het schrijven van 
jouw proefschrift! Geert, tof dat jij mijn paranimf wilt zijn, en natuurlijk veel succes met 
jouw promotiewerk, ik houje in de gaten! 
Kathelijn. ik beloof je, nu heb ik echt tijd om me op het '·Staf"-project te storten en UCB-
ijes mee op te werken! Bedankt voor aIle samenwerking tot nu toe (en het ons op de hoogte 
houden van aile roddels)! 
Paula. (onze stief-A.I.O.l. wil ik bedanken voor de vele gezamenlijke succesjes die we 
geboekt hebben. Jij bent iemand die altijd oprechte interesse hadlheeft in mijn 
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wetenschappelijke en persoonlijke doen en laten. Ik wens je alle goeds, en waar je ook voor 
kiest, arts of onderzoeker (of be ide!), ik weet zeker datje het goed zal doen. 
Ineke "van het secretariaat", Evelien, Ans en Jeanne waren en zijn altijd erg behulpzaam 
met het administratieve dat het werken in een lab en met name promoveren met zich 
meebrengt. Dank daarvoor. 
Ineke "'van de spoelkeuken" bedaukt voor het wassen van honderden UCB-flesjes, 
kweekschalen, scharen, pincetten al wat er nog meer vuil gemaakt wordt. 
Karola, jij bleef altijd heerlijk cool als ik weer eens met mijn dia's op de stoep stond. 
Gelukkig ging het vaak om wat kleine aanpassingen en tips als ik niet wist hoe ik het moest 
doerr. 
Els van Bodegom, Helen Kock en Henk Dronk, ondauks de nodige problemen in het 
'''nieuwe muishuis" bedankt voar de verzorging van al de SCID en NOD/SCID muizen die 
ik macht gebruiken in dit onderzoek. 
Alle moeders, bedankt voar het afstaan van liters navelstrengbloed! En de mensen van de 
afdeling verloskunde van het St. Fransiscus Gasthuis heel hartelijk bedankt voor het 
opvangen van al dat bloed. 
Ellen Nijs wil ik bijzonder bedanken voor al haar hulp bij het ontwerpen van het omslag. 
Jos. ik vind het ontzettend leuk dat jij mijn paranimf wil zijn! AIleen al het feit jou een keer 
in rokkostuum te l,mmen zien maah.'te het besluit jou te vragen makkelijk. Desi, kijk maar 
eens goed, hij is het echt! Lieve Tim en Janou. jullie zuIlen nog maar bar weinig snappen 
waarom Moni en Bram zover weg worren en maar soms een weekendje langs komen, maar 
vaak dwalen mijn gedachten afnaar jullie daar in dat "verre Limburg". 
Lieve Pap en Mam, hoewel wat in dit boekje staat jullie misschien boven je pet gaat, is dit 
werk niet voor niks aan jullie opgedragen. Van kleins af aan hebben jullie mij gemotiveerd 
te lezen, te leren maar vooral te doen wat ik leuk vond. Ook al hield dat in dat ik uit jullie 
beschermde Limburgse wereldje weg zou gaan. Niets was (is) teveel voor jullie. Bedankt 
v~~r alles! 
En Bram, lieverd, ik zal niet zeggen dat zonder jou ik het nooit gered had, maar het was weI 
heerlijk om af en toe frustraties en succesjes te kunnen bespreken met iemand die precies 
weet waar je het over hebt. Bedankt voor je lief de, zorg en steun. Nu is het jouw beurt en 
onthoud, wat ik kan, kanjij ook! 
Monique 
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